{
  "letters": 810938,
  "pages": 198,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Kiniksa Pharmaceuticals, Ltd.",
    "major_industry": "Pharmaceuticals",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 1,
          "title": "Securities Registration Information",
          "data": [
            {
              "key": "Title of each class",
              "value": "Class A Common Shares"
            },
            {
              "key": "Trading Symbol(s)",
              "value": "KNSA"
            },
            {
              "key": "Name of each exchange on which registered",
              "value": "The Nasdaq Stock Market LLC (Nasdaq Global Select Mark)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 2,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Item 1. Business",
              "value": ""
            },
            {
              "key": "Item 1A. Risk Factors",
              "value": ""
            },
            {
              "key": "Item 1B. Unresolved Staff Comments",
              "value": "123"
            },
            {
              "key": "Item 2. Properties",
              "value": "123"
            },
            {
              "key": "Item 3. Legal Proceedings",
              "value": "123"
            },
            {
              "key": "Item 4. Mine Safety Disclosures",
              "value": "123"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 2,
          "title": "PART II",
          "data": [
            {
              "key": "Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities",
              "value": "124"
            },
            {
              "key": "Item 6. Reserved.",
              "value": "124"
            },
            {
              "key": "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations",
              "value": "125"
            },
            {
              "key": "Item 7A. Quantitative and Qualitative Disclosures About Market Risk",
              "value": "139"
            },
            {
              "key": "Item 8. Financial Statements and Supplementary Data",
              "value": "139"
            },
            {
              "key": "Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure",
              "value": "139"
            },
            {
              "key": "Item 9A. Controls and Procedures",
              "value": "139"
            },
            {
              "key": "Item 9B. Other Information",
              "value": "140"
            },
            {
              "key": "Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.",
              "value": "140"
            },
            {
              "key": "PART III",
              "value": ""
            },
            {
              "key": "Item 10. Directors, Executive Officers and Corporate Governance",
              "value": "141"
            },
            {
              "key": "Item 11. Executive Compensation",
              "value": "141"
            },
            {
              "key": "Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters",
              "value": "141"
            },
            {
              "key": "Item 13. Certain Relationships and Related Transactions, and Director Independence",
              "value": "141"
            },
            {
              "key": "Item 14. Principal Accounting Fees and Services",
              "value": "141"
            },
            {
              "key": "PART IV Item 15. Exhibits and Financial Statement Schedules",
              "value": "142"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 2,
          "title": "Item 16. Form 10-K Summary",
          "data": [
            {
              "key": "Page",
              "value": "147"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 16,
          "title": "License and Acquisition Agreements",
          "data": [
            {
              "key": "Genentech License Agreement",
              "value": "In August 2022 we entered into a license agreement with Genentech, granting exclusive worldwide rights for development, manufacturing, and commercialization of vixarelimab."
            },
            {
              "key": "Upfront Payment",
              "value": "$80.0 million"
            },
            {
              "key": "Additional Payment",
              "value": "$20.0 million after first quarter of 2023 delivery."
            },
            {
              "key": "Contingent Payments",
              "value": "Up to $600.0 million in total before upstream financial obligations."
            },
            {
              "key": "Royalties",
              "value": "Tiered percentage royalties ranging from low-double digits to mid-teens."
            },
            {
              "key": "Genentech Responsibilities",
              "value": "Genentech has the exclusive right to development and commercialization, with ongoing clinical trial responsibilities."
            },
            {
              "key": "Termination Rights",
              "value": "Genentech can terminate the agreement at its discretion with prior notice."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 17,
          "title": "Territory license of mavrilimumab and ARCALYST payments",
          "data": [
            {
              "key": "Description",
              "value": "Eligible to receive payments for ARCALYST and mavrilimumab including regulatory and sales milestones."
            },
            {
              "key": "Payment Amount ARCALYST",
              "value": "$70.0 million"
            },
            {
              "key": "Payment Amount mavrilimumab",
              "value": "$576.0 million"
            },
            {
              "key": "Royalties Structure",
              "value": "Tiered percentage ranging from low-teens to low-twenties based on annual net sales."
            },
            {
              "key": "Collaboration Agreements",
              "value": "Huadong has exclusive rights in Huadong Territory."
            },
            {
              "key": "Termination Rights",
              "value": "Huadong can terminate with 12 months’ notice."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 19,
          "title": "MedImmune and Biogen Agreements Overview",
          "data": [
            {
              "key": "MedImmune Agreement - Payment Structure",
              "value": "Amendment in July 2020 established a new coronavirus field and deferred certain development and regulatory milestone payments. The agreement outlines milestone payments up to $15.0 million for subsequent indications, up to $85.0 million upon achieving annual net sales thresholds below $1.0 billion, and additional milestones aggregating up to $1.1 billion for net sales above $1.0 billion. It also specifies tiered royalties on annual net sales starting in the low double-digit percentages, escalating to 20%, payable until the expiration of licensed patents, regulatory exclusivity, or 10 years after first commercial sale. Termination provisions include insolvency, bankruptcy, material breach, or challenges to licensed patent rights."
            },
            {
              "key": "Biogen Asset Purchase Agreement",
              "value": "Entered in September 2016 to acquire all rights, title, and interest in certain assets related to vixarelimab and other antibodies, including associated patent rights and clinical data. The agreement involved an upfront payment of $11.5 million, a technology transfer payment of $0.5 million, and milestone payments of $14.3 million made in 2017 and 2019. Additional milestone obligations up to $315.0 million are contingent on achieving specified clinical, regulatory, and net sales milestones. It also includes tiered royalty obligations on annual net sales, with rates starting in the high single digits and capping below the teens, and provisions regarding termination and reversion of assets."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 20,
          "title": "Primatope Acquisition",
          "data": [
            {
              "key": "Acquisition Date",
              "value": "March 2019"
            },
            {
              "key": "Initial Payment",
              "value": "$15.0 million"
            },
            {
              "key": "Upfront Consideration",
              "value": "$10.0 million"
            },
            {
              "key": "Milestone Payments",
              "value": "$5.0 million"
            },
            {
              "key": "Final Milestone Payment Date",
              "value": "June 2019"
            },
            {
              "key": "Final Milestone Payment",
              "value": "$3.0 million"
            },
            {
              "key": "Class A common shares",
              "value": "Issued in June 2020 and September 2020"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 86,
          "title": "Clinical Development and Competitive Landscape for Mavrilimumab",
          "data": [
            {
              "key": "Summary",
              "value": "The document discusses clinical development of mavrilimumab and competitive programs that target GM-CSF signaling. It highlights the challenges faced in the competitive landscape, including potential mergers and acquisitions affecting resource concentration among competitors."
            },
            {
              "key": "Competitors",
              "value": "I-MAB Biopharma, Roivant Sciences Ltd., Humanigen, Inc."
            },
            {
              "key": "Risks",
              "value": "Results of clinical trials could lead to program modifications or discontinuation, and competitors may have more resources and expertise."
            },
            {
              "key": "Growth Strategy",
              "value": "The company is looking to acquire or in-license new product candidates or technologies and may engage in strategic transactions."
            },
            {
              "key": "Potential Challenges",
              "value": "Success is uncertain; the company may not realize intended benefits from transaction efforts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 87,
          "title": "Discussion on Product Candidates & Strategic Transactions",
          "data": [
            {
              "key": "Overview",
              "value": "The text outlines the challenges and requirements for developing, in-licensing, or acquiring product candidates, technologies, or businesses."
            },
            {
              "key": "Key Concerns",
              "value": "Significant payments, expenses, resource consumption, and potential risks in integrating new acquisitions or collaborations including difficulties in negotiation, cultural assimilation, and operational integration."
            },
            {
              "key": "Growth Strategy",
              "value": "Focus on research, development, commercialization, and strategic transactions such as licensing, collaborations, business combinations, and acquisitions to drive growth."
            },
            {
              "key": "Notable Examples",
              "value": "February 2022: Granted Huadong exclusive rights for developing and commercializing rilonacept and mavrilimumab in Asia Pacific (excluding Japan). August 2022: Entered a license agreement with Genentech for exclusive worldwide rights to develop and commercialize vixarelimab."
            },
            {
              "key": "Potential Risks",
              "value": "Failure to successfully identify or acquire product candidates; inability to secure favorable terms; challenges in executing complex strategic transactions that might lead to increased costs, integration difficulties, and potential dilution of existing shareholders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 127,
          "title": "Licensing and Acquisition Agreements – Huadong & Genentech Deals",
          "data": [
            {
              "key": "Huadong Collaboration Agreements - Upfront Payment",
              "value": "$22.0 million received (comprising $12.0 million for rilonacept license and $10.0 million for mavrilimumab license)"
            },
            {
              "key": "Revenue Recognition for Huadong Agreement",
              "value": "$10.0 million related to mavrilimumab recognized in 2022; $12.0 million for rilonacept deferred as of December 31, 2022"
            },
            {
              "key": "Contingent Payments (Huadong)",
              "value": "Eligible for additional development, regulatory, and sales-based milestone payments; tiered royalties in the low-teens to low-twenties percentage on annual net sales in the Huadong Territory"
            },
            {
              "key": "Genentech License Agreement - Upfront Payment",
              "value": "$80.0 million received, with an additional $20.0 million payment triggered in Q1 2023 after delivery of certain materials"
            },
            {
              "key": "Contingent Payments (Genentech)",
              "value": "Eligible to receive up to approximately $600.0 million, including development, regulatory, sales-based milestones and royalties (low double digits to mid-teens percentage)"
            },
            {
              "key": "Additional Context",
              "value": "Further details pertain to revenue recognition over the duration of clinical trial progress and material deliveries, as well as collaborative profit sharing for ARCALYST with Regeneron."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 183,
          "title": "Notes to Consolidated Financial Statements - Contract Assets, Liabilities and License & Acquisition Agreements",
          "data": [
            {
              "key": "Contract Assets (Genentech vixarelimab)",
              "value": "Ending Balance: 7,656; Reclassification: 7,656"
            },
            {
              "key": "Contract Liabilities (Genentech vixarelimab)",
              "value": "Additions: 14,290; Revenue Recognized: (21,946); Reclassification: 7,656; Ending Balance: 0"
            },
            {
              "key": "Contract Liabilities (Huadong rilonacept)",
              "value": "Additions: 12,000; Ending Balance: 12,000"
            },
            {
              "key": "Total Contract Liabilities",
              "value": "Additions: 26,290; Revenue Recognized: (21,946); Reclassification: 7,656; Ending Balance: 12,000"
            },
            {
              "key": "Biogen Asset Purchase Agreement - Upfront Payment",
              "value": "$11,500"
            },
            {
              "key": "Biogen Asset Purchase Agreement - Technology Transfer Payment",
              "value": "$500"
            },
            {
              "key": "Biogen Asset Purchase Agreement - Outstanding Milestone Payments",
              "value": "$165,000 remaining of up to $179,000"
            },
            {
              "key": "Biogen Asset Purchase Agreement - Additional Milestone Obligations",
              "value": "Potential payments up to $150,000 upon annual net sales milestones plus tiered royalties"
            },
            {
              "key": "Biogen Agreement - Retained Contracts Sublicense Fee",
              "value": "$150"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 184,
          "title": "Notes to Consolidated Financial Statements - Agreements and Acquisition Details",
          "data": [
            {
              "key": "Biogen Agreement Payment Obligations",
              "value": "Obligation to pay annual maintenance fees and clinical/regulatory milestone payments up to an aggregate of $1,575; termination occurs upon the expiration of payment obligations for the last product in the territory."
            },
            {
              "key": "Biogen Agreement Termination Provisions",
              "value": "Contract may be terminated by either party with 90 days’ notice, by mutual consent, or due to a material breach remaining uncured for 90 days (30 days for payment-related breaches)."
            },
            {
              "key": "Biogen Agreement Amendments",
              "value": "Amendment No. 1 in July 2017 clarified the scope of antibodies subject to the agreement; Amendment No. 2 in August 2022 modified terms including definitions (Net Sales, Indication, Product, Combination Product, Valid Claim) and increased tiered royalty rates by less than 1%."
            },
            {
              "key": "Research and Development Expenses",
              "value": "For the years ended December 31, 2022 and 2021, expenses of $56k and $53k were recorded respectively related to annual maintenance fees; in 2020, $106k was recorded primarily for a milestone payment and maintenance fees."
            },
            {
              "key": "Primatope Agreement and Acquisition",
              "value": "Entered in September 2017 as a stock purchase option agreement with Primatope Therapeutics for rights to the preclinical antibody KPL-404. The agreement included upfront payment of $500 and extension fees up to $800, with an exclusive call option. The Company determined it did not have control during the option period, but in January 2019 exercised the call option and in March 2019 acquired all outstanding securities of Primatope."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 185,
          "title": "Primatope Acquisition and License Agreements",
          "data": [
            {
              "key": "Acquisition Details",
              "value": "The Company made total payments of $15,000 at the closing of Primatope Acquisition, including $10,000 upfront and $5,000 in milestone payments."
            },
            {
              "key": "Milestone Payments",
              "value": "$3,000 paid in June 2019 for the final milestone payment."
            },
            {
              "key": "Subsidiary Status",
              "value": "Primatope became a wholly owned subsidiary of the Company."
            },
            {
              "key": "Expense Classification",
              "value": "Upfront and milestone payments recorded as research and development expense."
            },
            {
              "key": "BIDMC Agreement",
              "value": "Company acquired license to intellectual property rights with certain obligations like an annual maintenance fee and clinical milestone payments."
            },
            {
              "key": "Regeneron Agreement",
              "value": "Company entered into license for ARCALYST with upfront and milestone payments, and is responsible for development and commercialization."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 148,
          "title": "Corporate Officers and Directors Signatures",
          "data": [
            {
              "key": "Summary",
              "value": "Signature page from a corporate filing dated March 2, 2023 listing key executives and board members."
            },
            {
              "key": "CEO/Chairman",
              "value": "Sanj K. Patel – Chief Executive Officer and Chairman of the Board of Directors (signed on March 2, 2023)"
            },
            {
              "key": "CFO",
              "value": "Mark Ragosa – Chief Financial Officer (signed on March 2, 2023)"
            },
            {
              "key": "Chief Accounting Officer",
              "value": "Michael R. Megna – Group VP, Finance and Chief Accounting Officer (signed on March 2, 2023)"
            },
            {
              "key": "Lead Independent Director",
              "value": "Felix J. Baker – Lead Independent Director (signed on March 2, 2023)"
            },
            {
              "key": "Director",
              "value": "Stephen R. Biggar – Director (signed on March 2, 2023)"
            },
            {
              "key": "Director",
              "value": "G. Bradley Cole – Director (signed on March 2, 2023)"
            },
            {
              "key": "Director",
              "value": "Richard S. Levy – Director (signed on March 2, 2023)"
            },
            {
              "key": "Director",
              "value": "Thomas R. Malley – Director (signed on March 2, 2023)"
            },
            {
              "key": "Director",
              "value": "Tracey L. McCain – Director (signed on March 2, 2023)"
            },
            {
              "key": "Director",
              "value": "Kimberly J. Popovits – Director (signed on March 2, 2023)"
            },
            {
              "key": "Director",
              "value": "Barry D. Quart – Director (signed on March 2, 2023)"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": false,
      "elements": []
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 13,
          "title": "Phase 1 Clinical Trial Results of KPL-404",
          "data": [
            {
              "key": "Key Findings",
              "value": "Final results from Phase 1 trial met both primary objective and secondary endpoints."
            },
            {
              "key": "Dose Levels",
              "value": "0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg IV and 1 mg/kg, 5 mg/kg subcutaneously."
            },
            {
              "key": "Trial Design",
              "value": "Randomized, double-blind, placebo-controlled, single-ascending-dose."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 137,
          "title": "Accrued Research and Development Expenses",
          "data": [
            {
              "key": "Revenue Recognition",
              "value": "ASC 606 outlines a five-step process for recognizing revenue from contracts with customers."
            },
            {
              "key": "Product Revenue Recognition",
              "value": "Net revenue from product sales is recognized at the transaction price when the specialty pharmacy or specialty distributors obtains control of our products."
            },
            {
              "key": "Accrued R&D Expenses",
              "value": "We estimate accrued research and development expenses based on open contracts and purchase orders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 141,
          "title": "EXECUTIVE COMPENSATION",
          "data": [
            {
              "key": "proxy statement due date",
              "value": "within 120 days of December 31, 2022"
            },
            {
              "key": "incorporation",
              "value": "incorporated by reference into this Annual Report"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 141,
          "title": "DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE",
          "data": [
            {
              "key": "code of conduct",
              "value": "applies to all of our directors, officers and employees"
            },
            {
              "key": "website",
              "value": "www.kiniksa.com"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 141,
          "title": "SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT",
          "data": [
            {
              "key": "proxy statement due date",
              "value": "within 120 days of December 31, 2022"
            },
            {
              "key": "incorporation",
              "value": "incorporated by reference into this Annual Report"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 141,
          "title": "CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE",
          "data": [
            {
              "key": "proxy statement due date",
              "value": "within 120 days of December 31, 2022"
            },
            {
              "key": "incorporation",
              "value": "incorporated by reference into this Annual Report"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 141,
          "title": "PRINCIPAL ACCOUNTING FEES AND SERVICES",
          "data": [
            {
              "key": "proxy statement due date",
              "value": "within 120 days of December 31, 2022"
            },
            {
              "key": "incorporation",
              "value": "incorporated by reference into this Annual Report"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 144,
          "title": "Material Contracts and Agreements Filing Information",
          "data": [
            {
              "key": "Summary",
              "value": "The table lists material contracts and agreements filed by Kiniksa Pharmaceuticals with the SEC. It includes collaboration, licensing, supply, and employment agreements."
            },
            {
              "key": "Notable Employment Agreements",
              "value": "Amended and Restated Employment Agreements with Sanj K. Patel and Eben Tessari, and an Employment Agreement with Mark Ragosa."
            },
            {
              "key": "Other Agreements",
              "value": "Includes License Agreements (with Genentech, Inc. and F. Hoffmann-La Roche Ltd.), and Commercial and Clinical Supply Agreements with Regeneron Pharmaceuticals, Inc., as well as a Sublease Amendment with Shire Human Genetic Therapies, Inc."
            },
            {
              "key": "Filing Forms and Dates",
              "value": "SEC forms 10-Q, 8-K, and S-1 ranging from 2018 to 2022."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 145,
          "title": "10.39# Form of U.S. Performance Restricted Share Unit and Performance Cash Award Grant Notice and Agreement under the Rilonacept Long-Term Incentive Plan",
          "data": [
            {
              "key": "Form",
              "value": "8-K"
            },
            {
              "key": "File Number",
              "value": "001-38492"
            },
            {
              "key": "Exhibit Number",
              "value": "10.2"
            },
            {
              "key": "Date",
              "value": "12/16/19"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 146,
          "title": "Agreement Rilonacept Long-Term Plan Documentation and Exhibits",
          "data": [
            {
              "key": "Description",
              "value": "This table appears to be an exhibit index from a SEC filing. It lists various documents and exhibits related to the Rilonacept Long-Term Plan, including compensation agreements such as Performance Restricted Share Unit and Performance Cash Award agreements, executive certifications (e.g., of the Chief Financial Officer and Chief Executive Officer), and several Inline XBRL documents."
            },
            {
              "key": "Key Items",
              "value": "Forms of Performance Restricted Share Unit and Performance Cash Award Grant Notices and Agreements; Rilonacept Long-Term Incentive Plan Director; Non-Employee Compensation Program Restricted Share Agreement; Executive Officer and Certification documents"
            },
            {
              "key": "Filing Types and File Numbers",
              "value": "Includes filings such as S-8, 10-Q, S-1, 10-K with file numbers like '333-237589 001-38492' and '333-229394 001-38492'"
            },
            {
              "key": "Exhibit References",
              "value": "Exhibits referenced include '99.8 10.1', '10.25 21.1', along with Inline XBRL instance, schema, calculation, definition, label, and presentation linkbase documents"
            },
            {
              "key": "Additional Notes",
              "value": "Items marked with '#' indicate that they may relate to management contracts or compensatory plans. Some documents are certifications from executive officers and independent public accountants."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 166,
          "title": "Table of Contents & Notes to Consolidated Financial Statements (Continued)",
          "data": [
            {
              "key": "Patent Costs",
              "value": "The Company charges patent-related costs (filing and prosecuting patent applications) to operations as incurred, with these costs classified as selling, general and administrative expenses."
            },
            {
              "key": "Segment Information",
              "value": "The Company operates as a single operating segment with a focus on developing and delivering therapeutic medicines for patients with debilitating diseases and significant unmet medical need."
            },
            {
              "key": "Share-Based Compensation",
              "value": "Details on share-based awards granted to employees, directors, consultants, and non-employees. Awards include both service-based and performance-based vesting conditions. Compensation expense is recognized on a straight-line basis for service conditions, and for performance conditions when milestones are met. The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model, incorporating inputs such as share price volatility, expected term, risk-free interest rate, and expected dividend yield."
            },
            {
              "key": "Valuation Methodology",
              "value": "Uses the Black-Scholes model with inputs like historical volatility, expected term (using the 'simplified' method for plain-vanilla options), the U.S. Treasury yield curve for risk-free rate, and an assumption of no cash dividends."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 174,
          "title": "11. Share-Based Compensation",
          "data": [
            {
              "key": "Plan Overview",
              "value": "Details on the 2018 Incentive Award Plan that became effective on May 23, 2018, and replaced the 2015 Equity Incentive Plan."
            },
            {
              "key": "Award Types",
              "value": "Incentive share options, nonqualified share options, share appreciation rights, restricted shares, dividend equivalents, restricted share units, and other share- or cash-based awards."
            },
            {
              "key": "Reserved Shares under 2018 Plan",
              "value": "Initially 4,466,500 Class A common shares reserved; automatic annual increases starting January 1, 2019 based on 4% of outstanding shares."
            },
            {
              "key": "Available Shares Detail",
              "value": "As of December 31, 2022, 4,037,283 shares remained available; on January 1, 2023, an increase of 2,787,900 shares was recorded."
            },
            {
              "key": "2015 Equity Incentive Plan",
              "value": "Prior to May 23, 2018, awards were granted under the 2015 Plan; outstanding awards under the 2015 Plan included 1,956,543 Class A common shares as of December 31, 2022, and terms remain governed by the 2015 Plan."
            },
            {
              "key": "Additional Terms",
              "value": "Exercise prices and vesting schedules for share options are determined by the board of directors with different terms based on holder’s voting power and option term limits."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 175,
          "title": "Notes to Consolidated Financial Statements – Share Options and Employee Share Purchase Plan",
          "data": [
            {
              "key": "Employee Share Purchase Plan Effective Date",
              "value": "May 23, 2018"
            },
            {
              "key": "Initial Reserved Shares under ESPP",
              "value": "670,000 Class A common shares"
            },
            {
              "key": "Automatic Increase Terms for ESPP",
              "value": "Each January 1 from 2019 until 2028, the reserved shares may increase by the lesser of 1% of outstanding shares (on an as-converted basis) or a smaller number set by the board, with a cap of 6,420,000 shares."
            },
            {
              "key": "Available ESPP Shares as of December 31, 2022",
              "value": "604,290 Class A common shares"
            },
            {
              "key": "Share Options Outstanding (2021)",
              "value": "9,226,846 shares outstanding as of December 31, 2021"
            },
            {
              "key": "Share Options Outstanding (2022)",
              "value": "10,144,618 shares outstanding as of December 31, 2022"
            },
            {
              "key": "Share Options Exercisable (2022)",
              "value": "5,661,613 shares exercisable as of December 31, 2022 with an average remaining term of 6.19 years"
            },
            {
              "key": "Weighted Average Exercise Price Change",
              "value": "Decreased from $14.14 (2021) to $13.36 (2022)"
            },
            {
              "key": "Aggregate Intrinsic Value Change",
              "value": "Increased from $14,947 (2021) to $32,634 (2022)"
            },
            {
              "key": "Option Activity in 2022",
              "value": "2,929,315 shares granted, 383,106 shares exercised (cash proceeds $2,606 and intrinsic value $2,196), and 1,628,437 shares forfeited"
            },
            {
              "key": "Historical Exercise Data",
              "value": "2021: 795,404 shares exercised (intrinsic value $6,392; cash proceeds $5,311); 2020: 1,324,429 shares exercised (intrinsic value $18,271; cash proceeds $6,058)"
            },
            {
              "key": "Weighted-Average Grant-Date Fair Value per Share",
              "value": "2022: $7.66; 2021: $11.30; 2020: $11.38"
            },
            {
              "key": "Calculation of Aggregate Intrinsic Value",
              "value": "Difference between the exercise price and the fair value of the Company’s common shares for options with exercise prices below fair value"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 176,
          "title": "Financial Metrics and Risk Parameters",
          "data": [
            {
              "key": "Total fair value of share options vested (2022)",
              "value": "$21,229"
            },
            {
              "key": "Total fair value of share options vested (2021)",
              "value": "$22,870"
            },
            {
              "key": "Total fair value of share options vested (2020)",
              "value": "$17,931"
            },
            {
              "key": "Total unrecognized compensation expense related to unvested awards",
              "value": "$36,400"
            },
            {
              "key": "Risk-free interest rate (2022)",
              "value": "3.00 %"
            },
            {
              "key": "Risk-free interest rate (2021)",
              "value": "1.00 %"
            },
            {
              "key": "Risk-free interest rate (2020)",
              "value": "0.55 %"
            },
            {
              "key": "Expected term (2022)",
              "value": "6.17"
            },
            {
              "key": "Expected term (2021)",
              "value": "6.13"
            },
            {
              "key": "Expected term (2020)",
              "value": "6.21"
            },
            {
              "key": "Expected volatility (2022)",
              "value": "73.83 %"
            },
            {
              "key": "Expected volatility (2021)",
              "value": "76.05 %"
            },
            {
              "key": "Expected volatility (2020)",
              "value": "80.81 %"
            },
            {
              "key": "Expected dividend yield (2022)",
              "value": "—%"
            },
            {
              "key": "Expected dividend yield (2021)",
              "value": "—%"
            },
            {
              "key": "Expected dividend yield (2020)",
              "value": "—%"
            },
            {
              "key": "Rilonacept Long-Term Incentive Plan (RSU details)",
              "value": "Incentivizes eligible employees, fair value based on closing price, cash awards on achievement of milestones."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 177,
          "title": "Share-Based Compensation and RSU Activity Disclosure",
          "data": [
            {
              "key": "RSU Starting Balance (Dec 31, 2021)",
              "value": "885021 shares at $15.72 per share"
            },
            {
              "key": "RSU Granted in 2022",
              "value": "1479861 shares at $11.53 per share"
            },
            {
              "key": "RSU Vested in 2022",
              "value": "250805 shares vested (adjustment) at $14.81 per share"
            },
            {
              "key": "RSU Forfeited in 2022",
              "value": "371676 shares forfeited (adjustment) at $13.53 per share"
            },
            {
              "key": "RSU Ending Balance (Dec 31, 2022)",
              "value": "1742401 shares at $12.76 per share"
            },
            {
              "key": "Total Unrecognized Compensation Cost",
              "value": "$18,042"
            },
            {
              "key": "Weighted Average Remaining Vesting Period",
              "value": "3.23 years"
            },
            {
              "key": "Cost of Goods Sold (Stock-Based)",
              "value": "2022: $636M, 2021: $197M, 2020: N/A"
            },
            {
              "key": "Research and Development Expenses",
              "value": "2022: $6766M, 2021: $8450M, 2020: $8866M"
            },
            {
              "key": "Selling, General and Administrative Expenses",
              "value": "2022: $17718M, 2021: $16526M, 2020: $12009M"
            },
            {
              "key": "Total Stock-Based Compensation Expense",
              "value": "2022: $25120M, 2021: $25173M, 2020: $20875M"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 179,
          "title": "Revenue Recognition Methods for Vixarelimab Services",
          "data": [
            {
              "key": "Exclusive license for vixarelimab",
              "value": "Point in time; that is upon transfer of the license to Genentech. As control of the license was transferred on the Genentech Effective Date and Genentech could begin to use and benefit from the license on that date."
            },
            {
              "key": "Initial drug supply delivery",
              "value": "Point in time upon delivery."
            },
            {
              "key": "Drug product resupply delivery",
              "value": "Point in time upon delivery."
            },
            {
              "key": "Completion of the phase 2b clinical trial for vixarelimab",
              "value": "Over time; using the cost-to-cost input method, which is believed to best depict the transfer of control to the customer. Under the cost-to-cost input method, the percent of completion is based on the ratio of actual costs incurred as of the period end to the total estimated costs. Revenue is recorded as a percentage of the allocated transaction price times the percent of completion."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 189,
          "title": "Tax Rate Reconciliation Table",
          "data": [
            {
              "key": "Component",
              "value": "U.S. and Europe tax rate differential"
            },
            {
              "key": "2022",
              "value": "165.9"
            },
            {
              "key": "2021",
              "value": "1.9"
            },
            {
              "key": "2020",
              "value": "-0.8"
            },
            {
              "key": "Component",
              "value": "Research and development tax credits"
            },
            {
              "key": "2022",
              "value": "-21.5"
            },
            {
              "key": "2021",
              "value": "2.4"
            },
            {
              "key": "2020",
              "value": "2.4"
            },
            {
              "key": "Component",
              "value": "Share-based compensation"
            },
            {
              "key": "2022",
              "value": "13.2"
            },
            {
              "key": "2021",
              "value": "-0.4"
            },
            {
              "key": "2020",
              "value": "13.0"
            },
            {
              "key": "Component",
              "value": "Permanent differences"
            },
            {
              "key": "2022",
              "value": "null"
            },
            {
              "key": "2021",
              "value": "null"
            },
            {
              "key": "2020",
              "value": "-0.1"
            },
            {
              "key": "Component",
              "value": "U.S. state taxes, net of federal"
            },
            {
              "key": "2022",
              "value": "10.4"
            },
            {
              "key": "2021",
              "value": "-0.5"
            },
            {
              "key": "2020",
              "value": "0.1"
            },
            {
              "key": "Component",
              "value": "FDII"
            },
            {
              "key": "2022",
              "value": "-35.9"
            },
            {
              "key": "2021",
              "value": "14.0"
            },
            {
              "key": "2020",
              "value": "0.6"
            },
            {
              "key": "Component",
              "value": "Uncertain tax positions"
            },
            {
              "key": "2022",
              "value": "14.3"
            },
            {
              "key": "2021",
              "value": "0.2"
            },
            {
              "key": "2020",
              "value": "-0.2"
            },
            {
              "key": "Component",
              "value": "IP Transfer"
            },
            {
              "key": "2022",
              "value": "-343.9"
            },
            {
              "key": "2021",
              "value": "71.0"
            },
            {
              "key": "2020",
              "value": "null"
            },
            {
              "key": "Component",
              "value": "Other"
            },
            {
              "key": "2022",
              "value": "17.2"
            },
            {
              "key": "2021",
              "value": "-0.8"
            },
            {
              "key": "2020",
              "value": "-0.9"
            },
            {
              "key": "Component",
              "value": "Change in valuation allowance"
            },
            {
              "key": "2022",
              "value": "-1382.8"
            },
            {
              "key": "2021",
              "value": "-76.1"
            },
            {
              "key": "2020",
              "value": "-5.7"
            },
            {
              "key": "Component",
              "value": "Effective income tax rate"
            },
            {
              "key": "2022",
              "value": "-1563.1"
            },
            {
              "key": "2021",
              "value": "-0.9"
            },
            {
              "key": "2020",
              "value": "-3.3"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 194,
          "title": "Certification by Sanj K. Patel",
          "data": [
            {
              "key": "Certifying Officer Name",
              "value": "Sanj K. Patel"
            },
            {
              "key": "Position",
              "value": "Chief Executive Officer and Chairman of the Board of Directors"
            },
            {
              "key": "Report Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Reporting Date",
              "value": "March 2, 2023"
            },
            {
              "key": "Financial Statement Accuracy",
              "value": "Affirms that financial statements fairly present the financial condition"
            },
            {
              "key": "Disclosure Controls Statement",
              "value": "Acknowledges responsibility for establishing disclosure controls and procedures"
            },
            {
              "key": "Internal Control Evaluation",
              "value": "Evaluated the effectiveness of internal controls over financial reporting"
            },
            {
              "key": "Deficiencies and Weaknesses Disclosure",
              "value": "Disclosed all significant deficiencies and material weaknesses in internal control"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 14,
          "title": "Phase 2 Trial in Rheumatoid Arthritis Overview",
          "data": [
            {
              "key": "Trial Start Date",
              "value": "December 2021"
            },
            {
              "key": "Dose Levels",
              "value": "KPL-404 2mg/kg or 5mg/kg, respectively"
            },
            {
              "key": "Injection Frequency",
              "value": "subcutaneous injection every 2 weeks for 12 weeks"
            },
            {
              "key": "Primary Efficacy Endpoints",
              "value": "Pharmacokinetic data, incidence of treatment-emergent adverse events"
            },
            {
              "key": "Revised Cohort 3 Administration",
              "value": "5 mg/kg weekly or 5 mg/kg every 2 weeks superimposed with matching placebo"
            },
            {
              "key": "Expected Data Release",
              "value": "First half of 2024"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 18,
          "title": "Licensing and Collaboration Agreements – Regeneron and MedImmune",
          "data": [
            {
              "key": "Regeneron Agreement - Upfront Payment",
              "value": "$5.0 million"
            },
            {
              "key": "Regeneron Agreement - Milestone Payment (Q4 2020)",
              "value": "$7.5 million in connection with a specified regulatory milestone event"
            },
            {
              "key": "Regeneron Agreement - Milestone Payment (Q1 2021)",
              "value": "$20.0 million regulatory milestone payment"
            },
            {
              "key": "Regeneron Agreement - Profit Sharing",
              "value": "Evenly split profits on ARCALYST sales after deducting manufacturing, commercialization, and technology transfer costs"
            },
            {
              "key": "Regeneron Agreement - Additional Terms",
              "value": "Includes rights such as Regeneron's first negotiation over third-party promotional support beyond specified levels, requirement for prior written consent for sublicensing certain rights (especially outside the US), assignment restrictions, termination provisions (for convenience, safety concerns, material breach, or insolvency), and a linked commercial supply agreement for exclusive manufacturing and supply of ARCALYST."
            },
            {
              "key": "MedImmune Agreement - Overview",
              "value": "Entered in December 2017, providing an exclusive, sublicensable, worldwide license to intellectual property for mavrilimumab and related products, plus non-exclusive licenses and reference rights to manufacturing/regulatory documentation."
            },
            {
              "key": "MedImmune Agreement - Payments",
              "value": "Upfront payment of $8.0 million; additionally, a $5.0 million pass-through payment and a $10.0 million milestone payment in the year ended December 31, 2019; future clinical, regulatory and initial sales milestone payments up to $57.5 million are also contemplated."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 23,
          "title": "Table of Contents & Intellectual Property Overview",
          "data": [
            {
              "key": "Clinical Development Programs",
              "value": "The document lists multiple GM-CSF antagonist programs in clinical development (e.g., Mavrilimumab, plonmarlimab, gimsilumab, namilumab, lenzilumab) and notes the difference in targeting strategy (ligand vs receptor) compared to mavrilimumab."
            },
            {
              "key": "Intellectual Property Strategy",
              "value": "The text details the importance of obtaining and maintaining proprietary protection through patents and trade secrets. It describes plans to secure patent protection on drug candidates, manufacturing processes, formulations, and methods of use, as well as exclusive licenses (e.g., under the Regeneron Agreement for ARCALYST and licensing with BIDMC and acquisition of Primatope for KPL-404). It further includes details on granted patents, pending applications, expiration dates, and FDA-granted market exclusivity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 45,
          "title": "Table of Contents & Risk Factors Overview",
          "data": [
            {
              "key": "Sales, Marketing and Distribution",
              "value": "Supporting our sales, marketing and distribution capabilities, infrastructure and organization to commercialize ARCALYST and product candidates."
            },
            {
              "key": "Research and Development",
              "value": "Research, preclinical and clinical development of product candidates, including a Phase 2 clinical trial for KPL-404 in RA and an in-progress Phase 2b dose-ranging clinical trial for vixarelimab for prurigo nodularis as required by the Genentech Licensing Agreement."
            },
            {
              "key": "Manufacturing and Technology Transfer",
              "value": "Manufacturing products and product candidates for clinical or commercial use; increasing manufacturing capabilities; adding additional manufacturers or suppliers; performing technology transfer activities."
            },
            {
              "key": "Regulatory and Marketing Approvals",
              "value": "Seeking regulatory and marketing approvals for product candidates that successfully complete clinical trials."
            },
            {
              "key": "Clinical Trials and Additional Studies",
              "value": "Initiating additional preclinical studies and clinical trials for product candidates."
            },
            {
              "key": "Milestone Payments",
              "value": "Making milestone or other payments under current or future license, acquisition, collaboration, or other strategic transaction agreements."
            },
            {
              "key": "Product Expansion Strategies",
              "value": "Identifying, assessing and studying new or expanded indications, alternative dosing levels, frequencies, or administration methods for products or product candidates; acquiring or developing additional product candidates."
            },
            {
              "key": "Licensing, Acquisition and Collaborations",
              "value": "Entering into licensing, acquisition, collaboration or other strategic transaction agreements."
            },
            {
              "key": "Intellectual Property",
              "value": "Seeking to maintain, protect and expand the intellectual property portfolio."
            },
            {
              "key": "Human Resources and Infrastructure",
              "value": "Attracting and retaining skilled personnel and creating additional infrastructure to support product development and commercialization efforts."
            },
            {
              "key": "Risk Factors",
              "value": "Experiencing delays or issues related to these activities, including impacts from the COVID-19 pandemic, failed trials, complex or safety issues, regulatory challenges, and economic headwinds such as rising inflation."
            },
            {
              "key": "Financial Outlook",
              "value": "Noting that net losses may fluctuate significantly, affecting shareholder equity and working capital, with corporate profitability when achieved potentially unsustainable in subsequent periods."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 128,
          "title": "Research and Development Expenses",
          "data": [
            {
              "key": "Description",
              "value": "Research and development expenses consist primarily of costs incurred in connection with the research and development of our product candidates."
            },
            {
              "key": "Expenses include",
              "value": "• expenses incurred to conduct necessary preclinical studies and clinical trials required to obtain regulatory approval; • expenses incurred under agreements with CROs; • costs related to acquiring and manufacturing preclinical and clinical trial materials; • payments made under third-party licensing; • employee-related expenses; • costs related to compliance with regulatory requirements; • allocated facilities-related costs."
            },
            {
              "key": "Direct expenses tracking",
              "value": "Our direct research and development expenses are tracked on a program-by-program basis and consist primarily of external costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 129,
          "title": "Overview of Research & Development and Operating Expenses",
          "data": [
            {
              "key": "R&D Focus",
              "value": "Research and development activities are central to our business, with significant and sustained expenses expected over the next several years as clinical and preclinical development, regulatory filings, and related activities continue."
            },
            {
              "key": "Clinical Development Costs",
              "value": "Product candidates in later stages of clinical development incur higher costs largely due to increased trial size and duration."
            },
            {
              "key": "Milestone and Royalty Expenses",
              "value": "Additional expenses related to milestone and royalty payments are expected under license, acquisition, and similar agreements for acquiring rights to product candidates."
            },
            {
              "key": "Selling, General and Administrative Expenses",
              "value": "Expenses include salaries, benefits, travel, share-based compensation, external commercialization, marketing, and professional fees (legal, patent, accounting)."
            },
            {
              "key": "Other Income & Income Taxes",
              "value": "Other income is derived from interest on investments, and the tax discussion highlights a zero percent corporate tax rate for Bermuda operations and details of taxation for U.S. and European subsidiaries."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 138,
          "title": "R&D Expenses and Income Taxes Discussion",
          "data": [
            {
              "key": "Preclinical and Clinical Trials",
              "value": "Engagement with vendors, research laboratories, CROs, and CMOs for preclinical development and clinical studies, with expenses based on service estimates and contract negotiations."
            },
            {
              "key": "Accrued R&D Expenses",
              "value": "As of December 31, 2022, accrued research and development expenses totaled $8.4 million."
            },
            {
              "key": "Expense Prepayments",
              "value": "Non-refundable prepayments for goods and services are recorded either as prepaid expenses (if used within one year) or as long-term assets."
            },
            {
              "key": "Deferred Tax and Valuation Allowance",
              "value": "Income taxes are accounted for using the asset and liability method; a valuation allowance of $185.5 million was released during 2022."
            },
            {
              "key": "Accrual Adjustments",
              "value": "Service fee accruals are adjusted based on the estimated period and level of effort, with adjustments made if actual performance deviates."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 152,
          "title": "Audit Procedures for Accrued Research and Development Costs",
          "data": [
            {
              "key": "subject",
              "value": "Accrued Research and Development Costs"
            },
            {
              "key": "critical_audit_matter",
              "value": "Determination based on significant management judgment and auditor subjectivity"
            },
            {
              "key": "management_judgment",
              "value": "Significant judgment in estimating accrued R&D costs"
            },
            {
              "key": "audit_procedures",
              "value": "Testing management's estimation process, evaluating methodology, assessing progress of R&D activities, verifying invoicing and actual cost data"
            },
            {
              "key": "source",
              "value": "PricewaterhouseCoopers LLP, Boston, Massachusetts; March 2, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 165,
          "title": "Notes to Consolidated Financial Statements – Intangible Assets and R&D Costs",
          "data": [
            {
              "key": "Intangible Assets",
              "value": "Upon FDA approval and the commercial launch of ARCALYST in March 2021, the Company capitalized a $20,000 milestone payment to Regeneron as a finite-lived intangible asset, to be amortized on a straight-line basis over 20 years."
            },
            {
              "key": "Amortization and Expense Treatment",
              "value": "Amortization expense is recorded as cost of goods sold. Research and development costs, including personnel, share-based compensation, depreciation, third-party license fees, and clinical trial support, are expensed as incurred."
            },
            {
              "key": "Impairment of Long-Lived Assets",
              "value": "The Company assesses impairment when events indicate that asset carrying amounts may not be recoverable, comparing carrying value with fair value based on anticipated undiscounted net cash flows. No impairment losses have been recognized through December 31, 2022."
            },
            {
              "key": "Research Contract Costs",
              "value": "Costs from research and development-related contracts are recorded as R&D expenses as incurred, with accruals made based on progress, invoicing to date, and other communications. Significant judgments and estimates are involved in determining these accruals."
            },
            {
              "key": "R&D Cost Recognition",
              "value": "Non-refundable prepayments for goods or services used in R&D are recorded as prepaid expenses if to be used within one year, while those not used within one year are classified as other long-term assets and expensed as services are performed."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 186,
          "title": "Notes to Consolidated Financial Statements – Collaborations and License Agreements",
          "data": [
            {
              "key": "Collaboration Profit Sharing",
              "value": "The Company evenly splits profits on ARCALYST sales with Regeneron after deducting costs related to manufacturing and commercialization, including cost of goods sold, field force expenses, and marketing costs. Also includes deductions for technology transfer costs."
            },
            {
              "key": "Recorded Expenses",
              "value": "For the years ended December 31, 2022 and 2021, the Company recorded $24,071 and $835, respectively, as expenses related to the profit sharing agreement."
            },
            {
              "key": "Supply Agreements",
              "value": "Entered into a clinical supply agreement in September 2017 and later a commercial supply agreement with Regeneron, with the latter subject to termination upon technology transfer completion or termination of the Regeneron Agreement."
            },
            {
              "key": "Inventory and Purchase Commitments",
              "value": "Recorded inventories related to commercial product purchases ($21,599 for 2022 and $3,675 for 2021) and noted non-cancelable purchase commitments under the commercial supply agreement."
            },
            {
              "key": "MedImmune License Agreement",
              "value": "In December 2017, the Company entered into an exclusive, sublicensable worldwide license agreement with MedImmune for mavrilimumab technology. The upfront payment of $8,000 was recorded as research and development expense due to the acquired technology being classified as in-process R&D (asset acquisition) with no alternative future use."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 187,
          "title": "Notes to Consolidated Financial Statements – MedImmune Agreement Milestone Payments & Tax Considerations",
          "data": [
            {
              "key": "Milestone Payment Obligations",
              "value": "Obligation to make clinical, regulatory, and initial sales milestone payments up to $72,500 for the first two indications, including specific $5,000 and $10,000 payments under the MedImmune Agreement."
            },
            {
              "key": "Subsequent Indication Payments",
              "value": "Company is obligated to make clinical and regulatory milestone payments up to $15,000 for each subsequent indication."
            },
            {
              "key": "Amendment to MedImmune Agreement",
              "value": "In July 2020, a new coronavirus field was added and certain development and regulatory milestone payments were deferred."
            },
            {
              "key": "Royalty Structure",
              "value": "Tiered royalties on escalating tiers of annual net sales starting in low double-digit percentages up to twenty percent, subject to reductions upon certain events."
            },
            {
              "key": "Company Responsibilities",
              "value": "The Company is solely responsible for all development, manufacturing, commercial activities, and cost-bearing related to the licensed products, including clinical studies, patent filing, prosecution, and maintenance."
            },
            {
              "key": "Agreement Termination Provisions",
              "value": "Either party may terminate the agreement upon insolvency, bankruptcy, or a material breach remaining uncured for 90 days; MedImmune may additionally terminate if the Company challenges any licensed patent rights."
            },
            {
              "key": "R&D Expense Treatment",
              "value": "During the years ended December 31, 2022, 2021, and 2020, the Company did not record R&D expense in connection with milestone payments due under the MedImmune Agreement."
            },
            {
              "key": "Income Tax Considerations",
              "value": "As a Bermuda-incorporated company taxed at a zero percent rate, income tax benefits were not recorded; additional tax considerations include references to the CARES Act and TCJA changes regarding R&D expenditure deductions."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 7,
          "title": "ARCALYST Approval and Market Information",
          "data": [
            {
              "key": "Description",
              "value": "ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. FDA approved for recurrent pericarditis."
            },
            {
              "key": "FDA Approval Date",
              "value": "March 2021"
            },
            {
              "key": "Target Population",
              "value": "Adults and children 12 years and older"
            },
            {
              "key": "Commercial Availability",
              "value": "Yes, available through network of distributors in the US."
            },
            {
              "key": "Licensing Information",
              "value": "Exclusive license from Regeneron, granted exclusive rights to Huadong for the Asia Pacific region."
            },
            {
              "key": "Related Products",
              "value": "KPL-404, Mavrilimumab, Vixarelimab"
            },
            {
              "key": "Trial Information for KPL-404",
              "value": "Phase 1 clinical trial completed, Phase 2 initiated for RA."
            },
            {
              "key": "Expected Trial Data for KPL-404",
              "value": "First half of 2024"
            },
            {
              "key": "Vixarelimab agreement partners",
              "value": "Genentech, Inc. and F. Hoffmann-La Roche Ltd."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Drug Development Pipeline and Out-Licensing Agreements",
          "data": [
            {
              "key": "section",
              "value": "CARDIOVASCULAR FRANCHISE"
            },
            {
              "key": "program",
              "value": "ARCALYST (rilonacept)"
            },
            {
              "key": "target",
              "value": "Recurrent Pericarditis"
            },
            {
              "key": "stage",
              "value": "Commercial"
            },
            {
              "key": "details",
              "value": "IL-1α & IL-1β"
            },
            {
              "key": "section",
              "value": "CARDIOVASCULAR FRANCHISE"
            },
            {
              "key": "program",
              "value": "Mavrilimumab"
            },
            {
              "key": "target",
              "value": "Evaluating Development in Rare Cardiovascular Diseases"
            },
            {
              "key": "stage",
              "value": "Phase 1"
            },
            {
              "key": "details",
              "value": "GM-CSFRα"
            },
            {
              "key": "section",
              "value": "AUTOIMMUNE FRANCHISE"
            },
            {
              "key": "program",
              "value": "KPL-404"
            },
            {
              "key": "target",
              "value": "Rheumatoid Arthritis"
            },
            {
              "key": "stage",
              "value": "Phase 2"
            },
            {
              "key": "details",
              "value": "CD40/CD154"
            },
            {
              "key": "section",
              "value": "OUT-LICENSING AGREEMENTS"
            },
            {
              "key": "program",
              "value": "ARCALYST (rilonacept)"
            },
            {
              "key": "licensee",
              "value": "Huadong Medicine"
            },
            {
              "key": "territory",
              "value": "Asia Pacific Region, Excluding Japan"
            },
            {
              "key": "program",
              "value": "Mavrilimumab"
            },
            {
              "key": "licensee",
              "value": "Huadong Medicine"
            },
            {
              "key": "territory",
              "value": "Asia Pacific Region, Excluding Japan"
            },
            {
              "key": "program",
              "value": "Vixarelimab"
            },
            {
              "key": "licensee",
              "value": "Roche and Genentech"
            },
            {
              "key": "territory",
              "value": "Worldwide"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 9,
          "title": "Overview of ARCALYST and Its Development",
          "data": [
            {
              "key": "Product Name",
              "value": "ARCALYST"
            },
            {
              "key": "Description",
              "value": "Interleukin-1α and interleukin-1β cytokine trap used for treatment of recurrent pericarditis and other conditions."
            },
            {
              "key": "FDA Approval Date",
              "value": "March 2021"
            },
            {
              "key": "Indications",
              "value": "Recurrent pericarditis, CAPS (Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome), DIRA."
            },
            {
              "key": "Orphan Drug Designation",
              "value": "Granted in 2020 for recurrent pericarditis."
            },
            {
              "key": "Breakthrough Therapy Designation",
              "value": "Granted in 2019 for recurrent pericarditis."
            },
            {
              "key": "Sales Responsibility Transfer Date",
              "value": "March 2021"
            },
            {
              "key": "Patient Population",
              "value": "Approximately 40,000 patients in the U.S. for recurrent pericarditis."
            },
            {
              "key": "Clinical Trial Name",
              "value": "RHAPSODY"
            },
            {
              "key": "Clinical Trial Significance",
              "value": "Met primary and all major secondary endpoints with statistical significance."
            },
            {
              "key": "Long-Term Data Presentation Date",
              "value": "November 2022, American Heart Association’s Scientific Sessions."
            },
            {
              "key": "Exclusive Rights Granted To",
              "value": "Huadong for development and commercialization in Asia Pacific region."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 10,
          "title": "Mechanism of Action and Background on ARCALYST",
          "data": [
            {
              "key": "Product Name",
              "value": "ARCALYST"
            },
            {
              "key": "Indications",
              "value": "treatment of recurrent pericarditis"
            },
            {
              "key": "Approval Date",
              "value": "March 2021"
            },
            {
              "key": "Target Population",
              "value": "Adults and children 12 years and older"
            },
            {
              "key": "Market Size",
              "value": "Approximately 40,000 patients in the US per year"
            },
            {
              "key": "Core Target Population",
              "value": "Approximately 14,000 patients with persistent disease and inadequate response to therapy"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 11,
          "title": "Current Treatment Landscape for Recurrent Pericarditis and Our Solution",
          "data": [
            {
              "key": "Product Name",
              "value": "ARCALYST"
            },
            {
              "key": "Product Type",
              "value": "recombinant fusion protein"
            },
            {
              "key": "Indication",
              "value": "recurrent pericarditis"
            },
            {
              "key": "Approval Status",
              "value": "FDA-approved"
            },
            {
              "key": "Commercial Launch Year",
              "value": "2021"
            },
            {
              "key": "Commercial Strategy",
              "value": "focused and targeted approach with specialty salesforce"
            },
            {
              "key": "Salesforce Size",
              "value": "approximately 50 representatives"
            },
            {
              "key": "Key Focus Areas",
              "value": "high-volume accounts, prescribers, patient access, community education"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 12,
          "title": "KPL-404 Overview and Mechanism of Action",
          "data": [
            {
              "key": "Product Name",
              "value": "KPL-404"
            },
            {
              "key": "Description",
              "value": "Investigational monoclonal antibody inhibitor of CD40-CD154 interaction."
            },
            {
              "key": "Strategic Imperatives",
              "value": "1. Establish the unmet need for recurrent pericarditis patients. 2. Ensure ARCALYST is viewed as the product of choice for treatment. 3. Work on reimbursement for patient access. 4. Build patient support programs."
            },
            {
              "key": "Clinical Trial Phase",
              "value": "Phase 1 and Phase 2"
            },
            {
              "key": "Trial Result Summary",
              "value": "Positive final data from Phase 1 trial; well-tolerated with no serious adverse reactions."
            },
            {
              "key": "Enrolment Status",
              "value": "Completed for second and final cohort of the multiple ascending dose portion."
            },
            {
              "key": "Expected Data Availability",
              "value": "First half of 2024."
            },
            {
              "key": "Potential Indications",
              "value": "Autoimmune diseases, including rheumatoid arthritis, type 1 diabetes, lupus, multiple sclerosis."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 15,
          "title": "Mavrilimumab Product Development Overview",
          "data": [
            {
              "key": "Clinical Trials",
              "value": "Completed extensive Phase 1 and Phase 2 clinical program for RA, achieving defined endpoints."
            },
            {
              "key": "FDA Designation",
              "value": "Orphan Drug designation granted for Mavrilimumab for GCA."
            },
            {
              "key": "Current Status",
              "value": "No plan to initiate Phase 3 trial of mavrilimumab in GCA."
            },
            {
              "key": "Exclusive Rights",
              "value": "Granted to Huadong for development in Asia Pacific, excluding Japan."
            },
            {
              "key": "Mechanism of Action",
              "value": "Designed to inhibit GM-CSF signaling."
            },
            {
              "key": "Discovery Focus",
              "value": "Directed toward wholly owned molecules for new treatment targets."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 22,
          "title": "Competitive Products and Clinical Development Pipeline",
          "data": [
            {
              "key": "Overview",
              "value": "The document outlines substantial competition in the pharmaceutical market, highlighting the risk that competitors may discover, develop, or commercialize drugs more successfully."
            },
            {
              "key": "Target Indication",
              "value": "Recurrent Pericarditis (and other related inflammatory diseases)"
            },
            {
              "key": "Marketed and Development Products",
              "value": "ARCALYST is mentioned; Anakinra (KINERET) is approved for RA, CAPS, and DIRA; Canakinumab (ILARIS) is approved for several conditions (CAPS, TRAPS, HIDS, MKD, FMF, Still’s Disease, SJIA). Competing development programs include RPH-104 (Phase 2, IL-1α/IL-1β inhibition) and an oral cannabidiol (Phase 2) by Cardiol Therapeutics."
            },
            {
              "key": "Other Development Programs",
              "value": "Multiple agents targeting IL-1 pathways and the NLRP3 inflammasome are listed, including VTX2735, VTX3232, ZYIL-1, HT-6184, OLT1177, DFV-890, Selnoflast, NT-0167, NT-0796, Somalix, and Onzomelid. Additional programs targeting IL-1α modulation and the CD40/CD154 costimulatory pathway (e.g., KPL-404, CFZ-533/iscalimab for subcutaneous administration, and others for intravenous or potential subcutaneous administration) are also described."
            },
            {
              "key": "Mechanisms of Action",
              "value": "Descriptions include dual IL-1α and IL-1β inhibition, IL-1β inhibition alone, IL-1α inhibition alone, and antagonism of the CD40/CD154 co-stimulatory pathway."
            },
            {
              "key": "Competitive Implications",
              "value": "The varied development stages and mechanisms underline the competitive landscape in targeting recurrent pericarditis and related conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 25,
          "title": "Table of Contents - FDA Submission and Clinical Development Process",
          "data": [
            {
              "key": "IND Submission",
              "value": "Submission to FDA of an IND which must become effective before human clinical trials may begin."
            },
            {
              "key": "IRB/Ethics Approval",
              "value": "Approval by an independent institutional review board (IRB) or ethics committee at each clinical trial site before initiation of each trial."
            },
            {
              "key": "Clinical Trials Requirements",
              "value": "Performance of adequate and well-controlled human clinical trials in accordance with IND regulations and Good Clinical Practices (GCPs) to evaluate the safety and efficacy of the investigational product."
            },
            {
              "key": "BLA Submission for Marketing Approval",
              "value": "Submission to FDA of a Biologics License Application (BLA) that includes substantive evidence from preclinical testing and clinical trials regarding safety, purity, and potency."
            },
            {
              "key": "FDA Filing Determination",
              "value": "FDA determination within 60 days on whether to file the BLA for review."
            },
            {
              "key": "Manufacturing Inspections",
              "value": "Satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facilities to assess compliance with current Good Manufacturing Practices (cGMPs)."
            },
            {
              "key": "Site Audits",
              "value": "Potential FDA audits of the preclinical or clinical trial sites that generated the data in support of the BLA."
            },
            {
              "key": "User Fees",
              "value": "Payment of user fees for FDA review of the BLA."
            },
            {
              "key": "FDA Advisory Committee Review",
              "value": "Completion of an FDA advisory committee review (if applicable) as part of the FDA review and approval process before any commercial marketing or sale."
            },
            {
              "key": "Preclinical Studies and CMC Evaluations",
              "value": "Rigorous preclinical testing including laboratory evaluations, toxicity trials in animals, and CMC (Chemistry, Manufacturing, and Controls) assessments must be conducted, with all results submitted as part of the IND."
            },
            {
              "key": "IND Effective Timeline",
              "value": "An IND automatically becomes effective 30 days after FDA receipt unless concerns (e.g., CMC or preclinical issues) result in a clinical hold."
            },
            {
              "key": "Clinical Trial Protocols",
              "value": "Detailed clinical trial protocols including dosing, subject selection, inclusion/exclusion criteria, and safety/efficacy monitoring must be submitted to the FDA; subsequent protocol amendments are also subject to review."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 28,
          "title": "Regulatory Guidelines and Marketing Application Requirements",
          "data": [
            {
              "key": "Submission Type",
              "value": "Marketing application for a product with a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration"
            },
            {
              "key": "Pediatric Study Plan",
              "value": "Submit an initial Pediatric Study Plan (iPSP) within 60 days of an end-of-Phase 2 meeting or as early as practicable before beginning Phase 3 or Phase 2/3 trials. The plan must outline pediatric studies, including trial objectives, design, age groups, endpoints, and statistical approach or provide a justification for omitting details."
            },
            {
              "key": "FDA Review Process",
              "value": "After evaluating a BLA, the FDA issues either an approval letter authorizing commercial marketing with specified prescribing information or a Complete Response Letter detailing deficiencies and additional requirements."
            },
            {
              "key": "Post-Approval Requirements",
              "value": "Approval is subject to conditions such as precise indications, labeling changes, post-approval trials (including Phase 4), safety surveillance, and potential risk management measures (REMS) that may restrict marketing and affect profitability."
            },
            {
              "key": "Orphan Drug Designation",
              "value": "Under the Orphan Drug Act, designation is granted for drugs intended to treat rare diseases, providing financial incentives, grant funding, tax advantages, fee waivers, and potential market exclusivity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 33,
          "title": "Marketing Authorization",
          "data": [
            {
              "key": "Overview",
              "value": "Describes the regulatory framework in the EU for marketing authorization of medicinal products. Outlines that a medicinal product can only be marketed after obtaining a marketing authorization (MA) through submission of a marketing authorization application (MAA)."
            },
            {
              "key": "MA Types",
              "value": "Two types of MAs: 'Centralized MAs' issued by the European Commission based on the CHMP opinion, and 'National MAs' issued by individual EU member states, including procedures such as Mutual Recognition and Decentralized Procedures."
            },
            {
              "key": "Centralized Procedure",
              "value": "Compulsory for products like those from biotechnological processes, orphan medicinal products, advanced-therapy medicines, and products with a new active substance for specific diseases. Evaluation has a maximum timeframe of 210 days (excluding clock stops), with possibility of accelerated review in exceptional cases (150 days)."
            },
            {
              "key": "National and Decentralized Procedures",
              "value": "National MAs cover individual member states. A national MA can be recognized in other states, or if not previously authorized, approval can be pursued simultaneously via the decentralized procedure by submitting an identical dossier."
            },
            {
              "key": "PRIME Initiative",
              "value": "Launched by the EMA in March 2016 to support development of medicines that address unmet medical needs. Benefits include early regulatory dialogue, guidance on clinical trial design, and potential accelerated MAA assessment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 73,
          "title": "Potential for Biosimilar Competition and Regulatory Challenges",
          "data": [
            {
              "key": "Key Regulation",
              "value": "BPCIA (Biologics Control Act) provides an abbreviated approval pathway for biosimilars."
            },
            {
              "key": "Exclusivity Period",
              "value": "12 years exclusivity from reference product's approval for biosimilars."
            },
            {
              "key": "Regulatory Uncertainty",
              "value": "Complexity of the law creates uncertainty regarding its implementation."
            },
            {
              "key": "Market Impact",
              "value": "Opportunity for biosimilar competition for products like ARCALYST after exclusivity."
            },
            {
              "key": "Orphan Drug Designation",
              "value": "May seek Orphan Drug designation for product candidates, but benefits may not be guaranteed."
            },
            {
              "key": "Future Products",
              "value": "Potential for future products to qualify for 12-year exclusivity, subject to regulatory changes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 75,
          "title": "Product Designations and Approvals",
          "data": [
            {
              "key": "Fast Track Designation",
              "value": "Potential for rolling review of a BLA by the FDA."
            },
            {
              "key": "Breakthrough Therapy Designation",
              "value": "FDA may review sections of the BLA on a rolling basis."
            },
            {
              "key": "PRIME designation",
              "value": "EMA’s scheme aimed at enhancing support for medicines targeting unmet medical needs."
            },
            {
              "key": "Conditional Marketing Authorization",
              "value": "Granted when all safety and efficacy data are not available."
            },
            {
              "key": "Accelerated Assessment",
              "value": "May reduce assessment time from 210 days to 150 days."
            },
            {
              "key": "Exceptional Circumstances Marketing Authorization",
              "value": "Granted when comprehensive efficacy data cannot be provided."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 136,
          "title": "Capital Expenditure and Funding Requirements Discussion",
          "data": [
            {
              "key": "Operating Expense Funding",
              "value": "Existing cash, cash equivalents and short-term investments are expected to fund operating expenses and capital expenditure requirements for at least the next 12 months."
            },
            {
              "key": "Capital Expenditure Requirements",
              "value": "The company plans to invest in expanding operational, financial, and management systems; and expects significant expenses in product manufacturing, sales, marketing, and distribution."
            },
            {
              "key": "Additional Funding Options",
              "value": "There may be a need to pursue additional capital through public or private equity offerings, debt financings, licensing, collaboration, or strategic transactions, including in-licenses or acquisitions."
            },
            {
              "key": "Risks",
              "value": "Failure to raise additional funds could force delays or reductions in R&D programs, commercialization efforts, or overall operations."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 1,
          "title": "Financial Statements Table of Contents",
          "data": [
            {
              "key": "analysis_page",
              "value": "149"
            },
            {
              "key": "table_title",
              "value": "Financial Statements Table of Contents"
            },
            {
              "key": "table_summary",
              "value": "This table represents a table of contents for a financial report, listing various financial statements and their corresponding page numbers. It includes standard financial documents such as balance sheets, income statements, cash flow statements, and accompanying notes. The documents are arranged sequentially from pages F-2 through F-9."
            },
            {
              "key": "table_documents",
              "value": "Report of Independent Registered Public Accounting Firm (PCAOB ID 238) (~ be F-2), Consolidated Balance Sheets (F-5), Consolidated Statements of Operations and Comprehensive Income (Loss) (F-6), Consolidated Statements of Shareholders' Equity (F-7), Consolidated Statements of Cash Flows (F-8), Notes to Consolidated Financial Statements (F-9)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 125,
          "title": "Table of Contents - ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS",
          "data": [
            {
              "key": "description",
              "value": "This section outlines the management's discussion and analysis of the company's financial condition and results of operations. It emphasizes the need to consider forward-looking statements, which are subject to risks identified in SEC filings (e.g., Item 1A 'Risk Factors')."
            },
            {
              "key": "business_overview",
              "value": "The document provides an overview of the biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines. It details the portfolio of immune-modulating assets (ARCALYST®, KPL-404, and mavrilimumab), including licensing deals, acquisitions (e.g., acquisition of Primatope for KPL-404), and commercialization strategy in various global regions."
            },
            {
              "key": "regulatory_and_forward_looking",
              "value": "Contains forward-looking statements that involve risks and uncertainties as detailed in related SEC filings."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 126,
          "title": "Financial Performance, Licensing, and Revenue Recognition Details",
          "data": [
            {
              "key": "Investigational Product",
              "value": "Vixarelimab is an investigational monoclonal antibody inhibitor targeting OSMRβ. An exclusive worldwide license was granted to Genentech in September 2022 for its development and commercialization."
            },
            {
              "key": "Clinical Trial",
              "value": "A Phase 2b dose-ranging clinical trial for vixarelimab in the treatment of prurigo nodularis is in progress."
            },
            {
              "key": "Reliance on ARCALYST",
              "value": "Sustained profitability heavily depends on the continued commercialization of ARCALYST and the development of current/future product candidates."
            },
            {
              "key": "Net Income (2022)",
              "value": "$183.4 million recognized for the twelve months ended December 31, 2022, primarily from out-licensing activities and deferred tax asset valuation release."
            },
            {
              "key": "Net Loss (2021)",
              "value": "$157.9 million reported for the year ended December 31, 2021."
            },
            {
              "key": "Accumulated Deficit",
              "value": "$492.0 million as of December 31, 2022."
            },
            {
              "key": "Cash, Cash Equivalents and Short-term Investments",
              "value": "$190.6 million as of December 31, 2022, expected to fund operations for at least the next 12 months."
            },
            {
              "key": "Product Revenue Recognition",
              "value": "Revenue from ARCALYST is recognized at the point in time when control passes to the customer, with adjustments for discounts, rebates, and other allowances as per ASC 606."
            },
            {
              "key": "License and Collaboration Revenue",
              "value": "Includes upfront payments, royalty revenue, and milestone payments related to out-licensing and collaboration agreements."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 130,
          "title": "Financial Performance Comparison",
          "data": [
            {
              "key": "Product revenue, net (2022)",
              "value": "122524"
            },
            {
              "key": "Product revenue, net (2021)",
              "value": "38544"
            },
            {
              "key": "Product revenue change (2022 vs 2021)",
              "value": "Increase of 83980, which is 218%"
            },
            {
              "key": "License and collaboration revenue (2022)",
              "value": "97656"
            },
            {
              "key": "License and collaboration revenue (2021)",
              "value": "0"
            },
            {
              "key": "License revenue details",
              "value": "Includes $10.0M from the mavrilimumab Huadong Collaboration Agreement and $87.7M from the Genentech License Agreement; future deferred revenue expected from both agreements"
            },
            {
              "key": "Total revenue (2022)",
              "value": "220180"
            },
            {
              "key": "Total revenue (2021)",
              "value": "38544"
            },
            {
              "key": "Total revenue change (2022 vs 2021)",
              "value": "Increase of 181636, representing a 471% increase"
            },
            {
              "key": "Total operating expenses (2022)",
              "value": "210407"
            },
            {
              "key": "Total operating expenses (2021)",
              "value": "195180"
            },
            {
              "key": "Operating expenses change (2022 vs 2021)",
              "value": "Increase of 15227, approximately 8%"
            },
            {
              "key": "Income (loss) from operations",
              "value": "9773 in 2022 versus -156636 in 2021; change of 166409"
            },
            {
              "key": "Net income (loss)",
              "value": "183363 in 2022 versus -157924 in 2021; change of 341287"
            },
            {
              "key": "Summary",
              "value": "The table shows a significant financial turnaround from 2020 to 2022. Total revenue rose dramatically, driven by growth in both product revenue and license/collaboration revenue. The company moved from a net loss in 2021 to net income in 2022, while operating expenses saw a modest increase."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 131,
          "title": "Financial Expenses Analysis",
          "data": [
            {
              "key": "Cost of Goods Sold",
              "value": "Upon the first sale beginning in April 2021, cost of goods sold for ARCALYST was generated. For the year ended December 31, 2022, COGS was $22.9 million compared to $9.1 million in 2021, an increase of $13.8 million. Included in these figures are amortization amounts for the Regeneron payment of $1.0 million in 2022 and $0.8 million in 2021. The increase is primarily due to higher sales volume and an increased average cost per unit from previously expensed, repurposed clinical supply."
            },
            {
              "key": "Collaboration Expenses",
              "value": "Collaboration with Regeneron resulted in expenses of $24.1 million in 2022 versus $0.8 million in 2021, an increase of $23.2 million. This increase is largely due to higher sales revenue from ARCALYST and a $6.0 million payment under the rilonacept Huadong Collaboration Agreement. Future collaboration expenses are expected to continue in line with ARCALYST sales."
            },
            {
              "key": "Research and Development Expenses",
              "value": "R&D expenses decreased from $112.0 million in 2020 to $99.3 million in 2021, and further to $65.5 million in 2022 (a decrease of $33.8 million from 2021). Direct costs for the rilonacept program were $25.7 million in 2020, $10.8 million in 2021, and $0.9 million in 2022. A detailed table further breaks down R&D spending by program, noting significant declines (e.g., a 92% decrease for Rilonacept and a shift in personnel-related expenses) and notable increases like a 118% rise in expenses for the KPL-404 program."
            },
            {
              "key": "Additional Context",
              "value": "Expenses in 2022 were primarily associated with the close-out of the RHAPSODY trial, while in 2021 costs related to completing RHAPSODY and transitioning to its long-term extension, and in 2020 included execution of the trial, a regulatory milestone payment, and supply chain costs."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 132,
          "title": "Financial Performance and Expense Breakdown – R&D and SG&A Expenses",
          "data": [
            {
              "key": "KPL-404 Program Direct Costs 2022",
              "value": "$11.6 million"
            },
            {
              "key": "KPL-404 Program Direct Costs 2021",
              "value": "$5.3 million"
            },
            {
              "key": "KPL-404 Program Direct Costs 2020",
              "value": "$3.7 million"
            },
            {
              "key": "KPL-404 Phase 2 Trial (RA) Expense Notes",
              "value": "Expenses in 2022 related to first two cohorts of Phase 2 trial in RA (initiated Dec 2021); 2021 expenses mainly for manufacturing and start-up activities; 2020 expenses for Phase 1 trial including toxicology costs"
            },
            {
              "key": "Mavrilimumab Program Direct Costs 2022",
              "value": "$6.4 million"
            },
            {
              "key": "Mavrilimumab Program Direct Costs 2021",
              "value": "$30.7 million"
            },
            {
              "key": "Mavrilimumab Program Direct Costs 2020",
              "value": "$25.9 million"
            },
            {
              "key": "Mavrilimumab Expense Notes",
              "value": "2022 expenses mainly related to wind-down activities of Phase 3 COVID-19 ARDS trial; 2021 expenses related to Phase 2/3 trial; 2020 expenses include Phase 2 trial in GCA and initiation of COVID-19 ARDS trial"
            },
            {
              "key": "Vixarelimab Program Direct Costs 2022",
              "value": "$12.8 million"
            },
            {
              "key": "Vixarelimab Program Direct Costs 2021",
              "value": "$10.7 million"
            },
            {
              "key": "Vixarelimab Program Direct Costs 2020",
              "value": "$8.8 million"
            },
            {
              "key": "Vixarelimab Expense Notes",
              "value": "2022 expenses for ongoing Phase 2b trial in prurigo nodularis; 2021 for initiation of Phase 2b trial; 2020 for Phase 2a trial and exploratory Phase 2 trial in chronic pruritus"
            },
            {
              "key": "Unallocated R&D Expenses 2022",
              "value": "$33.9 million"
            },
            {
              "key": "Unallocated R&D Expenses 2021",
              "value": "$41.7 million"
            },
            {
              "key": "Unallocated R&D Expenses 2020",
              "value": "$47.9 million"
            },
            {
              "key": "Unallocated R&D Expense Adjustments",
              "value": "2022 decrease of $7.8 million due to reduced late-stage trial activity and reclassification of ARCALYST supply chain and quality costs; 2021 decrease of $6.2 million partly due to ARCALYST cost adjustments"
            },
            {
              "key": "SG&A Expenses 2022",
              "value": "$98.0 million"
            },
            {
              "key": "SG&A Expenses 2021",
              "value": "$85.9 million"
            },
            {
              "key": "SG&A Expenses 2020",
              "value": "$45.3 million"
            },
            {
              "key": "SG&A Personnel Share-based Compensation 2022",
              "value": "$17.7 million"
            },
            {
              "key": "SG&A Personnel Share-based Compensation 2021",
              "value": "$16.5 million"
            },
            {
              "key": "SG&A Personnel Share-based Compensation 2020",
              "value": "$12.0 million"
            },
            {
              "key": "Other Income 2022",
              "value": "$1.3 million"
            },
            {
              "key": "Other Income 2021",
              "value": "$0.1 million"
            },
            {
              "key": "Other Income 2020",
              "value": "$1.1 million"
            },
            {
              "key": "Other Income Notes",
              "value": "2022 increase driven by higher interest rates on U.S. Treasury notes and higher short term investment balances; 2021-2020 adjustments reflect changes in interest rates and investment balances"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 133,
          "title": "Table of Contents Benefit (Provision) for Income Taxes",
          "data": [
            {
              "key": "Income Tax Benefit (2022)",
              "value": "$172.3 million, primarily from the release of the valuation allowance on UK deferred tax assets"
            },
            {
              "key": "UK Deferred Tax Asset Details",
              "value": "Tax basis of intangible assets transferred to UK subsidiary in 2021 and 2022; release of valuation allowance indicates future higher income tax expense"
            },
            {
              "key": "Income Tax Provision (2021)",
              "value": "$1.4 million relating primarily to U.S. current taxes adjusted for FDII deduction and U.S. federal/state research credits"
            },
            {
              "key": "Deferred Tax Assets (2021)",
              "value": "Full valuation allowance of $127.9 million maintained as of December 31, 2021"
            },
            {
              "key": "Income Tax Provision (2020)",
              "value": "$5.2 million relating to recognition of the valuation allowance and current year tax expense"
            },
            {
              "key": "Liquidity (2022)",
              "value": "Cash, cash equivalents and short-term investments totaled $190.6 million as of December 31, 2022"
            },
            {
              "key": "Net Income/ Loss",
              "value": "2022: $183.4 million; 2021: ($157.9) million; 2020: ($161.4) million"
            },
            {
              "key": "Follow-On Offering - May 18, 2020",
              "value": "2,760,000 Class A common shares at $18.25 per share plus a concurrent private placement of 1,600,000 Class A1 common shares, aggregate gross proceeds of $79.6 million, net proceeds of $74.5 million"
            },
            {
              "key": "Follow-On Offering - July 24, 2020",
              "value": "5,952,381 Class A common shares at $21.00 per share and a concurrent private placement of 1,428,572 Class A1 common shares, aggregate gross proceeds of $155.0 million, estimated net proceeds of $146.0 million"
            },
            {
              "key": "Other Financial Commitments",
              "value": "Lease agreements for office, laboratory space, and vehicles with total future lease payments of $6.2 million, $3.5 million due within one year; milestone payments, royalties, and annual maintenance fees under third-party agreements"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 134,
          "title": "Cash Flow Statement Summary 2020-2022",
          "data": [
            {
              "key": "Net cash provided by (used in) operating activities 2022",
              "value": "5807"
            },
            {
              "key": "Net cash provided by (used in) operating activities 2021",
              "value": "-126298"
            },
            {
              "key": "Net cash provided by (used in) operating activities 2020",
              "value": "-136532"
            },
            {
              "key": "Net cash provided by (used in) investing activities 2022",
              "value": "-8078"
            },
            {
              "key": "Net cash provided by (used in) investing activities 2021",
              "value": "128635"
            },
            {
              "key": "Net cash provided by (used in) investing activities 2020",
              "value": "-23444"
            },
            {
              "key": "Net cash provided by financing activities 2022",
              "value": "2516"
            },
            {
              "key": "Net cash provided by financing activities 2021",
              "value": "5885"
            },
            {
              "key": "Net cash provided by financing activities 2020",
              "value": "227086"
            },
            {
              "key": "Net increase in cash and cash equivalents and restricted cash 2022",
              "value": "245"
            },
            {
              "key": "Net increase in cash and cash equivalents and restricted cash 2021",
              "value": "8222"
            },
            {
              "key": "Net increase in cash and cash equivalents and restricted cash 2020",
              "value": "67110"
            },
            {
              "key": "Summary",
              "value": "This table presents a three-year cash flow summary from 2020 to 2022 (in thousands). Notable observations include a significant improvement in operating activities, a substantial decrease in financing activities, and a marked decline in the overall net increase in cash."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 135,
          "title": "Statement of Cash Flows and Funding Requirements",
          "data": [
            {
              "key": "Investing Activities 2021",
              "value": "Provided $128.6 million of cash, consisting of $306.3 million from maturities of short-term investments, offset by $157.3 million of purchases of short-term investments and $20.0 million related to a regulatory milestone payment under the Regeneron Agreement."
            },
            {
              "key": "Investing Activities 2020",
              "value": "Used $23.4 million of cash, with $430.2 million spent on purchases of short-term investments and $0.3 million on purchases of property and equipment, partially offset by $407.1 million from maturities of short-term investments."
            },
            {
              "key": "Financing Activities 2022/2021",
              "value": "Net cash provided by financing activities was $2.5 million and $5.9 million for the respective years, primarily from the exercise of employee share options and the 2018 Employee Share Purchase Plan (2018 ESPP)."
            },
            {
              "key": "Financing Activities 2020",
              "value": "Net cash provided of $227.1 million, including $220.5 million from the issuance and sale of Class A common shares (with related follow-on public offerings and private placements) and $6.6 million from share options and the 2018 ESPP."
            },
            {
              "key": "Funding Requirements",
              "value": "The company anticipates significant expenses associated with commercializing ARCALYST and advancing product candidates through preclinical and clinical development, regulatory approvals, manufacturing enhancements, and sales infrastructure expansion. Additional costs may arise from in-licensing, acquisitions, milestone, royalty, and other payments under existing or future agreements."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 140,
          "title": "Changes in Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Disclosure Statement",
              "value": "There was no change in our internal control over financial reporting during the fourth quarter of the year ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting."
            },
            {
              "key": "Regulatory References",
              "value": "Rules 13a-15(f) and 15d-15(f) under the Exchange Act"
            },
            {
              "key": "ITEM 9B",
              "value": "Not applicable"
            },
            {
              "key": "ITEM 9C",
              "value": "Not applicable"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 142,
          "title": "Table of Contents PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES",
          "data": [
            {
              "key": "Financial Statements",
              "value": "See the “Index to Consolidated Financial Statements” on page F-1 for the list of financial statements filed as part of this report."
            },
            {
              "key": "Financial Statement Schedules",
              "value": "All schedules have been omitted because they are not required or because the required information is provided in the Consolidated Financial Statements or Notes thereto."
            },
            {
              "key": "Exhibits",
              "value": "See Exhibit Index."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 150,
          "title": "Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of Kiniksa Pharmaceuticals, Ltd.",
          "data": [
            {
              "key": "Report Type",
              "value": "Independent Auditor's Report"
            },
            {
              "key": "Company",
              "value": "Kiniksa Pharmaceuticals, Ltd."
            },
            {
              "key": "Financial Statements Covered",
              "value": "Consolidated balance sheets, consolidated statements of operations and comprehensive income (loss), shareholders’ equity, and cash flows"
            },
            {
              "key": "Audit Date/Period",
              "value": "As of December 31, 2022 and 2021; Three-year period ended December 31, 2022"
            },
            {
              "key": "Auditor's Opinion",
              "value": "The consolidated financial statements present fairly, in all material respects, the financial position of the Company and its results of operations and cash flows in conformity with US GAAP."
            },
            {
              "key": "Audit Basis",
              "value": "Audits conducted in accordance with PCAOB standards; responsibility of management for the financial statements; procedures performed to assess risk of material misstatement due to error or fraud."
            },
            {
              "key": "Critical Audit Matters",
              "value": "Identified and communicated to the audit committee; do not alter the overall opinion on the consolidated financial statements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 151,
          "title": "Realizability of UK Deferred Tax Assets and Accrued Research and Development Costs",
          "data": [
            {
              "key": "UK Deferred Tax Assets Income Tax Benefit",
              "value": "$185.5 million for the year ended December 31, 2022"
            },
            {
              "key": "Deferred Tax Assets Context",
              "value": "Result of differences between consolidated financial statement and tax basis of intangible assets transferred to Kiniksa UK using enacted tax rates"
            },
            {
              "key": "Management Judgment",
              "value": "Significant judgment in assessing positive and negative evidence, including cumulative UK income, ARCALYST sales estimates, and future profitability"
            },
            {
              "key": "Audit Procedures Emphasis",
              "value": "High auditor judgment and subjectivity in testing management's process for realizability and valuation allowance release"
            },
            {
              "key": "Accrued Research and Development Costs",
              "value": "$8.4 million as of December 31, 2022, based on estimates of outstanding obligations under R&D-related contracts"
            },
            {
              "key": "Accrual Estimation Factors",
              "value": "Based on progress towards completion, invoicing to date, communication from research institutions, and contract details"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 154,
          "title": "Revenue and Financial Statement",
          "data": [
            {
              "key": "Category: Revenue",
              "value": "2022: 220180, 2021: 38544, 2020: 0; Breakdown - Product revenue: 122524, License and collaboration revenue: 97656"
            },
            {
              "key": "Category: Operating Expenses",
              "value": "2022: 210407, 2021: 195180, 2020: 157363; Breakdown - Cost of goods sold: 22895, Collaboration expenses: 24071, Research and development: 65490, Selling, general and administrative: 97951"
            },
            {
              "key": "Category: Net Income/Loss",
              "value": "2022: 183363, 2021: -157924, 2020: -161381"
            },
            {
              "key": "Category: Per Share Data (2022)",
              "value": "Basic EPS: 2.64, Diluted EPS: 2.60, Weighted Avg Shares Basic: 69382275, Weighted Avg Shares Diluted: 70421322"
            },
            {
              "key": "Summary",
              "value": "The financial statement shows significant performance improvement from 2020 to 2022. Total revenue increased substantially from $38.5M in 2021 to $220.2M in 2022, driven by both product revenue and license/collaboration revenue. The company turned profitable in 2022 with a net income of $183.4M compared to losses in previous years. Earnings per share became positive, and operating expenses increased at a slower pace than revenue growth, indicating improved operational efficiency."
            },
            {
              "key": "Additional Financial Details",
              "value": "Other items mentioned include Income (loss) from operations, Other income, Income before income taxes, Benefit (provision) for income taxes, Net income per share (basic and diluted), and Weighted average common shares outstanding, along with comprehensive income details as noted in the accompanying notes."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 156,
          "title": "KINIKSA PHARMACEUTICALS, LTD. CONSOLIDATED STATEMENTS OF CASH FLOWS - Cash Flow Statement",
          "data": [
            {
              "key": "Operating Activities (2022)",
              "value": "5807"
            },
            {
              "key": "Operating Activities (2021)",
              "value": "-226298"
            },
            {
              "key": "Operating Activities (2020)",
              "value": "-36532"
            },
            {
              "key": "Investing Activities (2022)",
              "value": "-8078"
            },
            {
              "key": "Investing Activities (2021)",
              "value": "128635"
            },
            {
              "key": "Investing Activities (2020)",
              "value": "-23444"
            },
            {
              "key": "Financing Activities (2022)",
              "value": "2516"
            },
            {
              "key": "Financing Activities (2021)",
              "value": "5885"
            },
            {
              "key": "Financing Activities (2020)",
              "value": "227086"
            },
            {
              "key": "Net Income (Loss) (2022)",
              "value": "183363"
            },
            {
              "key": "Net Income (Loss) (2021)",
              "value": "-157924"
            },
            {
              "key": "Net Income (Loss) (2020)",
              "value": "-161381"
            },
            {
              "key": "Cash and Equivalents (End of Period) (2022)",
              "value": "122715"
            },
            {
              "key": "Cash and Equivalents (End of Period) (2021)",
              "value": "122470"
            },
            {
              "key": "Cash and Equivalents (End of Period) (2020)",
              "value": "114248"
            },
            {
              "key": "Summary",
              "value": "This table presents a detailed cash flow statement covering the years 2020-2022. Notable observations include a significant turnaround in net income from losses in 2020-2021 to a profit of $183,363 in 2022, improvement in operating activities from negative values in previous years to positive $5,807 in 2022, and a major decrease in financing activities from $227,086 in 2020 to $2,516 in 2022. Overall, the cash position remained relatively stable between 2021 and 2022."
            },
            {
              "key": "Right-of-use Asset - Operating Lease Obligation (Latest)",
              "value": "$2,876"
            },
            {
              "key": "Right-of-use Asset - Operating Lease Obligation (Prior)",
              "value": "$1,619"
            },
            {
              "key": "Additional Note",
              "value": "F-8 6,039"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 159,
          "title": "Table of Contents KINIKSA PHARMACEUTICALS, LTD. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)",
          "data": [
            {
              "key": "Summary of Significant Accounting Policies",
              "value": "Outlines the accounting treatment for cash and cash equivalents, short-term investments, credit risk concentrations, and restricted cash."
            },
            {
              "key": "Cash and Cash Equivalents",
              "value": "Classifies bank deposits, money market funds, and temporarily invested cash instruments (including U.S. Treasury notes) as cash equivalents."
            },
            {
              "key": "Short-Term Investments",
              "value": "Invests excess cash in U.S. Treasury notes and money market funds, reported as available-for-sale debt securities with fair value adjustments and unrealized gains/losses recorded in accumulated other comprehensive income."
            },
            {
              "key": "Concentrations of Credit Risk",
              "value": "Highlights the risk exposure from cash, cash equivalents, and short-term investments held at two financial institutions, along with trade receivables mainly from product revenue in the United States."
            },
            {
              "key": "Restricted Cash",
              "value": "Describes a previously restricted cash balance related to a lease letter of credit, released to operating cash following the lease expiration."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 160,
          "title": "Notes to Consolidated Financial Statements (Continued) – Fair Value Measurements and Leases",
          "data": [
            {
              "key": "Fair Value Measurements",
              "value": "Assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exit price in an orderly transaction in the principal or most advantageous market."
            },
            {
              "key": "Valuation Hierarchy",
              "value": "Measurements use a three-level hierarchy: Level 1 (quoted prices in active markets), Level 2 (observable inputs such as quoted prices for similar assets), and Level 3 (unobservable inputs like pricing models and discounted cash flow methodologies)."
            },
            {
              "key": "Cash Equivalents and Short-term Investments",
              "value": "These are determined at fair value based on Level 1 and Level 2 inputs."
            },
            {
              "key": "Leases Accounting",
              "value": "The Company assesses lease arrangements under ASC 842 to determine if an arrangement contains a lease, classifying leases as operating or finance leases. Right-of-use assets and lease liabilities are recorded based on the present value of minimum future lease payments, except for leases with a term of one year or less which are expensed on a straight-line basis."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 161,
          "title": "Notes to Consolidated Financial Statements – Property, Equipment, and Inventory",
          "data": [
            {
              "key": "Lease Accounting Policy",
              "value": "In accordance with ASU 2016-02, lease components (e.g., land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.) are combined into a single lease component. The entire arrangement consideration is allocated to the lease component resulting in an operating right-of-use asset that is amortized on a straight-line basis."
            },
            {
              "key": "Property and Equipment Depreciation",
              "value": "Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives. Maintenance and repairs are expensed as incurred, and gains or losses on disposals are recognized in the consolidated statement of operations and comprehensive income."
            },
            {
              "key": "Asset Useful Life Schedule",
              "value": "A table provides useful life estimates: Computer hardware and software (3-5 years), Laboratory equipment (5 years), Furniture, fixtures and vehicles (5-7 years), and Leasehold improvements (useful life based on the shorter of estimated life or lease term)."
            },
            {
              "key": "Inventory Valuation",
              "value": "Inventories are stated at the lower of cost (using FIFO) or estimated net realizable value. Costs for inventory in clinical trials are expensed as research and development until regulatory approval is probable. Impairments are recorded in cost of sales when identified."
            },
            {
              "key": "Patient Assistance Program",
              "value": "Vials to be distributed free under the patient assistance program are recognized as a selling expense when labeled as free goods."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 162,
          "title": "Notes to Consolidated Financial Statements – Revenue Recognition",
          "data": [
            {
              "key": "Revenue Recognition Framework",
              "value": "ASC 606 outlines a five-step process: (i) identify the contract with the customer, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the payment to the obligations, and (v) recognize revenue when performance obligations are satisfied."
            },
            {
              "key": "Application of ASC 606",
              "value": "The Company applies the model only when it is probable that the consideration will be collected and determines distinct performance obligations accordingly."
            },
            {
              "key": "Point in Time Recognition",
              "value": "Generally, revenue is recognized when control of the product is transferred to the customer, typically upon shipment from a third-party logistics provider."
            },
            {
              "key": "Product Revenue – ARCALYST",
              "value": "Following FDA approval on March 18, 2021, product revenue from ARCALYST began in April 2021. ARCALYST is distributed through a network of authorized specialty pharmacies and distributors."
            },
            {
              "key": "Payment Terms",
              "value": "Payment terms are between 30 to 35 days."
            },
            {
              "key": "Variable Consideration",
              "value": "Revenue is recorded net of discounts, allowances, rebates, chargebacks, returns, copay assistance, and fees. Estimates are based on historical trends and contractual terms."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 163,
          "title": "Notes to Consolidated Financial Statements: Allowances, Accruals, and Revenue Adjustments",
          "data": [
            {
              "key": "Overview",
              "value": "Раскрытие учетной политики компании относительно оценки и признания вычетов из выручки, включая государственные скидки, возвраты, дисконтные соглашения и сборы за дистрибуцию."
            },
            {
              "key": "Government Chargebacks and Rebates",
              "value": "Описаны суммы, возвращаемые или возмещаемые государственными программами и другими структурами, основанные на договорных условиях, исторических данных и изменениях в рыночных тенденциях."
            },
            {
              "key": "Cash Discounts",
              "value": "Оценка скидок по наличным платежам, проводимая на основе договорных условий и ожиданий будущих платежных моделей клиентов."
            },
            {
              "key": "Specialty Pharmacy & Distributor Fees",
              "value": "Платежи специализированным аптекам и дистрибьюторам за управление запасами и передачу данных по продажам, с оценкой начислений на основе продаж и контрактных ставок."
            },
            {
              "key": "Sales Returns",
              "value": "Отражение возвратов продукции, признанных как уменьшение выручки, при условии возврата товара по причине истечения срока годности или повреждения."
            },
            {
              "key": "Estimation Process",
              "value": "Оценки проводятся ежеквартально с учетом исторических данных, смесей плательщиков, исследований рынка и иных внутренних и внешних источников."
            },
            {
              "key": "Revenue Impact",
              "value": "Все вычеты отражаются как уменьшение выручки или начисленные обязательства, в зависимости от характера начислений."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 164,
          "title": "Table of Contents - KINIKSA PHARMACEUTICALS, LTD. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)",
          "data": [
            {
              "key": "Sales Returns Estimation",
              "value": "Estimates based primarily on industry information, return rates for similar products, and contractual agreement terms; considers known/expected marketplace changes specific to ARCALYST."
            },
            {
              "key": "Shipping and Handling",
              "value": "Shipping and handling activities are treated as fulfillment activities and not as a separate performance obligation."
            },
            {
              "key": "Other Incentives",
              "value": "Includes a co-pay assistance program for eligible patients with commercial insurance in the U.S., reducing the financial responsibility for the purchase price up to a specified dollar amount."
            },
            {
              "key": "Collaboration Revenue",
              "value": "Revenue from collaboration arrangements is analyzed under ASC Topic 808 and ASC 606. It involves assessing joint operating activities, identifying performance obligations, allocating total consideration based on standalone selling prices, including variable consideration subject to milestone achievements, and recording adjustments on a cumulative catch-up basis."
            },
            {
              "key": "Revenue Recognition",
              "value": "Revenue is recognized as control of the promised goods or services transfers to the collaboration partner either at a point in time or over time, with progress measured accordingly."
            },
            {
              "key": "Deferred Revenue",
              "value": "Consideration that does not meet revenue recognition criteria is recorded as deferred revenue and classified based on expected timing of recognition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 167,
          "title": "Table of Contents KINIKSA PHARMACEUTICALS, LTD. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)",
          "data": [
            {
              "key": "Comprehensive Income (Loss)",
              "value": "Explains that comprehensive income (loss) includes net income (loss) plus other changes in shareholders’ equity not resulting from transactions with shareholders. For years ended December 31, 2022, 2021, and 2020, the company’s other comprehensive income (loss) comprised unrealized gains (losses) on short-term investments and currency translation adjustments, net of tax."
            },
            {
              "key": "Net Income (Loss) per Share",
              "value": "Describes the computation of basic and diluted net income (loss) per share attributable to common shareholders by dividing net income (loss) by the weighted average number of common shares. It also explains the treatment of dilutive securities, and notes that in periods of net loss, diluted net loss per share equals basic net loss per share."
            },
            {
              "key": "Income Taxes",
              "value": "Details the use of the asset and liability method for accounting income taxes, including recognition of deferred tax assets and liabilities. Discusses the method of determining deferred tax amounts, valuation allowance for unrecognized deferred tax assets, and mentions that no income tax benefits are recorded for losses in Bermuda. It also outlines the tax provisions for U.S. and other foreign subsidiaries."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 168,
          "title": "Notes to Consolidated Financial Statements: Tax & Fair Value Disclosures",
          "data": [
            {
              "key": "Tax Disclosures",
              "value": "Discussion of federal and state research and development credits, the FDII deduction, share‐based compensation taxable events, deferred tax benefit on UK tax assets, and the evaluation of tax positions to determine recognized benefits."
            },
            {
              "key": "Fair Value Measurement",
              "value": "Disclosure on the fair value of financial assets and liabilities, including a two-step process for recognizing tax uncertainties and determination of fair value measurement levels (Level 1 for money market funds and Level 2 for U.S. Treasury notes)."
            },
            {
              "key": "Asset Levels Classification Table",
              "value": "Money market funds (Level 1): $20,929; U.S. Treasury notes (Level 2): $82,902; Total: $103,831. The majority (~80%) are Level 2."
            },
            {
              "key": "Assets Table",
              "value": "Cash equivalents—money market funds: $94,324 (Level 1) and Short-term investments—U.S. Treasury notes: $59,731 (Level 2); Total: $154,055."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 169,
          "title": "KINIKSA PHARMACEUTICALS, LTD. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Investment Portfolio Summary (December 31, 2022)",
              "value": "The table details U.S. Treasury notes investments: Cash equivalents with a fair value of 15,009 and short-term investments with a fair value of 67,893, yielding a total fair value of 82,902 with an amortized cost of 82,897 and minimal unrealized gains of 9."
            },
            {
              "key": "Investment Portfolio Summary (December 31, 2021)",
              "value": "The table shows short-term investments with an amortized cost of 59,745 and a fair value of 59,731, with minimal unrealized gains of 1 and unrealized losses of 15, reflecting a conservative investment strategy."
            },
            {
              "key": "Unrealized Loss Positions",
              "value": "As of December 31, 2022, 2 securities held in an unrealized loss position had an aggregate fair value of 7,471, compared to 11 securities with an aggregate fair value of 49,739 as of December 31, 2021. In both periods, these securities were held for less than 12 months, with no material change in credit risk and no other-than-temporary impairment identified."
            },
            {
              "key": "Product Revenue Comparison",
              "value": "Following FDA approval of ARCALYST on March 18, 2021, and its subsequent launch in April 2021, product revenue (net) increased from 38,544 in 2021 to 122,524 in 2022, representing approximately a 218% year-over-year growth."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 170,
          "title": "Balance and Adjustments Statement",
          "data": [
            {
              "key": "Balance at December 31, 2021",
              "value": "Total: 1,335 (Contractual Adjustments: 515, Government Rebates: 719, Returns: 101)"
            },
            {
              "key": "Current provisions relating to sales in the current year",
              "value": "Total: 12,178 (Contractual Adjustments: 7,366, Government Rebates: 4,543, Returns: 269)"
            },
            {
              "key": "Adjustments relating to prior years",
              "value": "Total: -19 (Returns: -19; no adjustments for contractual or rebates)"
            },
            {
              "key": "Payments/returns relating to sales in the current year",
              "value": "Total: -8,437 (Contractual Adjustments: -5,902, Government Rebates: -2,535, Returns: 0)"
            },
            {
              "key": "Payments/returns relating to sales in the prior years",
              "value": "Total: -1,158 (Contractual Adjustments: -515, Government Rebates: -643, Returns: 0)"
            },
            {
              "key": "Balance at December 31, 2022",
              "value": "Total: 3,899 (Contractual Adjustments: 1,464, Government Rebates: 2,084, Returns: 351)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 170,
          "title": "Balance and Adjustments Statement December 2020-2021",
          "data": [
            {
              "key": "Current provisions relating to sales in the current year",
              "value": "Total: 3,677 (Contractual Adjustments: 2,219, Rebates: 1,131, Returns: 327)"
            },
            {
              "key": "Payments/returns relating to sales in the current year",
              "value": "Total: -2,342 (Contractual Adjustments: -1,704, Rebates: -412, Returns: -226)"
            },
            {
              "key": "Balance at December 31, 2021",
              "value": "Total: 1,335 (Contractual Adjustments: 515, Rebates: 719, Returns: 101)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 170,
          "title": "Revenue-Related Reserves and Account Receivable Changes",
          "data": [
            {
              "key": "Reduction of accounts receivable",
              "value": "2022: -304, 2021: -50"
            },
            {
              "key": "Components of other current liabilities",
              "value": "2022: 4,203, 2021: 1,385"
            },
            {
              "key": "Total revenue-related reserves",
              "value": "2022: 3,899, 2021: 1,335"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 170,
          "title": "Inventory Note",
          "data": [
            {
              "key": "Inventory Capitalization",
              "value": "Commenced capitalization of ARCALYST inventory following FDA approval for recurrent pericarditis treatment."
            },
            {
              "key": "Product Relabeling",
              "value": "Certain ARCALYST products reclassified from R&D expense to finished goods for commercial sale."
            },
            {
              "key": "Zero Cost Inventory",
              "value": "No remaining zero cost inventory as of December 31, 2021."
            },
            {
              "key": "Specific Provision",
              "value": "Provision of $226 included in the return reserve for a damaged product return."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 171,
          "title": "Notes to Consolidated Financial Statements - KINIKSA PHARMACEUTICALS, LTD.",
          "data": [
            {
              "key": "Inventory Breakdown Comparison",
              "value": "The table presents inventory details for 2022 vs 2021. It shows that total inventory increased significantly from 3,675 in 2021 to 21,599 in 2022, with major contributions from work-in-process (rising from 0 to 6,312) and finished goods (increasing from 3,675 to 15,287)."
            },
            {
              "key": "Property and Equipment Breakdown",
              "value": "This table details the categories of property and equipment. Notably, the net property and equipment value decreased from 2,834 in 2021 to 1,658 in 2022 due to higher accumulated depreciation. The breakdown includes figures for furniture, fixtures, computer hardware, leasehold improvements, lab equipment, and construction in progress."
            },
            {
              "key": "Lease Cost Analysis",
              "value": "The table summarizes lease costs for the years 2020 to 2022. Operating lease costs increased from 1,578 in 2020 to 3,380 in 2022, and total lease cost rose from 1,745 to 3,512 over the period, reflecting significant increases in lease expenses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 172,
          "title": "Notes to Consolidated Financial Statements (KINIKSA PHARMACEUTICALS, LTD.)",
          "data": [
            {
              "key": "Lease - Weighted-average remaining lease term (2022)",
              "value": "1.63 years"
            },
            {
              "key": "Lease - Weighted-average discount rate (2022)",
              "value": "5.56%"
            },
            {
              "key": "Operating Leases - Future Minimum Lease Payments Schedule - 2023 Payment",
              "value": "3519"
            },
            {
              "key": "Operating Leases - Future Minimum Lease Payments Schedule - 2024 Payment",
              "value": "2671"
            },
            {
              "key": "Operating Leases - Total future minimum lease payments",
              "value": "6190"
            },
            {
              "key": "Operating Leases - Less imputed interest",
              "value": "-271"
            },
            {
              "key": "Operating Leases - Present value of lease liabilities",
              "value": "5919"
            },
            {
              "key": "Intangible Assets - Regulatory Milestone Financial Summary - Cost",
              "value": "20000"
            },
            {
              "key": "Intangible Assets - Regulatory Milestone Financial Summary - Accumulated Amortization",
              "value": "1750"
            },
            {
              "key": "Intangible Assets - Regulatory Milestone Financial Summary - Net Cost",
              "value": "18250"
            },
            {
              "key": "Intangible Assets - Regulatory Milestone Financial Summary - Secondary Cost",
              "value": "20000"
            },
            {
              "key": "Intangible Assets - Regulatory Milestone Financial Summary - Secondary Accumulated Amortization",
              "value": "750"
            },
            {
              "key": "Intangible Assets - Regulatory Milestone Financial Summary - Net Amount",
              "value": "19251"
            },
            {
              "key": "Future Amortization of Intangible Assets (next 5 periods)",
              "value": "1,000 each period (5 periods)"
            },
            {
              "key": "Accrued Expenses - Accrued research and development expenses (2022 vs 2021)",
              "value": "8378 vs 24977"
            },
            {
              "key": "Accrued Expenses - Accrued employee compensation and benefits (2022 vs 2021)",
              "value": "11213 vs 8916"
            },
            {
              "key": "Accrued Expenses - Accrued collaboration expenses (2022 vs 2021)",
              "value": "7522 vs 835"
            },
            {
              "key": "Accrued Expenses - Accrued legal, commercial and professional fees (2022 vs 2021)",
              "value": "2866 vs 2933"
            },
            {
              "key": "Accrued Expenses - Other (2022 vs 2021)",
              "value": "133 vs 370"
            },
            {
              "key": "Accrued Expenses - Total accrued expenses (2022 vs 2021)",
              "value": "30112 vs 38031"
            },
            {
              "key": "Other line item",
              "value": "F-24 $19,250 (repeated)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 178,
          "title": "Out-Licensing Agreements – Genentech License Agreement",
          "data": [
            {
              "key": "Agreement Initiation",
              "value": "August 2022"
            },
            {
              "key": "Effective Date",
              "value": "September 2022 (post Hart-Scott Rodino waiting period)"
            },
            {
              "key": "Parties Involved",
              "value": "KINIKSA PHARMACEUTICALS, LTD.; Genentech, Inc.; F. Hoffmann-La Roche Ltd"
            },
            {
              "key": "Rights Granted",
              "value": "Exclusive worldwide rights to develop, manufacture and commercialize vixarelimab and related antibodies"
            },
            {
              "key": "Upfront Payment",
              "value": "$80,000"
            },
            {
              "key": "Additional Payment",
              "value": "$20,000 in Q1 2023 following delivery of drug supplies"
            },
            {
              "key": "Contingent Payments",
              "value": "Up to approximately $600,000 based on development, regulatory and sales milestones"
            },
            {
              "key": "Royalty Terms",
              "value": "Tiered percentage royalties ranging from low-double digits to mid-teens on annual net sales with customary reductions and an aggregate minimum floor"
            },
            {
              "key": "Revenue Recognition Guidance",
              "value": "ASC 606"
            },
            {
              "key": "Clinical Trial Obligation",
              "value": "Company responsible for completing its Phase 2b clinical trial for vixarelimab in prurigo nodularis"
            },
            {
              "key": "Manufacturing Rights",
              "value": "Genentech has right to assume manufacturing responsibilities and to purchase additional drug substance at cost plus markup"
            },
            {
              "key": "Termination Provisions",
              "value": "Genentech may terminate with notice; either party may terminate for uncured breach or insolvency; also terminates upon termination of the Biogen Agreement"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 180,
          "title": "Notes to Consolidated Financial Statements - Collaboration Revenue and Huadong Agreements",
          "data": [
            {
              "key": "Collaboration Revenue",
              "value": "$87,656 (in thousands) recognized under the Genentech License Agreement for Phase 2b Clinical trial for vixarelimab and materials delivered"
            },
            {
              "key": "Huadong Collaboration Agreements",
              "value": "Two agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. granting exclusive development and commercialization rights in the Huadong Territory for rilonacept and mavrilimumab"
            },
            {
              "key": "Upfront Payment",
              "value": "$22,000 received; split as $12,000 for rilonacept and $10,000 for mavrilimumab"
            },
            {
              "key": "Potential Milestone Payments",
              "value": "Up to ~$70,000 for rilonacept and up to ~$576,000 for mavrilimumab based on development, regulatory, and sales milestones"
            },
            {
              "key": "Royalties",
              "value": "Tiered percentage royalties (low-teens to low-twenties) on annual net sales in the Huadong Territory subject to reductions and a minimum floor"
            },
            {
              "key": "Agreement Duration and Termination",
              "value": "Agreements continue until no further royalties are owed; includes termination rights upon notice or material breach"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 181,
          "title": "Notes to Consolidated Financial Statements - KINIKSA PHARMACEUTICALS, LTD.",
          "data": [
            {
              "key": "Agreement",
              "value": "mavrilimumab Huadong Collaboration Agreement"
            },
            {
              "key": "Key Promises",
              "value": "Exclusive license for mavrilimumab in the Huadong Territory and clinical manufacturing supply of materials"
            },
            {
              "key": "Revenue Recognition Guidance",
              "value": "ASC 606 applied; separation of performance obligations, variable consideration fully constrained for milestone payments, and revenue for royalties and sales milestones recognized upon meeting thresholds"
            },
            {
              "key": "Transaction Price",
              "value": "$10,000 upfront payment plus estimates of variable consideration on material shipments"
            },
            {
              "key": "Termination Rights",
              "value": "Company may terminate agreements if Huadong does not maintain material development or commercialization activities for over six months"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 182,
          "title": "Notes to Consolidated Financial Statements",
          "data": [
            {
              "key": "Collaboration Agreement",
              "value": "mavrilimumab Huadong"
            },
            {
              "key": "Performance Obligations",
              "value": "Delivery of exclusive license for mavrilimumab in Huadong Territory; Clinical manufacturing supply of certain materials for mavrilimumab products"
            },
            {
              "key": "Revenue Recognized",
              "value": "$10,000 during the year ended December 31, 2022"
            },
            {
              "key": "Rilonacept Collaboration Agreement",
              "value": "Exclusive license for rilonacept in the Huadong Territory; Clinical manufacturing supply of rilonacept products"
            },
            {
              "key": "Transaction Price",
              "value": "$12,000 upfront payment; estimate of variable consideration for clinical manufacturing supply"
            },
            {
              "key": "Revenue Recognition for Rilonacept",
              "value": "At a point in time upon transfer of materials"
            },
            {
              "key": "Royalty and Sales Milestones",
              "value": "Will be recognized as delivery occurs"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 188,
          "title": "NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)",
          "data": [
            {
              "key": "service_agreement_details",
              "value": "The Company, including Kiniksa UK, entered into agreements with Kiniksa US under which Kiniksa US provides management, commercial, manufacturing, and research and development services for a cost plus service fee."
            },
            {
              "key": "asset_transfer_info",
              "value": "The Company transferred its rights, title, and interest in various assets—including contracts (such as the Regeneron and Biogen Agreements), intellectual property rights, product filings, approvals, and related materials—to Kiniksa UK. These transfers occurred in January 2021 (ARCALYST-related), February 2022 (exclusive rights for developing and commercializing mavrilimumab in the Asia Pacific region, excluding Japan), and July 2022 (vixarelimab-related). Deferred tax assets were recorded due to the difference between the stepped-up tax basis and book basis."
            },
            {
              "key": "regional_performance_summary",
              "value": "Table data shows that Bermuda operations recorded losses in all years (2020: -161,983; 2021: -164,284; 2022: -84,067), while Foreign operations (U.S., U.K., Germany, France, Switzerland) improved with positive income increasing from 5,754 in 2020 to 95,093 in 2022. Overall, the consolidated performance shifted from significant losses in 2020 and 2021 to a profit of 11,026 in 2022."
            },
            {
              "key": "income_tax_benefit_summary",
              "value": "The income tax benefit (or provision) summary indicates a mix of current and deferred tax items. Notably, in 2022, significant deferred tax benefits from foreign operations (185,495) resulted in an overall tax benefit of 172,337, compared to tax provisions in previous years, with breakdowns provided for Bermuda, U.S. federal, U.S. state, and European regions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 190,
          "title": "Deferred Tax Assets and Uncertain Tax Positions Disclosures",
          "data": [
            {
              "key": "Overview",
              "value": "The document presents notes to consolidated financial statements for Kiniksa Pharmaceuticals, LTD. detailing deferred tax assets, valuation allowance adjustments, and uncertain tax positions."
            },
            {
              "key": "Valuation Allowance Roll-forward",
              "value": "A table shows valuation allowance changes over 2020-2022. In 2022, there was a significant decrease of $108,360 primarily due to the release of the UK deferred tax asset valuation allowance, which resulted in a benefit of $185,495."
            },
            {
              "key": "Deferred Tax Assets by Jurisdiction",
              "value": "The UK deferred tax assets were partially released based on positive evidence such as cumulative UK income and sales estimates for ARCALYST. The US deferred tax assets maintained a full allowance as of December 31, 2022."
            },
            {
              "key": "Unrecognized Tax Benefits",
              "value": "The disclosure presents another table tracking uncertainties in income tax provisions. The unrecognized tax benefits were $1,794 for 2022 compared to $545 in 2021, with commentary noting impacts from intellectual property transfers and research and development credits."
            },
            {
              "key": "Tax Position Recognition",
              "value": "The Company recognizes tax benefits from uncertain positions only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, basing the measurement on the largest benefit with >50% likelihood of realization."
            },
            {
              "key": "Future Considerations",
              "value": "Utilization of state R&D tax credits may be subject to limitations under Section 382 of the Internal Revenue Code due to potential ownership changes."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 191,
          "title": "Net Income and Share Information",
          "data": [
            {
              "key": "year",
              "value": "2022"
            },
            {
              "key": "net_income",
              "value": "183363"
            },
            {
              "key": "basic_shares",
              "value": "69382275"
            },
            {
              "key": "options",
              "value": "968512"
            },
            {
              "key": "unvested_rsus",
              "value": "70535"
            },
            {
              "key": "diluted_shares",
              "value": "70421322"
            },
            {
              "key": "basic_eps",
              "value": "2.64"
            },
            {
              "key": "diluted_eps",
              "value": "2.60"
            },
            {
              "key": "year",
              "value": "2021"
            },
            {
              "key": "net_income",
              "value": "-157924"
            },
            {
              "key": "basic_shares",
              "value": "68576810"
            },
            {
              "key": "options",
              "value": "0"
            },
            {
              "key": "unvested_rsus",
              "value": "0"
            },
            {
              "key": "diluted_shares",
              "value": "68576810"
            },
            {
              "key": "basic_eps",
              "value": "-2.30"
            },
            {
              "key": "diluted_eps",
              "value": "-2.30"
            },
            {
              "key": "year",
              "value": "2020"
            },
            {
              "key": "net_income",
              "value": "-161381"
            },
            {
              "key": "basic_shares",
              "value": "61842722"
            },
            {
              "key": "options",
              "value": "0"
            },
            {
              "key": "unvested_rsus",
              "value": "0"
            },
            {
              "key": "diluted_shares",
              "value": "61842722"
            },
            {
              "key": "basic_eps",
              "value": "-2.61"
            },
            {
              "key": "diluted_eps",
              "value": "-2.61"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 192,
          "title": "Notes to Consolidated Financial Statements – Anti-dilutive Securities, Commitments and Benefit Plans",
          "data": [
            {
              "key": "Anti-dilutive Securities - Share Options to Purchase Common Shares (2022)",
              "value": "8,403,074"
            },
            {
              "key": "Anti-dilutive Securities - Share Options to Purchase Common Shares (2021)",
              "value": "9,226,846"
            },
            {
              "key": "Anti-dilutive Securities - Share Options to Purchase Common Shares (2020)",
              "value": "9,958,858"
            },
            {
              "key": "Anti-dilutive Securities - Unvested RSUs (2022)",
              "value": "1,548,347"
            },
            {
              "key": "Anti-dilutive Securities - Unvested RSUs (2021)",
              "value": "885,021"
            },
            {
              "key": "Anti-dilutive Securities - Unvested RSUs (2020)",
              "value": "205,312"
            },
            {
              "key": "Total Anti-dilutive Shares (2022)",
              "value": "9,951,421"
            },
            {
              "key": "Total Anti-dilutive Shares (2021)",
              "value": "10,111,867"
            },
            {
              "key": "Total Anti-dilutive Shares (2020)",
              "value": "10,164,170"
            },
            {
              "key": "Manufacturing Commitments",
              "value": "Minimum payments of $22,851 due within one year under supply agreements (including clinical supply and commercial product commitments)"
            },
            {
              "key": "Benefit Plan Contributions (401(k))",
              "value": "Contributions of $1,683 in 2022, $1,558 in 2021, and $993 in 2020 with matching contributions provided (100% of first 3% and 50% of next 2%)"
            },
            {
              "key": "Indemnification Agreements",
              "value": "Agreements with board members, officers, and key personnel; maximum potential future payments are unlimited, but no material costs incurred to date"
            },
            {
              "key": "Legal Proceedings",
              "value": "The Company is not a party to any litigation and has not established contingency reserves for litigation liabilities"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 193,
          "title": "CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM",
          "data": [
            {
              "key": "Consent Statement",
              "value": "We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 and S-8 of Kiniksa Pharmaceuticals, Ltd. of our report relating to the financial statements as presented in this Form 10-K."
            },
            {
              "key": "Forms S-3 Numbers",
              "value": "333-264751, 333-264746, 333-248656, 333-238585"
            },
            {
              "key": "Forms S-8 Numbers",
              "value": "333-262971, 333-253514, 333-237589, 333-225196"
            },
            {
              "key": "Report Date",
              "value": "March 2, 2023"
            },
            {
              "key": "Auditing Firm",
              "value": "PricewaterhouseCoopers LLP"
            },
            {
              "key": "Location",
              "value": "Boston, Massachusetts"
            },
            {
              "key": "Exhibit Reference",
              "value": "Exhibit 23.1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 195,
          "title": "EXHIBIT 31.2 CERTIFICATION",
          "data": [
            {
              "key": "Certifier",
              "value": "Mark Ragosa"
            },
            {
              "key": "Role",
              "value": "Chief Financial Officer (Principal Financial Officer)"
            },
            {
              "key": "Company",
              "value": "Kiniksa Pharmaceuticals, Ltd."
            },
            {
              "key": "Report Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Certification Details",
              "value": "Certification statement attesting that the annual report contains no untrue or omitted material facts, and that financial statements fairly present the financial condition, results of operations, and cash flows. It also addresses the design and effectiveness of internal controls over financial reporting."
            },
            {
              "key": "Date",
              "value": "March 2, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 196,
          "title": "EXHIBIT 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002",
          "data": [
            {
              "key": "Certification Text",
              "value": "I, Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Directors of Kiniksa Pharmaceuticals, Ltd., certify that the Annual Report on Form 10-K for the period ended December 31, 2022 fully complies with applicable regulations and fairly presents the financial condition and results of operations of the Company."
            },
            {
              "key": "Legal Reference",
              "value": "18 U.S.C. §1350 as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002"
            },
            {
              "key": "Certification Date",
              "value": "March 2, 2023"
            },
            {
              "key": "Certifier",
              "value": "Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer)"
            },
            {
              "key": "Report",
              "value": "Annual Report on Form 10-K for the period ended December 31, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 197,
          "title": "EXHIBIT 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350",
          "data": [
            {
              "key": "Company",
              "value": "Kiniksa Pharmaceuticals, Ltd."
            },
            {
              "key": "Signatory",
              "value": "Mark Ragosa"
            },
            {
              "key": "Position",
              "value": "Chief Financial Officer (Principal Financial Officer)"
            },
            {
              "key": "Report",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Report Period Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Certification Date",
              "value": "March 2, 2023"
            },
            {
              "key": "Regulatory Reference",
              "value": "18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 124,
          "title": "Dividends Policy",
          "data": [
            {
              "key": "Current Dividend Status",
              "value": "We have never declared or paid any cash dividends on our common shares."
            },
            {
              "key": "Future Dividend Intentions",
              "value": "We intend to retain all of our future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future."
            },
            {
              "key": "Factors for Dividend Declaration",
              "value": "Future determination to declare and pay dividends will be made at the discretion of the board of directors, considering general economic conditions, financial condition, available cash, capital requirements, etc."
            },
            {
              "key": "Legal Restrictions on Dividends",
              "value": "Under the Bermuda Companies Act 1981, a company may not declare or pay dividends if it cannot pay its liabilities as they become due or if the realizable value of its assets would be less than its liabilities."
            },
            {
              "key": "Rights of Common Shares",
              "value": "Each common share is entitled to dividends if, as and when declared by the board of directors, subject to any preferred dividend right of preferred shares."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 114,
          "title": "Table of Contents - Common Shares and Voting Structure",
          "data": [
            {
              "key": "Multi-Class Voting Structure Description",
              "value": "Due to the multi-class voting structure, executive officers and certain senior management collectively control a significant portion of voting power."
            },
            {
              "key": "Aggregate Voting Power Percentages (as of December 31, 2022)",
              "value": "Class A common shares: approximately 66%, Class B common shares: approximately 34%"
            },
            {
              "key": "Management Voting Control",
              "value": "Executive officers and certain senior management hold both Class A and Class B common shares representing about 30% of the aggregate voting power."
            },
            {
              "key": "Conversion Rights",
              "value": "Holders of Class B common shares can convert portions into Class B1 or Class A common shares with advance notice; similarly, conversion rights apply for Class B1 and Class A1 shares subject to certain restrictions."
            },
            {
              "key": "Affiliated Directors Influence",
              "value": "Entities affiliated with certain directors can convert their holdings (upon required prior notice) resulting in control of approximately 78% of aggregate voting power."
            },
            {
              "key": "Impact on Share Price",
              "value": "Conversion rights and concentrated control may adversely affect the price of Class A common shares, contributing to volatility."
            },
            {
              "key": "Market Volatility Factors",
              "value": "Extreme market volatility from factors like COVID-19, inflation, and global economic conditions may further influence share price fluctuations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 153,
          "title": "Assets, Liabilities and Shareholders' Equity Statement",
          "data": [
            {
              "key": "Company Name",
              "value": "KINIKSA PHARMACEUTICALS, LTD."
            },
            {
              "key": "Document Type",
              "value": "Consolidated Balance Sheets"
            },
            {
              "key": "Summary",
              "value": "This table represents a balance sheet comparing financial positions across two periods. The total assets increased from $232,800 to $459,672, with significant growth in cash equivalents and property/equipment. The company's financial health appears to have improved, with accumulated deficit reducing from -$675,397 to -$492,034, and total shareholders' equity increasing from $185,037 to $396,149."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 155,
          "title": "Shareholders' Equity Statement",
          "data": [
            {
              "key": "date",
              "value": "December 31, 2019"
            },
            {
              "key": "shares",
              "value": "54937628"
            },
            {
              "key": "amount",
              "value": "15"
            },
            {
              "key": "additional_paid_in_capital",
              "value": "581467"
            },
            {
              "key": "accumulated_other_comprehensive_income",
              "value": "33"
            },
            {
              "key": "accumulated_deficit",
              "value": "-356092"
            },
            {
              "key": "total_shareholders_equity",
              "value": "225423"
            },
            {
              "key": "date",
              "value": "December 31, 2020"
            },
            {
              "key": "shares",
              "value": "68215022"
            },
            {
              "key": "amount",
              "value": "18"
            },
            {
              "key": "additional_paid_in_capital",
              "value": "829424"
            },
            {
              "key": "accumulated_other_comprehensive_income",
              "value": "-34"
            },
            {
              "key": "accumulated_deficit",
              "value": "-517473"
            },
            {
              "key": "total_shareholders_equity",
              "value": "311935"
            },
            {
              "key": "date",
              "value": "December 31, 2021"
            },
            {
              "key": "shares",
              "value": "69060403"
            },
            {
              "key": "amount",
              "value": "18"
            },
            {
              "key": "additional_paid_in_capital",
              "value": "860482"
            },
            {
              "key": "accumulated_other_comprehensive_income",
              "value": "-66"
            },
            {
              "key": "accumulated_deficit",
              "value": "-675397"
            },
            {
              "key": "total_shareholders_equity",
              "value": "185037"
            },
            {
              "key": "date",
              "value": "December 31, 2022"
            },
            {
              "key": "shares",
              "value": "null"
            },
            {
              "key": "amount",
              "value": "null"
            },
            {
              "key": "additional_paid_in_capital",
              "value": "null"
            },
            {
              "key": "accumulated_other_comprehensive_income",
              "value": "null"
            },
            {
              "key": "accumulated_deficit",
              "value": "-492034"
            },
            {
              "key": "total_shareholders_equity",
              "value": "396149"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 158,
          "title": "Follow-on Offerings, Private Placements and Liquidity",
          "data": [
            {
              "key": "Currency Translation",
              "value": "Transactions in other currencies are recorded at prevailing exchange rates; monetary assets/liabilities are re-measured at balance sheet date rates; foreign subsidiaries’ local currencies are translated into USD with adjustments reported in accumulated other comprehensive income."
            },
            {
              "key": "Offering 1 Date",
              "value": "May 18, 2020"
            },
            {
              "key": "Offering 1 Type",
              "value": "Follow-on offering and concurrent private placement"
            },
            {
              "key": "Offering 1 Details",
              "value": "2,760,000 Class A common shares and 1,600,000 Class A1 common shares at $18.25 per share"
            },
            {
              "key": "Offering 1 Gross Proceeds",
              "value": "$79,570"
            },
            {
              "key": "Offering 1 Net Proceeds",
              "value": "$74,495"
            },
            {
              "key": "Offering 2 Date",
              "value": "July 24, 2020"
            },
            {
              "key": "Offering 2 Type",
              "value": "Follow-on offering and concurrent private placement"
            },
            {
              "key": "Offering 2 Details",
              "value": "5,952,381 Class A common shares and 1,428,572 Class A1 common shares at $21.00 per share"
            },
            {
              "key": "Offering 2 Gross Proceeds",
              "value": "$155,000"
            },
            {
              "key": "Offering 2 Net Proceeds",
              "value": "$146,037"
            },
            {
              "key": "Liquidity - Cash & Equivalents (Dec 31, 2022)",
              "value": "$190,608"
            },
            {
              "key": "Accumulated Deficit (Dec 31, 2022)",
              "value": "$492,034"
            },
            {
              "key": "Net Income (Year Ended Dec 31, 2022)",
              "value": "$183,363"
            },
            {
              "key": "Operating Cash Provided",
              "value": "$5,807"
            },
            {
              "key": "Future Viability",
              "value": "Dependent on ARCALYST sales and ability to obtain additional financing through various sources or strategic transactions"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 173,
          "title": "Common Shares and Capital Structure Adjustments",
          "data": [
            {
              "key": "R&D Expense Adjustment",
              "value": "$2,223 recorded as an out-of-period adjustment due to a decrease in accrued research and development expenses"
            },
            {
              "key": "May 18, 2020 Follow-on Offering",
              "value": "Issued 2,760,000 Class A common shares and 1,600,000 Class A1 common shares at $18.25 per share; aggregate gross proceeds of $79,570K and net proceeds of $74,495K after underwriting discounts and fees"
            },
            {
              "key": "July 24, 2020 Follow-on Offering",
              "value": "Issued 5,952,381 Class A common shares and 1,428,572 Class A1 common shares at $21.00 per share; aggregate gross proceeds of $155,000K and net proceeds of $146,037K after deductions"
            },
            {
              "key": "Authorized Shares",
              "value": "200,000,000 shares authorized with a par value of $0.000273235 as of December 31, 2022"
            },
            {
              "key": "Dividend Policy",
              "value": "No cash dividends declared or paid through December 31, 2022"
            },
            {
              "key": "Voting Rights",
              "value": "Class A common shares: one vote; Class B common shares: ten votes; Class A1 and Class B1 common shares: no voting rights"
            },
            {
              "key": "Conversion Rights",
              "value": "Class B common shares convert automatically under certain transfers or at holder’s election into Class A or Class B1 common shares; Class A1 common shares convertible into Class A common shares; Class B1 convertible under similar conditions; no conversion rights for Class A common shares"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 4,
          "title": "Risk Factors",
          "data": [
            {
              "key": "Decision of third-party payors",
              "value": "Not to cover or maintain coverage of ARCALYST or current/future product candidates."
            },
            {
              "key": "Clinical development process issues",
              "value": "Lengthy and expensive with uncertain outcomes, impacted by COVID-19 and geopolitical issues."
            },
            {
              "key": "Regulatory authority decisions",
              "value": "Whether to clear products for clinical development or approve for marketing."
            },
            {
              "key": "Anticipation of adverse events",
              "value": "Ability to prevent adverse events caused by products."
            },
            {
              "key": "Product improvement",
              "value": "Ability to improve product candidates."
            },
            {
              "key": "Identification of product candidates",
              "value": "Ability to acquire, discover, or develop additional candidates."
            },
            {
              "key": "Business combinations and collaborations",
              "value": "Ability to undertake strategic transactions and realize value."
            },
            {
              "key": "Manufacturing capabilities",
              "value": "Ability to manufacture products to regulatory specifications."
            },
            {
              "key": "Growth management",
              "value": "Ability to manage growth effectively."
            },
            {
              "key": "Product liability claims",
              "value": "Ability to avoid claims and maintain insurance."
            },
            {
              "key": "Regulatory exclusivity",
              "value": "Ability to obtain regulatory exclusivity."
            },
            {
              "key": "Regulatory requirements",
              "value": "Federal, state, and foreign requirements applicable to products."
            },
            {
              "key": "Intellectual property rights",
              "value": "Obtaining, maintaining, and enforcing IP rights."
            },
            {
              "key": "Ownership concentration",
              "value": "Ownership by executive officers and directors may limit shareholder influence."
            },
            {
              "key": "Attracting skilled personnel",
              "value": "Ability to attract and retain skilled staff."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 5,
          "title": "RISK FACTORS",
          "data": [
            {
              "key": "Business Risks",
              "value": "Our business is subject to numerous risks and uncertainties that could affect investment."
            },
            {
              "key": "Product Revenue",
              "value": "We have recently begun generating product revenue and incurred significant operating losses."
            },
            {
              "key": "Funding Requirements",
              "value": "We will require significant additional funding for development and commercialization of products."
            },
            {
              "key": "Commercial Success Dependency",
              "value": "Our success depends heavily on the commercialization of ARCALYST."
            },
            {
              "key": "Market Acceptance",
              "value": "There may be challenges in gaining sustained market acceptance for ARCALYST."
            },
            {
              "key": "Third-party Payor Coverage",
              "value": "Commercialization success depends on third-party payor funding and coverage policies."
            },
            {
              "key": "Market Opportunities",
              "value": "The market opportunities for our products may be smaller than estimated."
            },
            {
              "key": "Clinical Development Challenges",
              "value": "Clinical development is lengthy, expensive, and entails uncertain timelines."
            },
            {
              "key": "Delays in Clinical Trials",
              "value": "Substantial delays may occur in preclinical or clinical trials."
            },
            {
              "key": "Reliance on Third Parties",
              "value": "We rely on third parties like CROs for research activities, which may impact development."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 6,
          "title": "Risk Factors",
          "data": [
            {
              "key": "Dependence on Third-Party Manufacturers",
              "value": "We rely on third parties, including independent contract manufacturing organizations (“CMOs”) to manufacture our product candidates for preclinical and clinical development."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "All of our products and current product candidates have been licensed or acquired from other parties; if those parties did not adequately protect, we are unable to commercialize our products."
            },
            {
              "key": "Competition Risk",
              "value": "We face significant competition from other biotechnology and pharmaceutical companies, which may result in others discovering, developing or commercializing drugs before us."
            },
            {
              "key": "Growth Strategy Execution",
              "value": "We may not successfully execute our growth strategy to identify, discover, develop, license or acquire additional product candidates or technologies."
            },
            {
              "key": "Strategic Transactions Risks",
              "value": "We may seek to acquire businesses or undertake strategic transactions which may not be successful or on favorable terms."
            },
            {
              "key": "Collaboration and Licensing Risks",
              "value": "We have entered and seek to enter into collaboration, licensing or transactions that may not yield the expected value."
            },
            {
              "key": "Ownership Concentration Risks",
              "value": "Concentration of ownership may prevent new investors from influencing significant corporate decisions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 21,
          "title": "Third-Party Manufacturing, Technology Transfer, and Competitive Risks",
          "data": [
            {
              "key": "Technology Transfer",
              "value": "Under certain circumstances, technology transfer may be initiated by Regeneron as early as March 2023."
            },
            {
              "key": "CMO Utilization",
              "value": "Engaged CMOs for fill/finish operations, production of mavrilimumab drug substance/product, and qualified CMOs for KPL-404 drug product production."
            },
            {
              "key": "In-House vs. Outsourced Operations",
              "value": "Most process development is performed internally, while late-stage clinical manufacturing, process qualification, validation, and commercial supply rely on CMOs."
            },
            {
              "key": "Compliance Requirements",
              "value": "CMOs are required to conduct manufacturing in compliance with cGMP or similar foreign requirements."
            },
            {
              "key": "Risk Exposure",
              "value": "Reliance on third-party manufacturers exposes the company to risks, including potential disruptions from technology transfers and manufacturing issues."
            },
            {
              "key": "Commercial Operations and Competition",
              "value": "The text details ongoing commercialization strategies for ARCALYST and highlights the competitive landscape including challenges from other pharmaceutical and biotechnology companies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 24,
          "title": "Mavrilimumab – Intellectual Property and Regulatory Risks",
          "data": [
            {
              "key": "Exclusive License",
              "value": "The company has an exclusive license under the MedImmune Agreement, covering granted patents and pending patent applications related to mavrilimumab in the US and other jurisdictions."
            },
            {
              "key": "Patent Portfolio",
              "value": "Includes three granted US patents and 109 patents granted in other countries such as Canada, Australia, Europe, and Asia; pending applications are also in place in multiple jurisdictions."
            },
            {
              "key": "Patent Expiration and Extensions",
              "value": "Composition of matter patents generally expire in 2027, with potential extensions via patent term adjustments if applicable under US law and other jurisdictions."
            },
            {
              "key": "Risk Factors",
              "value": "There are risks that pending patent applications may not issue and that extensions or favorable adjustments to patent terms may not be secured, potentially impairing the ability to protect proprietary technology."
            },
            {
              "key": "Regulatory Environment",
              "value": "Discussion includes extensive government regulation by the FDA and other authorities concerning the research, development, and marketing of biologic drugs, emphasizing the need for substantial time and financial resources to meet regulatory requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 29,
          "title": "Expedited Review, Orphan Drug Exclusivity and FDA Programs",
          "data": [
            {
              "key": "Orphan Drug Exclusivity Risk",
              "value": "A designated Orphan Drug may lose exclusivity if approved for a broader use than the indication for which it was designated, or if the FDA later deems the designation request materially defective or if manufacturing cannot meet patient needs."
            },
            {
              "key": "Expedited Review Programs",
              "value": "The FDA offers Fast Track, Breakthrough Therapy, accelerated approval, and priority review programs to expedite development and review of drugs for serious or life-threatening conditions."
            },
            {
              "key": "Regulatory Conditions",
              "value": "Programs may involve rolling review of sections of the BLA, more intensive FDA interactions from early phases, and pre-approval of promotional materials, affecting commercial launch timing."
            },
            {
              "key": "Risk of Withdrawal",
              "value": "If required confirmatory trials for accelerated approval are not conducted in a timely manner or fail to verify benefit, the product may face expedited withdrawal procedures."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 30,
          "title": "FDA Regulatory Compliance and Post-Approval Risks",
          "data": [
            {
              "key": "Content Overview",
              "value": "Discussion of FDA regulatory requirements post product approval, including Fast Track and Breakthrough Therapy designations, accelerated approval, and the limitations of these designations in expediting product development."
            },
            {
              "key": "Post-Approval Obligations",
              "value": "Highlights the pervasive and ongoing regulatory oversight by the FDA, including monitoring, recordkeeping, reporting of adverse events, and restrictions related to product promotion and off-label use."
            },
            {
              "key": "Compliance and Manufacturing",
              "value": "Emphasizes the need for ongoing compliance with cGMP regulations, quality control, and the reliance on third-party manufacturers, with potential enforcement actions if standards are not maintained."
            },
            {
              "key": "Regulatory Risks",
              "value": "Outlines potential consequences such as withdrawal of product approval, recalls, enforcement actions, fines, and other regulatory restrictions in case of non-compliance or discovery of product issues."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 36,
          "title": "Regulatory Risks and Compliance Challenges in Pharmaceutical Operations",
          "data": [
            {
              "key": "Compliance Risks",
              "value": "Failure to comply with EU and national laws governing clinical trials, manufacturing approvals, marketing authorizations, and related regulatory requirements can lead to administrative, civil, or criminal penalties."
            },
            {
              "key": "Potential Penalties",
              "value": "Penalties include delays or refusals in authorizing clinical trials or marketing, product withdrawals, recalls, seizures, suspensions or variations of marketing authorizations, production or distribution restrictions, injunctions, fines, and criminal charges."
            },
            {
              "key": "Brexit and UK Regulatory Framework",
              "value": "Post-Brexit, Great Britain follows retained EU laws with adaptations. The UK now has its own regulatory procedures through the MHRA, including changes to licensing and authorization processes. EU MAs have been converted or grandfathered into UK MAs, with separate mechanisms for companies established in the UK versus the EEA."
            },
            {
              "key": "Rest of the World Regulations",
              "value": "Outside the EU and the United States, different regulatory requirements apply for clinical trials, product licensing, pricing, and related activities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 39,
          "title": "Coverage, Pricing and Reimbursement Risks in Pharmaceutical Operations",
          "data": [
            {
              "key": "Reporting and Oversight",
              "value": "Mentions reporting obligations and oversight if subject to a corporate integrity agreement or other resolution agreements addressing non-compliance, which may lead to operational curtailment or restructuring."
            },
            {
              "key": "Coverage Uncertainty",
              "value": "Highlights significant uncertainty regarding the coverage status of biological products, impacting the ability to obtain adequate insurance reimbursement."
            },
            {
              "key": "Cost Containment Measures",
              "value": "Describes actions by the United States government, state legislatures, and foreign governments to implement cost containment programs, including price-controls and restrictions on reimbursement."
            },
            {
              "key": "Impact on Product Adoption",
              "value": "Explains that inadequate coverage and reimbursement from third-party payors may reduce physician utilization and the overall marketability of product candidates."
            },
            {
              "key": "International Variability",
              "value": "Notes that pricing, coverage, and reimbursement criteria differ significantly between regions and payors, adding complexity to market entry and profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 40,
          "title": "Government Price Reporting and Pharmaceutical Pricing Controls",
          "data": [
            {
              "key": "Overview",
              "value": "The document outlines the systems governing pricing and reimbursement for pharmaceutical products, including positive and negative list systems that restrict marketing until a government-agreed reimbursement price is set."
            },
            {
              "key": "Pricing Controls",
              "value": "Member states may impose controls such as fixed prices, direct or indirect profit controls, volume-based arrangements, caps, and reference pricing mechanisms."
            },
            {
              "key": "Risk Factors",
              "value": "There is intense downward pressure on healthcare costs and high barriers to entry for new products due to pricing controls, reimbursement limitations, and cross-border import competition."
            },
            {
              "key": "Regulatory Programs",
              "value": "Key programs include the Medicaid Drug Rebate Program (MDRP), the 340B drug pricing program, and the VA Federal Supply Schedule (FSS) pricing program which require strict adherence and reporting."
            },
            {
              "key": "Compliance and Penalties",
              "value": "Manufacturers must report pricing data accurately to CMS and HRSA. Incorrect submissions or failure to submit can result in resubmission requirements, civil monetary penalties, and exclusion from programs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 41,
          "title": "Regulatory and Legislative Risks in Healthcare",
          "data": [
            {
              "key": "Agencies Involved",
              "value": "VA, U.S. Department of Defense, U.S. Coast Guard, U.S. Public Health Service (including the Indian Health Service)"
            },
            {
              "key": "Rebates and Penalties",
              "value": "Rebates on products purchased by military personnel and dependents via TRICARE; civil monetary penalties risk if false or delayed information is submitted"
            },
            {
              "key": "Healthcare Cost Containment",
              "value": "Legislation in individual states to limit healthcare costs, including prescription drugs; drug price transparency laws requiring notice of price increases and reporting of factors affecting these increases"
            },
            {
              "key": "Regulatory Challenges",
              "value": "Potential changes in FDA policies (e.g., through the 21st Century Cures Act, FDA Reauthorization Act) that could delay regulatory approval of product candidates"
            },
            {
              "key": "Legislative Acts Impacting Healthcare",
              "value": "ACA, Budget Control Act of 2011, American Taxpayer Relief Act of 2012, American Rescue Plan Act of 2021, among others, affecting rebates, funding cuts, and payment methodologies"
            },
            {
              "key": "Business Risks",
              "value": "Risk of losing marketing approval and profitability if unable to adapt to evolving regulatory requirements and legislative changes"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 44,
          "title": "Risk Factors, Corporate Information and Disclosures",
          "data": [
            {
              "key": "Employee Vaccination Requirement",
              "value": "All employees entering our workplaces in the United States must be fully vaccinated against COVID-19, subject to a reasonable accommodation process."
            },
            {
              "key": "Additional Safety Measures",
              "value": "Safety measures include providing personal protective equipment and recommending that employees stay home while feeling unwell."
            },
            {
              "key": "Corporate Information",
              "value": "Exempted company incorporated under the laws of Bermuda in July 2015; registered office at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda."
            },
            {
              "key": "Contact Details",
              "value": "Telephone: +44 808-189-6257; Website: www.kiniksa.com."
            },
            {
              "key": "SEC Filing Information",
              "value": "The Annual Report and related documents are filed with the SEC. Website content is not incorporated by reference into the Annual Report."
            },
            {
              "key": "Risk Factors Overview",
              "value": "Includes significant risk factors such as financial position and capital needs, ongoing operating losses, the speculative nature of biopharmaceutical product development, dependency on the commercialization of ARCALYST and future product candidates, and detailed historical financial performance (e.g., net income of $183.4 million from out-licensing and an accumulated deficit of $492.0 million as of December 31, 2022). Continued losses are anticipated."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 46,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Financing Requirement",
              "value": "Substantial additional financing is required to support product development, research and development programs, and commercialization efforts."
            },
            {
              "key": "Risk of Funding Failure",
              "value": "If the necessary capital is not obtained on acceptable terms, the company may be forced to delay, limit, reduce, or cease product development, research programs, and commercialization efforts."
            },
            {
              "key": "Capital Intensive Operations",
              "value": "The development and commercialization of biopharmaceutical products, such as ARCALYST, is highly capital intensive."
            },
            {
              "key": "Operational and Commercial Costs",
              "value": "Expenses may increase due to support for sales, marketing, distribution, infrastructure expansion, clinical trials, and potential milestone and royalty payments."
            },
            {
              "key": "Factors Impacting Funding Needs",
              "value": "Key factors include the ability to commercialize existing products, timing and amount of sales revenue, competitive landscape, clinical trial and manufacturing costs, and external economic or geopolitical events."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 47,
          "title": "Risk Factors and Contingencies - Table of Contents",
          "data": [
            {
              "key": "Preclinical Activities",
              "value": "Number, size, and type of preclinical activities and potential additional clinical trials."
            },
            {
              "key": "Regulatory Approval Costs",
              "value": "Costs, timing, and outcomes of pursuing regulatory approvals; potential requirements for additional studies, post-marketing studies, or implementation of a REMS."
            },
            {
              "key": "Milestone and Payment Obligations",
              "value": "Timing and amounts of milestone and other payments under agreements with parties such as Regeneron, MedImmune, Biogen, and others for in-licensing or acquisition of products."
            },
            {
              "key": "Out-License Revenue",
              "value": "Timing and amount of payments that may be received under agreements with entities like Huadong and Genentech for out-licensing products."
            },
            {
              "key": "Product Development Costs",
              "value": "Costs for identifying, assessing, and studying new or expanded indications, alternative dosing, or new administration methods."
            },
            {
              "key": "Acquisition and Development Expenses",
              "value": "Costs related to future in-licensing, acquisition, development, or discovery of additional product candidates and strategic transactions."
            },
            {
              "key": "Adaptation to Market and Technological Changes",
              "value": "Time and cost required to respond to evolving technological and market developments."
            },
            {
              "key": "Intellectual Property Costs",
              "value": "Expenses involved in filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights."
            },
            {
              "key": "Litigation Risks",
              "value": "Potential litigation including product liability, intellectual property disputes, collaboration agreement disputes, and employment-related disputes."
            },
            {
              "key": "Public Company Expenses",
              "value": "Ongoing costs associated with the obligations of being a public company."
            },
            {
              "key": "Human Resources Challenges",
              "value": "Risks related to the need and ability to hire and retain skilled personnel."
            },
            {
              "key": "Capital Market Receptivity",
              "value": "Risks from the capital markets, particularly in relation to fundraising for biopharmaceutical companies."
            },
            {
              "key": "Macro-Economic and Geopolitical Factors",
              "value": "Adverse impacts related to the COVID-19 pandemic and the ongoing war in Ukraine on the global economy and business operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 48,
          "title": "Risks Related to Commercialization and Financing",
          "data": [
            {
              "key": "Product Development and Commercialization",
              "value": "Details plans for product development, research and development programs, and commercialization efforts for product candidates, including ARCALYST."
            },
            {
              "key": "Financing Risks",
              "value": "Highlights the risk that raising additional capital through various means (securities offerings, debt, licensing, collaboration, strategic transactions) may lead to dilution of shareholders and impose restrictive covenants."
            },
            {
              "key": "Operational Constraints",
              "value": "Discusses potential limitations on expanding operations, reliance on external financing, and the risk of having to relinquish rights to technologies or products."
            },
            {
              "key": "Commercialization Challenges",
              "value": "Mentions risks associated with sustaining revenue growth from ARCALYST and other product candidates, including recruiting and retaining sales and marketing talent."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 49,
          "title": "Risk Factors – Commercialization, Production and Market Acceptance",
          "data": [
            {
              "key": "unmet_medical_need",
              "value": "Our inability to establish the unmet medical need for a given disease."
            },
            {
              "key": "product_choice",
              "value": "Our inability to enable our products to be viewed as the product of choice within approved indications."
            },
            {
              "key": "reimbursement_access",
              "value": "Our inability or delay in gaining or maintaining reimbursement and broad patient access at a price that reflects the value of ARCALYST or future products."
            },
            {
              "key": "materials_support",
              "value": "Our inability to equip customer-facing personnel with effective materials, including medical and sales literature, to educate healthcare providers."
            },
            {
              "key": "production_delay",
              "value": "Delays in producing sufficient quantities of ARCALYST or future products at an acceptable cost or quality, including those arising from quality assurance concerns or regulatory changes."
            },
            {
              "key": "distribution_issue",
              "value": "Our inability, or that of our third-party partners, to distribute products effectively and in a timely manner."
            },
            {
              "key": "training_support",
              "value": "Our inability to provide prescribers and patients with adequate support and training regarding the preparation and administration of ARCALYST or future products."
            },
            {
              "key": "patient_support",
              "value": "Our inability to develop robust patient support programs to optimize the patient and customer experience."
            },
            {
              "key": "infrastructure_failure",
              "value": "Our inability to develop or sustain sufficient operational functions and infrastructure to support our commercial activities."
            },
            {
              "key": "unforeseen_costs",
              "value": "Unforeseen costs and expenses associated with creating and maintaining a sales, marketing, and access organization."
            },
            {
              "key": "covid_impact",
              "value": "Disruptions caused by the evolving COVID-19 pandemic may exacerbate difficulties, delays, and unforeseen costs."
            },
            {
              "key": "market_acceptance",
              "value": "Risk that current or future products may not gain adequate market acceptance by prescribers, patients, or third-party payors, potentially impairing revenue generation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 50,
          "title": "Commercialization and Market Acceptance Risk Factors for ARCALYST and Future Products",
          "data": [
            {
              "key": "Market Introduction Timing",
              "value": "The timing of market introduction is a critical factor affecting commercial success."
            },
            {
              "key": "Disease Awareness",
              "value": "Understanding the severity and epidemiology of the disease impacts product uptake."
            },
            {
              "key": "Competing Products",
              "value": "The number and clinical profile of competing products, approved or not, influence market dynamics."
            },
            {
              "key": "Product Advantages/Disadvantages",
              "value": "Perceived potential advantages or disadvantages of ARCALYST relative to alternative treatments are considered."
            },
            {
              "key": "Evidence of Safety and Efficacy",
              "value": "The ability to provide acceptable evidence of safety and efficacy is required for sustained use."
            },
            {
              "key": "Side Effects",
              "value": "The prevalence and severity of any side effects play a role in market acceptance."
            },
            {
              "key": "Regulatory Labeling",
              "value": "Product labeling requirements and potential changes mandated by regulatory authorities are critical."
            },
            {
              "key": "Ease of Administration",
              "value": "Convenience and ease of administration relative to alternative therapies can affect uptake."
            },
            {
              "key": "Pricing and Cost Factors",
              "value": "Pricing, including patient out-of-pocket costs, budget impact, affordability, and cost-effectiveness are key factors."
            },
            {
              "key": "Market Acceptance and Sales Effectiveness",
              "value": "The effectiveness of sales, marketing, and distribution activities, along with market acceptance of price increases, influences revenue."
            },
            {
              "key": "Coverage and Reimbursement",
              "value": "Availability of adequate coverage, reimbursement, and payment from third-party payors is crucial for commercialization."
            },
            {
              "key": "Revenue Impact",
              "value": "Failure to achieve market acceptance for ARCALYST or future products could adversely affect revenue generation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 51,
          "title": "Table of Contents - Risk Factors Related to Coverage and Reimbursement",
          "data": [
            {
              "key": "Coverage and Reimbursement Risks",
              "value": "There is significant uncertainty in executing coverage and reimbursement strategies in various markets, which could limit the commercial potential of ARCALYST and other product candidates if approved."
            },
            {
              "key": "Cost Control by Payors",
              "value": "Governmental authorities, private insurers, and other third-party payors are actively trying to control costs by delaying reimbursements, limiting coverage breadth, restricting reimbursement levels, and increasing patient cost burdens."
            },
            {
              "key": "Impact on Market Access",
              "value": "Delays or limitations in obtaining reimbursement, along with restrictive coverage criteria, may adversely affect product commercialization, including potential exclusion from formularies or payer coverage lists."
            },
            {
              "key": "Competitive Price Pressures",
              "value": "The entry of low-cost alternatives including generics, biosimilars, and lower-price branded drugs may trigger challenging price negotiation methodologies, impacting relative value assessments and reimbursement rates."
            },
            {
              "key": "Potential Future Changes",
              "value": "Any established coverage and reimbursement may be reduced or eliminated in the future, further affecting the pricing and demand for ARCALYST and other product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 52,
          "title": "Risks Related to Price Increases and Payor Concessions",
          "data": [
            {
              "key": "Overview",
              "value": "The document outlines the potential risks associated with increasing the prices of commercialized products such as ARCALYST. It highlights that despite periodic price increases, unfavorable actions by third-party payors (including governmental authorities and private health insurers) may result in the imposition of price concessions."
            },
            {
              "key": "Potential Impacts",
              "value": "Such price concessions could force the company to grant significant discounts, reduce overall revenue generation, lengthen the timeline to profitability, and necessitate dilutive capital-raising efforts. These factors in turn could harm both the company’s financial performance and its capability to expand in new territories."
            },
            {
              "key": "Operational Concerns",
              "value": "If payors demand similar concessions based on reference pricing or change reimbursement policies, the company may face reduced coverage and reimbursement, which would materially impact its commercial success and patient access to its therapeutics."
            },
            {
              "key": "Risk Factors",
              "value": "The narrative emphasizes risks including loss of favorable payor coverage, potential negative revenue impacts, and the broader commercial growth limitations due to adverse market actions and regulatory pricing pressures."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 53,
          "title": "Risk Factors Related to Market, Pricing, and Liability",
          "data": [
            {
              "key": "Market Size and Patient Access Risk",
              "value": "The total addressable market for products may be lower than expected due to diagnostic criteria, limited patient populations, and challenges in identifying new patients."
            },
            {
              "key": "Pricing and Reimbursement Risk",
              "value": "Governmental price controls, mandatory discounts, legislated rebates, and international reference pricing may delay commercial launches and reduce net prices."
            },
            {
              "key": "Regulatory Approval and Commercialization Risk",
              "value": "Varying international regulatory frameworks related to marketing approvals, pricing, and reimbursement could adversely affect revenue generation."
            },
            {
              "key": "Product Liability Risk",
              "value": "Potential product liability lawsuits related to commercialization and clinical testing of ARCALYST or product candidates could incur substantial liabilities and limit market demand."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 54,
          "title": "Risk Factors: Liability, Insurance, and Commercialization Challenges",
          "data": [
            {
              "key": "Reputation and Media Risk",
              "value": "Potential injury to reputation and significant negative media attention may adversely affect the business."
            },
            {
              "key": "Regulatory and Litigation Risk",
              "value": "Regulatory investigations could result in costly recalls, product modifications, and expensive litigation defense, including substantial monetary awards to trial participants."
            },
            {
              "key": "Insurance Coverage Concerns",
              "value": "Existing product liability insurance may be inadequate due to deductibles, coverage limitations, and rising costs, increasing potential liabilities."
            },
            {
              "key": "Sales and Marketing Challenges",
              "value": "Difficulties in maintaining or establishing effective sales, marketing, and distribution capabilities may delay product launches and impair revenue generation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 55,
          "title": "Risks and Challenges in International Commercialization",
          "data": [
            {
              "key": "Market Penetration",
              "value": "Dependence on success in penetrating markets outside the United States with additional regulatory burdens."
            },
            {
              "key": "Regulatory Approval",
              "value": "The necessity to obtain separate regulatory approval in non-US markets, with complex and varying safety, efficacy, clinical trial, manufacturing, and pricing requirements."
            },
            {
              "key": "Third Party Collaborations",
              "value": "Reliance on collaborations and managed access programs, which may limit direct control over commercialization efforts."
            },
            {
              "key": "Economic and Political Risks",
              "value": "Exposure to risks including governmental controls, political and economic instability, trade restrictions, and tariff changes."
            },
            {
              "key": "Additional Commercial Risks",
              "value": "Risks related to reimbursement challenges, longer shipping lead times, language barriers, intellectual property protection issues, and foreign currency exchange rate fluctuations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 56,
          "title": "Risk Factors – Regulatory and Commercialization Challenges",
          "data": [
            {
              "key": "Coverage and Reimbursement",
              "value": "Limited or unavailable reimbursement and unsatisfactory pricing levels could materially harm our business."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Ongoing regulatory requirements including manufacturing, labeling, post-marketing trials, and inspections increase expenses and impose additional burdens."
            },
            {
              "key": "Product Approval & Restrictions",
              "value": "Regulatory approvals may come with limitations, conditions such as REMS, and requirements for additional trials, potentially affecting marketing and sales."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 58,
          "title": "Regulatory and Compliance Restrictions",
          "data": [
            {
              "key": "Anti-Kickback Statute",
              "value": "Prohibits knowingly soliciting, offering, receiving, or providing remuneration to induce referrals or orders under federal and state healthcare programs such as Medicare and Medicaid."
            },
            {
              "key": "False Claims Act",
              "value": "Imposes criminal and civil penalties for knowingly submitting or causing the submission of false or fraudulent claims to the federal government."
            },
            {
              "key": "Foreign Corrupt Practices Act (FCPA)",
              "value": "Prohibits U.S. companies and representatives from paying, promising to pay, or authorizing payment to foreign officials to obtain or retain business, and requires accurate record keeping."
            },
            {
              "key": "HIPAA",
              "value": "Imposes civil and criminal liability for schemes to defraud healthcare benefit programs and for falsifying or concealing material facts in connection with healthcare benefits."
            },
            {
              "key": "Physician Payment Transparency (Sunshine Act)",
              "value": "Requires manufacturers to report financial interactions with healthcare providers, including physicians and certain non-physician practitioners."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 60,
          "title": "Risks Related to Product Development",
          "data": [
            {
              "key": "Risk Section",
              "value": "Risks Related to Product Development"
            },
            {
              "key": "Dependency",
              "value": "Heavy reliance on the success of one or more products and product candidates in clinical development"
            },
            {
              "key": "Regulatory Approval",
              "value": "No marketing or promotion allowed before obtaining FDA or comparable regulatory approvals"
            },
            {
              "key": "Critical Factors",
              "value": "Advancement of clinical trials, positive clinical data, successful site activation, and timely regulatory approvals"
            },
            {
              "key": "Potential Impact",
              "value": "Failure to advance product candidates or secure regulatory approvals could significantly harm business operations"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 61,
          "title": "Risk Factors Related to Product Candidates and Commercialization Challenges",
          "data": [
            {
              "key": "Successful development of manufacturing processes",
              "value": "Successful development of manufacturing processes and transfer to CDMO facilities."
            },
            {
              "key": "Regulatory compliance",
              "value": "Compliance with all regulatory requirements."
            },
            {
              "key": "Production capacity",
              "value": "Sufficient supply of product candidates within approved specifications."
            },
            {
              "key": "Patent protection",
              "value": "Establishment and maintenance of patent and trade secret protection."
            },
            {
              "key": "Commercial launch",
              "value": "Timely and successful commercial launch of product candidates."
            },
            {
              "key": "Adoption of products",
              "value": "Adoption of products by patients and payors."
            },
            {
              "key": "Competition",
              "value": "Effective competition with other therapies."
            },
            {
              "key": "Healthcare coverage",
              "value": "Establishment of adequate healthcare coverage and reimbursement."
            },
            {
              "key": "Intellectual property rights",
              "value": "Enforcement and defense of intellectual property rights."
            },
            {
              "key": "Post-marketing compliance",
              "value": "Continued compliance with post-marketing requirements."
            },
            {
              "key": "Safety profile",
              "value": "Maintenance of acceptable safety profile post-approval."
            },
            {
              "key": "Commercialization risks",
              "value": "Potential significant delays or inability to commercialize products."
            },
            {
              "key": "Revenue generation risks",
              "value": "Need for sufficient revenue from commercialization to continue operations."
            },
            {
              "key": "Capital needs",
              "value": "Substantial additional financing may be required."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 62,
          "title": "Clinical Drug Development Risk Factors",
          "data": [
            {
              "key": "Overview",
              "value": "Clinical drug development is lengthy and expensive, with uncertain timelines and outcomes. There is significant risk associated with delays in clinical trials and challenges in demonstrating safety and efficacy."
            },
            {
              "key": "Regulatory Approval Risks",
              "value": "The process requires extensive clinical trials and regulatory approvals (e.g., IND, CTA, BLA, MAA). Failure to obtain such approvals may hinder commercialization of product candidates."
            },
            {
              "key": "Trial Delays and Uncertainties",
              "value": "Trials may experience delays or may not be conducted or completed as planned. Unfavorable or statistically insignificant results can occur, exemplified by the December 2021 phase 3 trial of mavrilimumab in COVID-19-related ARDS."
            },
            {
              "key": "Impact of External Factors",
              "value": "Factors such as the COVID-19 pandemic, regulatory feedback, and additional study requirements can further delay or complicate clinical trials."
            },
            {
              "key": "Business Risk",
              "value": "Failure to successfully conduct clinical trials and secure regulatory approval poses material risks to the business, impacting the ability to recoup significant investments in clinical development."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 63,
          "title": "Risks Related to Clinical Trials",
          "data": [
            {
              "key": "Risk of delays in clinical trials",
              "value": "Events that have and may in the future delay or prevent commencement or successful completion of clinical development of product candidates include inability to generate sufficient preclinical or in vivo or in vitro data."
            },
            {
              "key": "Regulatory challenges",
              "value": "Delays or failure in reaching consensus with regulatory agencies on trial design or obtaining regulatory approval."
            },
            {
              "key": "CRO and clinical site negotiations",
              "value": "Delays in reaching agreements with prospective CROs and clinical trial sites."
            },
            {
              "key": "Ethics approvals",
              "value": "Difficulties in obtaining IRB or ethics committee approval at each clinical trial site."
            },
            {
              "key": "Participant enrollment challenges",
              "value": "Difficulty in identifying and enrolling suitable participants."
            },
            {
              "key": "Protocol amendments",
              "value": "Amendments to clinical trial protocols impacting study criteria, endpoints, or design."
            },
            {
              "key": "Collaboration issues with patient groups",
              "value": "Difficulty collaborating with patient groups and investigators."
            },
            {
              "key": "Third-party compliance issues",
              "value": "Failure of CROs and medical institutions to adhere to clinical trial requirements."
            },
            {
              "key": "GCP compliance",
              "value": "Failure to perform in accordance with FDA’s good clinical practices."
            },
            {
              "key": "COVID-19 impacts",
              "value": "Participants not completing trials or withdrawing due to demands or pandemic-related measures."
            },
            {
              "key": "Serious adverse events",
              "value": "Participants experiencing serious adverse events or undesirable side effects."
            },
            {
              "key": "Safety issues",
              "value": "Occurrence of adverse events associated with a product candidate that outweigh potential benefits."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 64,
          "title": "Risk Factors Related to Clinical Trials and Regulatory Delays",
          "data": [
            {
              "key": "regulatory_changes",
              "value": "Changes in regulatory requirements, policies and guidance that require amending or submitting new clinical protocols."
            },
            {
              "key": "clinical_trial_costs",
              "value": "The cost of clinical trials being greater than anticipated."
            },
            {
              "key": "clinical_study_priority",
              "value": "Strategic decisions regarding clinical study prioritization for capital preservation purposes."
            },
            {
              "key": "data_collection_failures",
              "value": "Failure by the company, CROs, or third parties to properly collect, analyze, and assess clinical data, affecting assay performance and other activities."
            },
            {
              "key": "negative_trial_outcomes",
              "value": "Clinical trials producing negative, inconclusive, or uncompetitive results, potentially leading to additional trials or modifications in development programs."
            },
            {
              "key": "replication_failures",
              "value": "Failure to replicate safety, efficacy, or other data from earlier preclinical studies and clinical trials."
            },
            {
              "key": "adverse_events",
              "value": "Occurrence of adverse or other unexpected events not observed in earlier studies."
            },
            {
              "key": "trial_suspensions",
              "value": "Suspensions or terminations of clinical trials by the company, IRBs, Data Safety Monitoring Boards, or regulatory authorities."
            },
            {
              "key": "supply_issues",
              "value": "Failure of manufacturers or the company to produce phase-appropriate, cGMP-compliant supplies for clinical trials."
            },
            {
              "key": "manufacturing_delays",
              "value": "Delays in manufacturing, testing, releasing, validating, or importing/exporting stable quantities of product candidates."
            },
            {
              "key": "business_disruptions",
              "value": "Disruptions to business operations, including supply chain and manufacturing, exacerbated by the COVID-19 pandemic."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 66,
          "title": "Risk Factors: Impact of War in Ukraine and COVID-19 on Clinical Operations",
          "data": [
            {
              "key": "War in Ukraine",
              "value": "The document notes that the ongoing war in Ukraine may materially affect clinical activities and product candidate development timelines, impacting global economy, equity capital markets, and clinical operations."
            },
            {
              "key": "COVID-19 Impact",
              "value": "The COVID-19 pandemic and related measures are described as having significant adverse effects on preclinical studies and clinical trials, with potential disruptions including delays, production impediments, and interruptions in trial operations."
            },
            {
              "key": "Supply Chain Disruptions",
              "value": "There are concerns over interruptions in the production, delivery, and release of product candidates and clinical trial materials resulting from global shipping delays, raw material supply issues, and manufacturing disruptions."
            },
            {
              "key": "Clinical Trial Challenges",
              "value": "The text details various obstacles such as travel restrictions, staffing shortages, difficulties with site initiation, and risks of COVID-19 infections among trial participants, all impacting trial conduct and data integrity."
            },
            {
              "key": "Regulatory Delays",
              "value": "The risk of delays in regulatory review and approval processes is highlighted, including possible interruptions at agencies like the FDA, which could affect the acceptance of clinical trial data."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 68,
          "title": "Risk Factors in Clinical Trials and Product Safety",
          "data": [
            {
              "key": "Clinical Trial Enrollment Risks",
              "value": "Difficulties in recruiting eligible participants due to strict eligibility criteria, proximity to clinical sites, and competing clinical trials, which may increase costs and delay timelines."
            },
            {
              "key": "Safety and Adverse Events Risks",
              "value": "Potential for undesirable side effects and adverse events, including immunosuppression and specific risks such as pulmonary alveolar proteinosis (PAP) associated with mavrilimumab, which could interrupt or delay clinical trials and regulatory approvals."
            },
            {
              "key": "Regulatory and Commercial Impact",
              "value": "Safety concerns and trial disruptions may lead to delayed or denied regulatory approvals, negatively impacting the product candidates’ commercial prospects and revenue generation."
            },
            {
              "key": "External Factors: COVID-19",
              "value": "The ongoing COVID-19 pandemic may further complicate participant enrollment and trial execution, exacerbating recruitment challenges and increasing costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 69,
          "title": "Regulatory and Safety Risks in Clinical Trials",
          "data": [
            {
              "key": "Dosing and Clinical Effect",
              "value": "Relevant doses do not reach the lungs in sufficient quantities to induce PAP and human trials have not demonstrated a clinical impact on pulmonary function tests attributable to mavrilimumab."
            },
            {
              "key": "Adverse Side Effects",
              "value": "If clinical trials reveal unacceptable severity and prevalence of certain side effects, regulatory authorities (FDA or others) may suspend, terminate, or deny further trials."
            },
            {
              "key": "Third Party Implications",
              "value": "Similar side effects observed in molecules developed by third parties may influence regulatory decisions and affect the entire class of molecules."
            },
            {
              "key": "Regulatory Actions",
              "value": "Regulatory authorities could order cessation of product development, require additional warnings or changes to product administration, or even withdraw product approvals if adverse effects are significant."
            },
            {
              "key": "Commercial and Legal Consequences",
              "value": "Potential outcomes include market withdrawal, additional clinical trials, legal liabilities, restricted promotion, decreased sales, and harm to reputation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 70,
          "title": "Risks Related to Interim Data and Regulatory Approval",
          "data": [
            {
              "key": "Interim Data Risks",
              "value": "Interim, preliminary, and topline data from clinical and preclinical trials may be subject to change upon further analysis, audit, and verification, which may significantly affect the development and approval of the product candidate."
            },
            {
              "key": "Regulatory Approval Risks",
              "value": "The lengthy, unpredictable, and resource-intensive regulatory approval processes may delay or prevent commercialization of the product candidates, potentially harming business prospects, operating results, and share price volatility."
            },
            {
              "key": "Data Discrepancies Impact",
              "value": "Material differences between interim data and final data, or disagreement with third-party analyses, may adversely impact regulatory approvals and the perceived value of the product candidate."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 72,
          "title": "Table of Contents - Risk Factors",
          "data": [
            {
              "key": "Clinical trial endpoints",
              "value": "The results of clinical trials may not meet the primary or secondary endpoints of the applicable trial or the level of statistical significance required by regulatory authorities."
            },
            {
              "key": "Regulatory disagreement with data interpretation",
              "value": "Regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials."
            },
            {
              "key": "Insufficient clinical trial data",
              "value": "The data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA, sBLA or other submission or to obtain regulatory approval in the United States or elsewhere."
            },
            {
              "key": "Enrollment and participant issues",
              "value": "The number of participants required may be larger than anticipated, enrollment may be slower, dropouts may be higher, or suitable participants may not be recruited."
            },
            {
              "key": "Third-party contractor compliance risk",
              "value": "Our third-party contractors may fail to comply with data quality and regulatory requirements or meet their contractual obligations in a timely manner, or at all."
            },
            {
              "key": "Manufacturing and quality approval risk",
              "value": "Regulatory authorities may not believe that we have sufficiently demonstrated our ability to manufacture products to the requisite level of quality standards, or may fail to approve our manufacturing processes or facilities."
            },
            {
              "key": "Integrity of clinical trial conduct",
              "value": "Regulatory authorities may not believe that on-site inspections and data audits have sufficiently demonstrated the quality and integrity of the clinical trial conduct and data submitted."
            },
            {
              "key": "Supply and quality issues",
              "value": "The supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate."
            },
            {
              "key": "Adverse effects and unexpected characteristics",
              "value": "Our product candidates may have undesirable side effects, toxicities or other unexpected characteristics, leading to rejection, suspension or termination of clinical trials."
            },
            {
              "key": "Regulatory change risks",
              "value": "Approval policies or regulations may change significantly, rendering our clinical data, manufacturing process and supporting information insufficient for approval."
            },
            {
              "key": "Approval limitation risk",
              "value": "Even if approved, regulatory authorities might approve our product candidates for fewer indications or more limited patient populations than requested, or impose conditions that harm commercial prospects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 74,
          "title": "Orphan Drug Designation and Regulatory Exclusivity Risks",
          "data": [
            {
              "key": "Regulatory Framework",
              "value": "Describes U.S. Orphan Drug Act and EU criteria for orphan drug designation, including patient population thresholds and exclusivity conditions."
            },
            {
              "key": "Exclusivity Period (US)",
              "value": "Seven years of market exclusivity granted upon approval for the designated indication."
            },
            {
              "key": "Exclusivity Period (EU)",
              "value": "Ten years of market exclusivity, potentially reduced to six years if criteria are not maintained."
            },
            {
              "key": "Competitive Risk",
              "value": "Risk that competitors may obtain orphan drug exclusivity for similar products, limiting approval of competing applications."
            },
            {
              "key": "Regulatory Designations",
              "value": "Discussion of additional pathways such as Breakthrough Therapy and Fast Track designations, which are not guaranteed to accelerate approval or secure exclusivity."
            },
            {
              "key": "Potential Loss of Exclusivity",
              "value": "Orphan Drug exclusivity may be lost if designation is found to be defective or if adequate manufacturing is not maintained."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 76,
          "title": "Regulatory and Marketing Authorization Risks",
          "data": [
            {
              "key": "Marketing Authorization Type",
              "value": "Under exceptional circumstances; similar to conditional marketing authorization but with permanent exemption from providing missing data."
            },
            {
              "key": "Data Set Completeness",
              "value": "Applicant does not hold complete data set legally required for full marketing authorization."
            },
            {
              "key": "Risk-Benefit Review",
              "value": "Annual review of the risk-benefit balance, with potential withdrawal if no longer favorable."
            },
            {
              "key": "Regulatory Authority Discretion",
              "value": "Broad discretion by EU and FDA regulatory authorities to grant accelerated, conditional, or exceptional approvals."
            },
            {
              "key": "Approval Delays",
              "value": "Potential delays or inability to obtain marketing approvals may adversely impact business and financial performance."
            },
            {
              "key": "Impact of Regulatory Disruptions",
              "value": "Disruptions at agencies (e.g., FDA shutdowns, staff furloughs, relocation of EMA) may delay product development and commercialization."
            },
            {
              "key": "Business Impact",
              "value": "Regulatory failures or delays could force modifications or cessation of development efforts, harming financial condition and revenue prospects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 77,
          "title": "Risks Related to Regulatory Inspections, Manufacturing, and Third-Party Dependence",
          "data": [
            {
              "key": "COVID-19 Impact on Inspections",
              "value": "FDA postponed inspections of domestic and foreign facilities; resumed domestic inspections when feasible, but continued monitoring and changes due to evolving pandemic and potential virus resurgence."
            },
            {
              "key": "Regulatory Delay Risk",
              "value": "Prolonged government shutdowns or global health concerns could delay regulatory reviews and impact timely processing of regulatory submissions."
            },
            {
              "key": "Reliance on Third-Party Manufacturing",
              "value": "Contracting with third parties for ARCALYST manufacturing and clinical supplies increases risk of insufficient supply, delays, impaired development or commercialization efforts."
            },
            {
              "key": "Manufacturing and Supply Chain Risks",
              "value": "Issues such as equipment failure, inability to source replacement parts, production interruptions, and potential recalls could adversely affect business operations."
            },
            {
              "key": "Exclusive Manufacturing Dependency",
              "value": "Reliance on Regeneron and its CMOs as sole manufacturers for ARCALYST with limited control over production operations heightens risk of supply disruptions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 80,
          "title": "Risk Factors: Hazardous Materials and Manufacturing Risks",
          "data": [
            {
              "key": "Exposure to Hazardous Materials",
              "value": "The document details the use, storage, handling, and disposal of hazardous materials, which poses risks of contamination and environmental damage."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Risks associated with adhering to complex and frequently changing environmental laws and regulations are highlighted."
            },
            {
              "key": "Manufacturing Challenges",
              "value": "Issues in manufacturing processes, potential for contamination, deviations from standard processes, and the impact on product quality and supply are described."
            },
            {
              "key": "Third-Party Risks",
              "value": "Reliance on third-party manufacturers and suppliers increases the risk of supply disruptions and quality control issues."
            },
            {
              "key": "Financial and Legal Liability",
              "value": "Potential liabilities from hazardous incidents, clean-up costs, and the possibility of business interruptions are emphasized."
            },
            {
              "key": "Supply Chain Disruption",
              "value": "Potential disruptions from manufacturing or supply issues can delay product commercialization and impact revenue."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 83,
          "title": "Risk Factors – Third Party Dependencies in Clinical Trials",
          "data": [
            {
              "key": "Reliance on Third Parties",
              "value": "The document emphasizes the reliance on external entities such as independent investigators, CROs, clinical trial sites, medical institutions, and laboratories to conduct preclinical studies and clinical trials for product candidates."
            },
            {
              "key": "Regulatory Compliance and Risks",
              "value": "It highlights the need for these third parties to comply with applicable regulatory requirements (e.g., GLP, GCP, cGMP) and that failure to do so could jeopardize regulatory approvals or require repeating trials, potentially incurring civil penalties or enforcement actions."
            },
            {
              "key": "Limited Direct Control",
              "value": "The content notes that while contracts and quality monitoring mechanisms exist, the company has limited direct control over the operational performance, scheduling, and resource allocation of these third-party organizations."
            },
            {
              "key": "External Disruptions",
              "value": "Risks are also described in connection with external events such as staffing issues, disruptions due to epidemic/pandemic (e.g., COVID-19), and geopolitical events (e.g., war in Ukraine), which can adversely impact clinical trial operations."
            },
            {
              "key": "Impact on Business and Trial Integrity",
              "value": "The failure of third parties to perform as required could delay product candidate commercialization, impact the integrity of clinical data, and potentially delay regulatory approvals."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 84,
          "title": "Risk Factors Related to Third-Party Clinical Trial Operations",
          "data": [
            {
              "key": "Context",
              "value": "Discussion on how failures or underperformance by CROs, subcontractors, and clinical trial sites can adversely impact clinical operations."
            },
            {
              "key": "Risk Factors",
              "value": "Potential non-compliance with contractual obligations, difficulties in controlling subcontractor performance, regulatory compliance issues, changes in priorities, and financial distress among service providers."
            },
            {
              "key": "Impact",
              "value": "Delays in clinical trial execution, increased costs, potential repetition or extension of trials, impaired regulatory approval, and delays in commercialization of product candidates."
            },
            {
              "key": "Confidentiality Concerns",
              "value": "Need to share proprietary trade secrets with third-party providers increases the risk of misappropriation or unauthorized disclosure, which may harm competitive positioning."
            },
            {
              "key": "Overall Concern",
              "value": "These factors highlight significant risks that could materially harm the company's clinical operations, financial outcomes, and market competitiveness."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 85,
          "title": "Risk Factors – Competition and Intellectual Property",
          "data": [
            {
              "key": "risk_description",
              "value": "If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed."
            },
            {
              "key": "competition",
              "value": "Substantial competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide."
            },
            {
              "key": "drug_development_environment",
              "value": "The development and commercialization of new drugs and biologics is highly competitive; competitors may discover, develop, or commercialize drugs before us."
            },
            {
              "key": "competitor_details",
              "value": "Competitors include large pharmaceutical companies, biotech firms, academic institutions, government agencies, and other research organizations."
            },
            {
              "key": "clinical_programs",
              "value": "Mentions various clinical-stage development programs, including those for recurrent pericarditis and other indications, with details about programs for molecules such as RPH-104, cannabidiol, anakinra, canakinumab, and others."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 88,
          "title": "Risk Factors and Collaboration Challenges",
          "data": [
            {
              "key": "Tax Consequences",
              "value": "Transactions or arrangements may have unfavorable tax consequences for US shareholders."
            },
            {
              "key": "Territory-Specific Rights",
              "value": "Granting territory-specific rights for products or candidates may reduce their attractiveness for future business development."
            },
            {
              "key": "Sublicense Consent Requirement",
              "value": "The right to grant a sublicense of licensed intellectual property requires the consent of the applicable licensor."
            },
            {
              "key": "Collaboration Success Dependency",
              "value": "Success of collaborations, licenses, or strategic transactions depends heavily on the efforts and resources committed by collaborators or sublicensees."
            },
            {
              "key": "Past Collaboration Failures",
              "value": "The company has experienced collaboration failure in the past and may face similar issues in the future."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "Risks include inadequate prosecution, maintenance, or defense of intellectual property, potentially resulting in litigation or reduced patentability."
            },
            {
              "key": "Financial and Operational Risks",
              "value": "Potential delays, disputes, or refusals to pay milestone and royalty payments could impact the company's ability to meet upstream obligations. Additionally, management's focus on development and expansion may divert attention from day-to-day operations."
            },
            {
              "key": "Additional Capital Needs",
              "value": "Termination of strategic arrangements could require additional capital for further development or commercialization."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 89,
          "title": "Risk Factors and Intellectual Property Considerations",
          "data": [
            {
              "key": "System Implementation Challenges",
              "value": "The new system requires specific skills and expertise for setup, maintenance, and utilization, potentially necessitating additional resource expenditure."
            },
            {
              "key": "Employee Overload and Resource Limitations",
              "value": "Limited internal resources force employees to perform activities beyond their regular scope, risking managerial, operational, and financial errors."
            },
            {
              "key": "Expansion and Development Risks",
              "value": "Company development and expansion may increase costs, diverting financial resources from other projects such as product candidate development and commercialization."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "Inadequate protection or narrow patent scope could allow competitors to develop similar technology, undermining the commercialization and competitive advantage of products like ARCALYST, KPL-404, and mavrilimumab."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 91,
          "title": "Patent Risk Factors and Regulatory Uncertainties",
          "data": [
            {
              "key": "Patent Expiration",
              "value": "Patents protecting product candidates, such as ARCALYST and mavrilimumab, are subject to expiration risks. For ARCALYST, U.S. patents have expired and European patents expire in 2023. Mavrilimumab patents expire in 2027 in both the U.S. and Europe, not including any potential extensions or adjustments."
            },
            {
              "key": "Regulatory Exclusivity",
              "value": "Due to the long development and regulatory review process, reliance on regulatory exclusivity is expected. The period of exclusivity varies by country and is triggered by the product candidate's regulatory approval, which is uncertain."
            },
            {
              "key": "Patent Term Limitations",
              "value": "In-licensed patent portfolios may already have experienced considerable loss of patent term, reducing the competitive protection that the patents provide. This raises concerns about the adequacy of protection against competitors."
            },
            {
              "key": "Patent Prosecution Challenges",
              "value": "The patent prosecution process is expensive and time-consuming, often resulting in narrowed claims and uncertainty regarding the scope, validity, and enforceability of issued patents."
            },
            {
              "key": "Coordination Risks with Licensees",
              "value": "In cases where technology is in-licensed or out-licensed, control over filing, prosecution, and maintenance may be limited, potentially exposing the patents to risks if coordinated efforts are misaligned."
            },
            {
              "key": "Uncertainty in Patent Position",
              "value": "Publications and delays in patent application disclosures make it hard to ascertain if the company was first in making or filing for the inventions, further adding to the uncertainty around competitive patent positions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 92,
          "title": "Patent Invalidation and Enforcement Risk",
          "data": [
            {
              "key": "Overview",
              "value": "The issuance of a patent is not conclusive regarding inventorship, scope, validity, enforceability or term."
            },
            {
              "key": "Third-Party Challenges",
              "value": "Our owned and licensed patents may be subject to third-party challenges such as prior art submissions, derivation, re-examination, interference, post-grant review, or inter partes review proceedings."
            },
            {
              "key": "Global Litigation Risks",
              "value": "Patents in the United States, Europe, and other jurisdictions may face opposition proceedings that could narrow, invalidate, or render them unenforceable."
            },
            {
              "key": "Operational Impact",
              "value": "Such proceedings can be expensive, time-consuming and may divert technical and managerial resources, potentially harming the business."
            },
            {
              "key": "Potential Business Consequences",
              "value": "An adverse determination may result in loss of exclusivity, reduced protection duration, diminished royalty obligations, and challenges in stopping competitors from commercializing similar technology."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 93,
          "title": "Table of Contents protection",
          "data": [
            {
              "key": "Risk Description",
              "value": "The text outlines risks related to insufficient patent protection and challenges to IP rights that could negatively affect the commercialization of product candidates."
            },
            {
              "key": "Licensing Agreements",
              "value": "Details agreements with Regeneron (ARCALYST), MedImmune (mavrilimumab), and BIDMC (KPL-404), which require maintaining diligent development efforts, milestone payments, and adherence to license terms."
            },
            {
              "key": "Obligations and Disputes",
              "value": "Highlights the potential for disputes over diligence obligations, scope of granted rights, payment terms, infringement issues, sublicense rights, IP ownership, and transfer rights."
            },
            {
              "key": "Business Impact",
              "value": "Any adverse outcomes from IP protection challenges, delays in clinical trials, or breaches in licensing agreements could limit the period of market exclusivity and harm the business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 95,
          "title": "Intellectual Property and Patent Litigation Risks",
          "data": [
            {
              "key": "Patent Infringement Risk",
              "value": "The document discusses concerns that activities related to KPL-404 and mavrilimumab might infringe existing patents, including challenges in overcoming the statutory presumption of validity of U.S. patents."
            },
            {
              "key": "Licensing Challenges",
              "value": "It highlights potential difficulties in obtaining licenses to third-party patents, noting that competitors may have advantages due to their size and resources."
            },
            {
              "key": "Litigation Exposure",
              "value": "The text emphasizes the possibility of litigation, which could delay or halt development, impose financial liabilities including damages and legal fees, and require redesigning or ceasing certain business operations."
            },
            {
              "key": "Competitive and Strategic Impact",
              "value": "There is a broader risk concerning reliance on acquiring or in-licensing crucial intellectual property rights in a competitive area, potentially affecting the company’s market position and development efforts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 96,
          "title": "Intellectual Property Litigation Risk",
          "data": [
            {
              "key": "Litigation Exposure",
              "value": "Discussion of potential patent litigation including counterclaims, invalidity challenges, and risks related to enforcement of patents."
            },
            {
              "key": "Risk Factors",
              "value": "Potential adverse impact on business due to high litigation costs, resource diversion, and exposure of confidential information."
            },
            {
              "key": "Competitor Capability",
              "value": "Competitors may have greater resources and broader patent portfolios to challenge intellectual property claims."
            },
            {
              "key": "Unpredictability",
              "value": "Litigation outcomes are unpredictable and may result in loss of patent protection for key product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 99,
          "title": "Risk Factors: Trade Secrets and Patent Litigation",
          "data": [
            {
              "key": "Patent Application Option",
              "value": "In Europe, beginning no earlier than October 1, 2022, European patent applications can become a 'Unitary Patent' subject to the jurisdiction of the new Unitary Patent Court (UPC)."
            },
            {
              "key": "UPC Uncertainty",
              "value": "As the UPC is a new court with no existing precedents, its rulings are unpredictable, thereby increasing the uncertainty of any litigation involving a Unitary Patent."
            },
            {
              "key": "Trade Secret Protection",
              "value": "The document highlights that failure to adequately protect trade secrets may harm the business and competitive position, despite measures such as patents, confidentiality agreements, and security protocols."
            },
            {
              "key": "Enforcement Challenges",
              "value": "It notes difficulties in monitoring unauthorized use, detecting breaches, and the high costs and unpredictability associated with enforcing intellectual property rights and trade secret protections."
            },
            {
              "key": "Competitor Risks",
              "value": "There is a risk that competitors could replicate or independently develop similar technologies, thereby eroding the competitive advantages derived from proprietary technology."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 100,
          "title": "Risk Factors: Trademark, Trade Secret, and Geopolitical Risks",
          "data": [
            {
              "key": "Trade Secret Risks",
              "value": "Reliance on third parties forces the company to share trade secrets, increasing the risk of misappropriation or disclosure, which could benefit competitors."
            },
            {
              "key": "Trademark and Trade Name Challenges",
              "value": "Inadequate protection and registration of trademarks or trade names could hinder brand recognition and lead to potential infringement or genericization issues."
            },
            {
              "key": "Regulatory and Approval Concerns",
              "value": "Product names, even if used as trademarks, must be approved by the FDA. Objections can require significant resources to resolve."
            },
            {
              "key": "Geopolitical and Market Risks",
              "value": "The ongoing war in Ukraine and associated sanctions against Russia have destabilized global markets, disrupted supply chains, and increased financial and operational uncertainty."
            },
            {
              "key": "Overall Business Impact",
              "value": "Inability to protect intellectual property and manage geopolitical risks may adversely affect the company's market position, operations, and financial results."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 101,
          "title": "Impact of Global Events on Business Operations",
          "data": [
            {
              "key": "Global Risks",
              "value": "Adverse effects on global economy and financial markets due to sanctions and military actions."
            },
            {
              "key": "Supply Chain",
              "value": "Potential disruptions in global supply chains impacting operations."
            },
            {
              "key": "Capital Raising",
              "value": "Inability to raise additional capital under acceptable terms."
            },
            {
              "key": "Clinical Trials",
              "value": "Disruptions in clinical trials due to geopolitical conflicts."
            },
            {
              "key": "Cybersecurity Risks",
              "value": "Increased likelihood of cyberattacks due to geopolitical tensions."
            },
            {
              "key": "COVID-19 Pandemic",
              "value": "Significant adverse impact of the COVID-19 pandemic on operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 102,
          "title": "Risk Factors: COVID‑19 Impact on Business Operations",
          "data": [
            {
              "key": "COVID-19 Pandemic Impact",
              "value": "Prolonged pandemic and emergence of new variants may lead to staffing shortages, production slowdowns/stoppages, and disruptions in delivery systems."
            },
            {
              "key": "Operational Risks",
              "value": "Implementation of workplace protocols and vaccination requirements can help, but do not guarantee prevention of virus spread among employees, potentially affecting business operations."
            },
            {
              "key": "Clinical and Commercialization Risks",
              "value": "Impact on preclinical studies and clinical trials may delay or prevent regulatory approvals, affecting the commercialization of products like ARCALYST and other product candidates."
            },
            {
              "key": "Supply Chain Disruptions",
              "value": "Third party manufacturers, suppliers, and availability of critical materials (e.g. vials, stoppers, sterile water, needles) may be affected, posing risks to production and supply."
            },
            {
              "key": "Economic Downturn Risks",
              "value": "A severe or prolonged economic downturn resulting from the pandemic could cause disruptions in financial markets and lead to lower than anticipated revenue."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 103,
          "title": "Disruptions to Capital Markets and Regulatory Uncertainty",
          "data": [
            {
              "key": "Brexit Impact",
              "value": "The UK’s withdrawal from the EU has led to a distinct regulatory regime, creating uncertainty in global economic conditions and financial markets."
            },
            {
              "key": "Capital Raising Challenges",
              "value": "Disruptions may adversely impact the ability to raise additional capital on acceptable terms."
            },
            {
              "key": "Regulatory Changes",
              "value": "Transition to retained EU law and upcoming legislative changes (e.g. the Retained EU Law Bill 2022) introduce risks regarding future regulation of medicinal products."
            },
            {
              "key": "Clinical Trials and Supply Chain Disruption",
              "value": "Uncertainty around alignment with EU clinical trial regulations and delays in marketing authorization may increase costs and complicate the conduct of clinical trials, including disruptions from the EMA relocation."
            },
            {
              "key": "Market Volatility and Political Instability",
              "value": "Increased market volatility, asset valuation fluctuations, and noted political instability in the UK further compound the risks."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 104,
          "title": "Risk Factors and Regulatory Compliance",
          "data": [
            {
              "key": "Product Development Delays",
              "value": "The framework may add considerably to the development lead time to marketing authorization and commercialization in the EU/UK, potentially hindering clinical trials and approval of products like ARCALYST."
            },
            {
              "key": "Political Instability and Brexit Impact",
              "value": "Political instability in the EU due to Brexit could negatively affect credit markets, foreign direct investments, and global economic conditions, reducing market liquidity and access to capital."
            },
            {
              "key": "Adverse Effect on Business",
              "value": "These factors may have a material adverse effect on the company’s business, financial condition, and results of operations, potentially reducing the share price."
            },
            {
              "key": "Medicaid Drug Rebate Program (MDRP) Risks",
              "value": "Failure to comply with reporting and payment obligations under the MDRP may lead to additional reimbursement requirements, penalties, sanctions, fines, and even termination from the program."
            },
            {
              "key": "340B Program Obligations",
              "value": "Participation in the 340B program requires adherence to pricing and reporting regulations, with violations potentially resulting in civil monetary penalties and additional disputes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 106,
          "title": "Regulatory and Legislative Risk Factors",
          "data": [
            {
              "key": "Legislative Interest",
              "value": "Increasing legislative and enforcement attention in the U.S. regarding specialty drug pricing practices, aimed at transparency and cost reduction."
            },
            {
              "key": "CMS Final Rule & Medicare Advantage",
              "value": "In May 2019, CMS issued a final rule allowing Medicare Advantage Plans to implement step therapy for Part B drugs, highlighting regulatory changes."
            },
            {
              "key": "IRA Provisions",
              "value": "The Inflation Reduction Act (IRA) mandates price negotiations with Medicare beginning in 2026, rebates to penalize excessive price increases, and changes to discount programs, with uncertain implementation."
            },
            {
              "key": "Regulatory Uncertainty",
              "value": "Ongoing uncertainty regarding the implementation of the IRA and future U.S. federal healthcare reforms, which may affect reimbursement policies and pricing pressures."
            },
            {
              "key": "International Regulatory Impact",
              "value": "Similar legislative and regulatory challenges in the EU and other markets could delay approvals and affect the commercialization of product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 107,
          "title": "Risk Factors - Global Economic and Operational Risks",
          "data": [
            {
              "key": "Global Economic Conditions",
              "value": "Unfavorable global economic and operational conditions, including inflation and interest rate increases, may adversely affect the business, its financial condition, and operations."
            },
            {
              "key": "COVID-19 Pandemic",
              "value": "The COVID-19 pandemic has impacted operations and could continue to affect business processes, regulatory approvals, and the supply chain."
            },
            {
              "key": "War in Ukraine",
              "value": "The ongoing war in Ukraine and related measures against Russia could negatively impact the global economy, equity markets, and clinical operations."
            },
            {
              "key": "Financial Market Volatility",
              "value": "Recent volatility, including diminished liquidity and credit availability, rising interest rates, and economic instability, could impair manufacturing, marketing, and sales activities."
            },
            {
              "key": "International Business Risks",
              "value": "Risks include complexities due to conflicting laws and regulations, challenges in obtaining regulatory approvals internationally, and exposure to foreign exchange fluctuations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 108,
          "title": "Risk Factors: Regulatory and Cybersecurity Concerns",
          "data": [
            {
              "key": "Regulatory & Compliance Risks",
              "value": "Concerns related to maintaining accurate information, control over clinical activities, and compliance with the U.S. Foreign Corrupt Practices Act and its provisions."
            },
            {
              "key": "Cybersecurity Risks",
              "value": "Potential failures of information technology systems, cyberattacks, security breaches, and vulnerabilities stemming from remote work, third-party contractors, and evolving cyber threats."
            },
            {
              "key": "Operational Impact",
              "value": "Disruptions could lead to material interruptions in business operations, development program delays, increased costs for data recovery, and challenges in regulatory approval efforts."
            },
            {
              "key": "Data Privacy & Protection",
              "value": "Risks associated with failure to comply with data protection laws, potential unauthorized access, and inadequate cybersecurity insurance coverage."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 110,
          "title": "Enforcement of Data Protection Requirements and Potential Fines",
          "data": [
            {
              "key": "Overview",
              "value": "Discussion on enforcement of data protection requirements under GDPR, UK GDPR, and related regulations."
            },
            {
              "key": "Regulations Mentioned",
              "value": "GDPR, UK GDPR, ePrivacy Regulation, EU Clinical Trials Regulation, and reference to US-EU data transfer mechanisms."
            },
            {
              "key": "Potential Fines",
              "value": "Fines of up to €20 million or 4% of annual global revenues, whichever is greater, with similar fines under UK GDPR."
            },
            {
              "key": "US-EU Data Transfer Framework",
              "value": "Invalidation of Privacy Shield, limitations on use of Standard Contractual Clauses (SCCs), and announcement of a new EU-US Data Privacy Framework not yet fully implemented."
            },
            {
              "key": "Risk Implications",
              "value": "Noncompliance could result in additional costs, regulatory investigations, penalties, adverse publicity, and operational impacts."
            }
          ],
          "currency": "EUR"
        },
        {
          "type": "risk_factor",
          "page": 111,
          "title": "Risk Factors - Legal, Reputational, and Operational Risks",
          "data": [
            {
              "key": "Legal Proceedings",
              "value": "Risk from securities class action, derivative lawsuits, and other legal proceedings could result in substantial financial costs and divert management’s attention."
            },
            {
              "key": "Government Enforcement Action",
              "value": "Any threatened or actual government enforcement action may generate adverse publicity and require substantial resource allocation."
            },
            {
              "key": "Insurance Coverage",
              "value": "Limited director and officer liability insurance coverage, subject to deductibles and coverage limitations, may not fully cover potential liabilities."
            },
            {
              "key": "Social Media Risk",
              "value": "Use of social media by employees, contractors, and clinical trial participants carries risks including noncompliance, reputational damage, and potential legal liabilities."
            },
            {
              "key": "Key Personnel Dependency",
              "value": "Heavy reliance on the expertise and retention of key executives and senior management, whose departure could adversely affect business operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 112,
          "title": "Recruitment, Retention and Personnel-Related Risks",
          "data": [
            {
              "key": "Recruitment and Retention Challenges",
              "value": "The document emphasizes the critical importance of recruiting and retaining qualified scientific, clinical, regulatory, manufacturing, and sales personnel. Failure to secure these key employees, including executive officers and senior management, could impede research, development, and commercialization objectives."
            },
            {
              "key": "Leadership Succession Risk",
              "value": "Replacing executive officers, senior management, and other key personnel is challenging due to a limited talent pool, which could disrupt business operations and strategic planning."
            },
            {
              "key": "Employee Misconduct and Regulatory Compliance",
              "value": "There is a significant risk associated with potential misconduct by employees, principal investigators, CROs, consultants, and other service providers. Such misconduct may include fraudulent activities, noncompliance with regulatory standards, insider trading, and other improper actions that could lead to legal penalties and reputational harm."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 115,
          "title": "Table of Contents / Risk Factors",
          "data": [
            {
              "key": "Revenue Generation",
              "value": "Ability to generate revenue through the successful commercialization of products and product candidates, if approved"
            },
            {
              "key": "Market Size",
              "value": "Size of the market for products and product candidates, if approved"
            },
            {
              "key": "Clinical Trials",
              "value": "Results, delays in commencement, enrollment, and completion of clinical trials for product candidates"
            },
            {
              "key": "Regulatory Approval",
              "value": "Failures in obtaining approval for product candidates"
            },
            {
              "key": "Competitive Landscape",
              "value": "Results and potential impact of competitive products or technologies"
            },
            {
              "key": "Manufacturing Capability",
              "value": "Ability to manufacture and successfully produce products and product candidates"
            },
            {
              "key": "Financial Estimates",
              "value": "Actual or anticipated changes in financial results, capitalization, development timelines, or securities analysts' recommendations"
            },
            {
              "key": "Expenses",
              "value": "Level of expenses related to products, product candidates, or clinical development programs"
            },
            {
              "key": "Comparative Financials",
              "value": "Variations in financial results or those of similar companies"
            },
            {
              "key": "Financing and Corporate Transactions",
              "value": "Financing or other corporate transactions, or the inability to obtain additional funding"
            },
            {
              "key": "Investor Expectations",
              "value": "Failure to meet or exceed the expectations of the investment community"
            },
            {
              "key": "Regulatory and Legal Developments",
              "value": "Regulatory or legal developments in the United States and other countries"
            },
            {
              "key": "Key Personnel",
              "value": "Recruitment or departure of key personnel"
            },
            {
              "key": "Intellectual Property",
              "value": "Developments or disputes concerning patent applications, issued patents or other proprietary rights"
            },
            {
              "key": "Strategic Transactions",
              "value": "Efforts to discover, develop, acquire, or in-license additional product candidates; entering into collaborations or strategic transaction agreements"
            },
            {
              "key": "Healthcare Payment Systems",
              "value": "Changes in the structure of healthcare payment systems"
            },
            {
              "key": "Market Conditions in Pharma/Biotech",
              "value": "Market conditions in the pharmaceutical and biotechnology sectors"
            },
            {
              "key": "Economic and Political Conditions",
              "value": "General economic, industry, and market conditions including global political turmoil, war in Ukraine, global health emergencies, and rising inflation rates"
            },
            {
              "key": "Share and Control Changes",
              "value": "Changes in voting control or sales of shares by executive officers and other senior management"
            },
            {
              "key": "COVID-19 Impact",
              "value": "Impact of the COVID-19 pandemic, including risks from new virus variants, on commercialization, preclinical studies, clinical trials, operations, and financial condition"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 116,
          "title": "Table of Contents – Risk Factors",
          "data": [
            {
              "key": "COVID-19 Impact",
              "value": "The COVID-19 pandemic and the measures taken (or their easing) could have a significant adverse impact on the business, operations, and financial position, affecting manufacturers, CROs, and regulatory interactions."
            },
            {
              "key": "War in Ukraine",
              "value": "The ongoing war in Ukraine has introduced significant market volatility and economic instability that may materially impact the business, operations, and financial position."
            },
            {
              "key": "Global Economic & Political Conditions",
              "value": "Adverse global economic and political conditions, including concerns about debt, inflation, and interest rates, may affect the business and share price."
            },
            {
              "key": "Equity Research and Analyst Coverage",
              "value": "Negative reports or downgrades by equity research analysts, or a reduction in coverage, could lead to declines in share price and trading volume."
            },
            {
              "key": "Share Conversion and Resale Impact",
              "value": "Sales of Class A common shares, including those issuable upon conversion of other share classes, and large holdings by executives and management, could cause a decline in share prices."
            },
            {
              "key": "Investor Rights & Share Registration",
              "value": "Certain shareholders having registration rights and the potential conversion of other share classes are factors that may also impact the market price."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 118,
          "title": "Risk Factors: Compliance, Internal Controls, Anti-Takeover Provisions and Dividend Policy",
          "data": [
            {
              "key": "Increased Compliance Costs",
              "value": "Regulations have increased our legal and financial compliance costs, making some activities more time-consuming and costly, particularly as a result of being a large accelerated filer and no longer qualifying as an emerging growth company."
            },
            {
              "key": "Internal Control Over Financial Reporting",
              "value": "Section 404 requires management to report on internal control over financial reporting. This process is costly and challenging, requiring internal resources, outside consultants, and continuous improvements. There is a risk that controls may not be deemed effective, potentially affecting market confidence."
            },
            {
              "key": "Anti-Takeover Provisions",
              "value": "The company's amended and restated bye-laws include anti-takeover features such as a classified board, removal only for cause, high voting thresholds for certain transactions, a multiclass share structure, and restrictions on director nominations. These provisions may discourage or delay change of control transactions and impact shareholder outcomes."
            },
            {
              "key": "Dividend Policy",
              "value": "The company does not anticipate paying cash dividends in the foreseeable future and has historically not declared or paid dividends, opting instead to retain future earnings to finance business growth."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 121,
          "title": "Tax Law Changes and Economic Substance Risks",
          "data": [
            {
              "key": "Risk Description",
              "value": "Changes in tax laws, tax rates, tax practices, tax treaties, and interpretations by tax authorities could adversely impact the company's tax position and effective tax rate."
            },
            {
              "key": "Jurisdictions Affected",
              "value": "Europe (including the United Kingdom), the United States, Bermuda, and other jurisdictions."
            },
            {
              "key": "Economic Substance Regulations",
              "value": "Under Bermuda Economic Substance Act 2018 and related regulations, certain entities must meet substance requirements. The company, not being engaged in 'relevant activities', is not currently obliged but will monitor its status."
            },
            {
              "key": "Potential Consequences",
              "value": "Increased effective tax rates, costly audits, interest, penalties, and reputational damage if tax policy changes or misinterpretations occur."
            },
            {
              "key": "Uncertainty Factors",
              "value": "Future tax audits, changes in valuation of deferred tax assets and liabilities, non-deductible expenses, and adjustments to share-based compensation taxation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 122,
          "title": "Tax Risk Disclosure on PFIC Classification",
          "data": [
            {
              "key": "PFIC Analysis",
              "value": "The document discusses an analysis determining that the company and its subsidiaries were not classified as a PFIC for the taxable year ended December 31, 2021, and outlines plans for the year ending December 31, 2022."
            },
            {
              "key": "Adverse Tax Consequences",
              "value": "It highlights that if classified as a PFIC, adverse U.S. federal income tax consequences may arise for U.S. Holders, including ordinary income treatment on gains, application of deferred interest charges, and additional reporting requirements."
            },
            {
              "key": "PFIC Test Criteria",
              "value": "A non-U.S. company is considered PFIC if at least 75% of its gross income is passive or if at least 50% of the value of its assets is attributable to assets that produce passive income."
            },
            {
              "key": "U.S. Holder Definition",
              "value": "The text defines a U.S. Holder as an individual, corporation, estate, or trust subject to U.S. federal income tax, with specific conditions outlined for trusts."
            },
            {
              "key": "Controlled Foreign Corporation",
              "value": "It is mentioned that the company is expected to be classified as a controlled foreign corporation for the taxable year ended December 31, 2022, which could subject certain U.S. Holders to further tax reporting requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 139,
          "title": "ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK",
          "data": [
            {
              "key": "Risk Exposure",
              "value": "Interest Rate Risk – exposure to market risk due to changes in interest rates affecting interest income sensitivity."
            },
            {
              "key": "Portfolio Composition",
              "value": "Cash, cash equivalents and short-term investments, including money market funds and U.S. Treasury notes."
            },
            {
              "key": "Market Conditions",
              "value": "General level of U.S. interest rates increased substantially in 2022."
            },
            {
              "key": "External Factors",
              "value": "COVID-19 pandemic, global political turmoil, and the ongoing war in Ukraine."
            },
            {
              "key": "Impact Assessment",
              "value": "A 10% immediate change in market interest rates would not materially affect the fair market value of the investment portfolio, financial position, or results of operations due to the short-term nature of the instruments."
            },
            {
              "key": "Additional Disclosures",
              "value": "Subsequent items on financial statements, accountant disagreements, and internal control disclosures are also noted in the table of contents."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 157,
          "title": "Table of Contents - NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Business Description",
              "value": "Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets targets a spectrum of underserved cardiovascular and autoimmune conditions."
            },
            {
              "key": "Risk Factors",
              "value": "The document highlights various risks and uncertainties common to small commercial stage companies in the biopharmaceutical industry. These include dependence on third parties (such as contract research and manufacturing organizations), limited regulatory approval experience, potential failure of R&D efforts, challenges in protecting technology, competition, uncertainties regarding the commercial viability of product candidates (e.g., ARCALYST), impacts from the COVID-19 pandemic, and geopolitical issues such as the war in Ukraine."
            },
            {
              "key": "Consolidation Principles",
              "value": "The consolidated financial statements include the Company and its wholly owned subsidiaries (including Kiniksa US, Primatope, Kiniksa UK and others) with elimination of significant intercompany accounts and transactions."
            },
            {
              "key": "Use of Estimates",
              "value": "Preparation of the financial statements according to GAAP requires management to make estimates and assumptions affecting asset and liability amounts, revenue recognition, R&D expenses, valuation of deferred tax assets, and share-based awards."
            },
            {
              "key": "Reporting Currency",
              "value": "The financial results of the Company's global activities are reported in U.S. dollars (USD), while some foreign subsidiaries use their local currencies as their functional currency."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 3,
          "title": "Forward-Looking Statements",
          "data": [
            {
              "key": "Purpose",
              "value": "Contains forward-looking statements regarding the company's products, financial position, and strategic objectives."
            },
            {
              "key": "Risks",
              "value": "Statements involve known and unknown risks and uncertainties that may cause actual results to differ."
            },
            {
              "key": "Examples of Forward-Looking Terms",
              "value": "Includes terms like 'may', 'will', 'should', 'expect', 'anticipate', etc."
            },
            {
              "key": "Predictions",
              "value": "Forward-looking statements are mere predictions based on current expectations."
            },
            {
              "key": "Referenced Sections",
              "value": "Sections titled 'Summary Risk Factors', 'Risk Factors', and 'Management’s Discussion and Analysis' provide additional context."
            },
            {
              "key": "Company Specific Risks",
              "value": "Includes commercialization ability, capital needs, manufacturing capabilities, market acceptance, competitive products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 67,
          "title": "Challenges in Clinical Trials due to COVID-19 and Participant Enrollment Issues",
          "data": [
            {
              "key": "Challenges",
              "value": "Prompting changes in local regulations as part of a response to the COVID-19 pandemic, which may require changes in clinical trial conduct."
            },
            {
              "key": "Limiting Factors",
              "value": "Delaying necessary interactions with local regulatory authorities and limiting employee resources for conducting clinical trials."
            },
            {
              "key": "Impact on Development",
              "value": "Could significantly impede, delay, limit or prevent clinical development and lead to regulatory approval delays."
            },
            {
              "key": "Enrollment Issues",
              "value": "Difficulty enrolling participants in clinical trials due to limited patient numbers and competing studies."
            },
            {
              "key": "Critical Success Factors",
              "value": "Identifying and qualifying participants is critical for success of clinical trials."
            },
            {
              "key": "Risks Associated",
              "value": "Product candidates modulate the immune system and carry risks associated with immunosuppression."
            },
            {
              "key": "Competition Impact",
              "value": "Competing clinical trials may limit participant availability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 117,
          "title": "Executive Compensation and Disclosure Exemptions for Smaller Reporting Companies",
          "data": [
            {
              "key": "Class A common shares registration rights",
              "value": "Holders affiliated with certain directors are entitled to registration rights under the Securities Act."
            },
            {
              "key": "Executive compensation disclosure",
              "value": "Smaller reporting companies have reduced disclosure requirements for executive compensation."
            },
            {
              "key": "Potential dilution",
              "value": "Future capital raises could lead to dilution of existing shareholders."
            },
            {
              "key": "Attractiveness of shares",
              "value": "Reliance on exemptions may affect market attractiveness of Class A common shares."
            },
            {
              "key": "Compliance costs",
              "value": "Public company compliance incurs significant expenses and management time."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 123,
          "title": "Table of Contents and Corporate Tax Implications",
          "data": [
            {
              "key": "U.S. shareholder implications",
              "value": "An individual that is a United States shareholder may not be allowed certain tax deductions or foreign tax credits."
            },
            {
              "key": "Reporting obligations",
              "value": "Failure to comply may subject the shareholder to significant monetary penalties."
            },
            {
              "key": "Consult tax advisors",
              "value": "U.S. Holders should consult their tax advisors regarding the application of these rules."
            },
            {
              "key": "Properties",
              "value": "U.S. headquarters located in Lexington, MA; leased space specifics mentioned."
            },
            {
              "key": "Legal Proceedings",
              "value": "The company is not party to any material legal proceedings."
            },
            {
              "key": "Mine Safety Disclosures",
              "value": "Not applicable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 147,
          "title": "Table of Contents ITEM 16. FORM 10-K SUMMARY",
          "data": [
            {
              "key": "Summary",
              "value": "None."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 26,
          "title": "Table of Contents - Clinical Trial Regulatory Guidelines",
          "data": [
            {
              "key": "IRB Approval Requirement",
              "value": "Each clinical trial must be reviewed and approved by an Institutional Review Board (IRB) at every institution to ensure risks are minimized; the IRB also approves the informed consent forms and oversees the trial until its completion."
            },
            {
              "key": "Data Safety Monitoring Board",
              "value": "Some studies include oversight by an independent Data Safety Monitoring Board that authorizes study progress at designated checkpoints based on key safety data and may halt the trial if unacceptable safety risks are identified."
            },
            {
              "key": "FDA and Sponsor Oversight",
              "value": "The FDA or the sponsor may suspend a clinical trial at any time if participants are exposed to an unacceptable health risk, and IRBs can suspend or terminate a trial if requirements are not met."
            },
            {
              "key": "Clinical Trial Phases",
              "value": "The document outlines sequential phases (Phase 1, Phase 2, Phase 3, and Phase 4) describing objectives such as safety, dose optimization, efficacy demonstration, and long-term observation."
            },
            {
              "key": "Manufacturing and Preclinical Studies",
              "value": "Concurrently with clinical trials, companies must complete preclinical studies and develop manufacturing processes in accordance with cGMP, ensuring consistent product quality through testing, packaging, and stability studies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 27,
          "title": "Table of Contents BLA Review and Approval",
          "data": [
            {
              "key": "Submission Requirements",
              "value": "A BLA includes results from preclinical studies and clinical trials, along with detailed information on product chemistry, manufacture, controls, and proposed labeling."
            },
            {
              "key": "Substantial Evidence",
              "value": "The application must provide substantial evidence supporting the safety, purity, and potency (or efficacy) of the product candidate, including both positive and negative findings."
            },
            {
              "key": "FDA Filing Process",
              "value": "Within 60 days of submission, the FDA reviews BLAs to ensure they are complete for substantive review. Incomplete applications require resubmission with additional information."
            },
            {
              "key": "Review Timelines",
              "value": "For original BLAs, the FDA has ten months from the filing date for standard review, or six months for priority reviews, with the overall process typically taking around twelve months."
            },
            {
              "key": "Inspections",
              "value": "Pre-approval inspections of manufacturing facilities (and possibly clinical trial sites) are conducted to ensure compliance with cGMP and GCP requirements."
            },
            {
              "key": "Risk Evaluation and Mitigation (REMS)",
              "value": "The FDA may require a REMS plan, which can include measures like medication guides, communication plans, and restricted distribution methods, to ensure the drug's benefits outweigh its risks."
            },
            {
              "key": "Pediatric Data Requirements",
              "value": "Under the Pediatric Research Equity Act (PREA), the application must provide data assessing the product’s safety and efficacy for all relevant pediatric populations."
            },
            {
              "key": "User Fee",
              "value": "Submission of a BLA is typically subject to a substantial application user fee."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 31,
          "title": "Regulatory Framework for Biosimilars and Foreign Government Regulation",
          "data": [
            {
              "key": "Penalties and Enforcement",
              "value": "Injunctions or the imposition of civil or criminal penalties; consent decrees; corporate integrity agreements; debarment or exclusion from federal healthcare programs; mandated modification of promotional materials and labeling; issuance of corrective information."
            },
            {
              "key": "Biosimilars Approval Pathway",
              "value": "An abbreviated approval pathway for biosimilars under the BPCIA, requiring demonstration of biosimilarity through analytical studies, animal studies, and clinical trials, along with requirements for interchangeability to yield the same clinical results as the reference product."
            },
            {
              "key": "Exclusivity Period",
              "value": "A reference biological product is granted 12 years of data exclusivity from the time of first licensure, with a biosimilar application not accepted until four years after that date, noting that a supplement does not trigger a new exclusivity period."
            },
            {
              "key": "Foreign Regulatory Environment",
              "value": "Products must obtain marketing authorizations in jurisdictions outside the United States. The approval process may involve additional testing and administrative review, and non-compliance with foreign regulatory requirements can lead to fines, suspension or withdrawal of approvals, product recalls, seizure, operating restrictions, and criminal prosecution."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 32,
          "title": "Regulatory Framework in the European Union: Non-Clinical Studies and Clinical Trials",
          "data": [
            {
              "key": "Overview",
              "value": "Describes regulatory controls for preclinical and clinical research in the EU, including adherence to GLP for non-clinical studies and GCP for clinical trials."
            },
            {
              "key": "EU Clinical Trials Regulation (CTR)",
              "value": "Adopted in April 2014 and applicable from January 31, 2022, replacing the previous Clinical Trials Directive with a centralized application process via CTIS."
            },
            {
              "key": "Submission Process",
              "value": "Introduces a single submission for all concerned member states, with a joint assessment and individual state assessments for specific national requirements."
            },
            {
              "key": "Ethical and Safety Standards",
              "value": "Clinical trials must adhere to ICH guidelines on GCP, ethical standards from the Declaration of Helsinki, and non-clinical studies must follow GLP principles under EU Directive 2004/10/EC."
            },
            {
              "key": "Sponsor Responsibilities",
              "value": "Non-EU sponsors must appoint an EU legal representative, secure clinical trial insurance, and are liable for ‘no fault’ compensation in most member states."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 34,
          "title": "Regulatory Aspects of Marketing Authorization and Exclusivity",
          "data": [
            {
              "key": "Conditional Marketing Authorization",
              "value": "In the EU, a 'conditional' Marketing Authorization (MA) may be granted when not all safety and efficacy data are available. It is valid for one year and must be renewed annually until all conditions, such as providing pending study data or enhanced safety measures, are fulfilled. Failure to meet these conditions leads to cessation of renewal."
            },
            {
              "key": "Exceptional Circumstances MA",
              "value": "MA may also be granted under exceptional circumstances if the sponsor is unable to provide comprehensive data on efficacy and safety under normal conditions. Unlike the conditional MA, there is no obligation to provide missing data. Although granted definitively, its risk-benefit balance is reviewed annually, and the authorization will be withdrawn if the balance worsens."
            },
            {
              "key": "Data and Marketing Exclusivity",
              "value": "Newly authorized reference products in the EU typically receive eight years of data exclusivity and an additional two years of market exclusivity (total of ten years). This period can be extended to up to eleven years if the MA holder secures authorization for new therapeutic indications offering a significant clinical benefit."
            },
            {
              "key": "Orphan Medicinal Products",
              "value": "Products designated as orphan medicinal products in the EU must address life-threatening or chronically debilitating conditions affecting a limited patient population or where investment return is insufficient without orphan status. Such products are eligible for various financial incentives and receive ten years of market exclusivity, during which similar products cannot be approved for the same indication."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 35,
          "title": "Table of Contents and Regulatory Framework for Orphan Medicinal Products",
          "data": [
            {
              "key": "Orphan Drug Exclusivity",
              "value": "Describes the ten-year market exclusivity in the EU for orphan drugs, conditions for reduction based on profitability and criteria compliance, and stipulations regarding supplementary protection certificates."
            },
            {
              "key": "Pediatric Investigation Plan (PIP)",
              "value": "Explains the requirement for MAAs to include pediatric study results in compliance with an agreed PIP, deferrals, or waivers based on efficacy, safety, or therapeutic benefit in pediatric populations."
            },
            {
              "key": "Marketing Authorization (MA) and Post-Approval Requirements",
              "value": "Details the obligations once MA is granted, including inclusion of pediatric study data, risk management plan (RMP) updates, pharmacovigilance system requirements, and compliance with advertising regulations."
            },
            {
              "key": "Regulatory Oversight",
              "value": "Highlights the comprehensive regulatory oversight by agencies such as EMA, the European Commission, and national authorities, along with obligations for expedited reporting and safety monitoring (e.g., PSURs, QPPV appointment)."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 37,
          "title": "Healthcare Regulatory Compliance and Risks",
          "data": [
            {
              "key": "Regulatory Compliance",
              "value": "Clinical trials must comply with GCP requirements, applicable regulatory standards, and ethical principles from the Declaration of Helsinki."
            },
            {
              "key": "Non-compliance Consequences",
              "value": "Failure to comply can result in fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution."
            },
            {
              "key": "U.S. Healthcare Laws",
              "value": "Federal, state, and foreign healthcare laws, including FDA restrictions, anti-kickback, false claims, and transparency laws regulate pharmaceutical business practices."
            },
            {
              "key": "Anti-Kickback Statute",
              "value": "Prohibits offering or receiving remuneration to induce or reward the purchase, lease, or ordering of reimbursable goods or services; broadly interpreted to include anything of value."
            },
            {
              "key": "False Claims Act",
              "value": "Outlaws knowingly submitting or causing the submission of false claims for payment to the government, with significant monetary penalties and the possibility of treble damages."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 38,
          "title": "Regulatory Compliance and Enforcement in Healthcare Programs",
          "data": [
            {
              "key": "Medicaid and State Programs",
              "value": "Items and services reimbursed under Medicaid and other state programs are subject to specific compliance requirements."
            },
            {
              "key": "Civil Monetary Penalties",
              "value": "Federal civil monetary penalty laws impose fines for offering or transferring remuneration that may influence beneficiary selection in healthcare programs."
            },
            {
              "key": "HIPAA and Criminal Statutes",
              "value": "The Health Insurance Portability and Accountability Act of 1996 (HIPAA) established criminal statutes addressing fraud, embezzlement, obstruction, and falsification related to healthcare benefits."
            },
            {
              "key": "Physician Payments Sunshine Act",
              "value": "Mandates annual reporting for covered manufacturers regarding payments and transfers of value to physicians and other healthcare providers, with penalties for non-compliance."
            },
            {
              "key": "Increased Regulation",
              "value": "There is a trend of increased federal and state regulation, including restrictions on marketing practices and mandatory compliance programs."
            },
            {
              "key": "Enforcement Trends",
              "value": "Recent increases in scrutiny, investigations, prosecutions, convictions, and settlements highlight the growing regulatory risk in the healthcare industry."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 42,
          "title": "Regulatory and Legislative Updates on Pharmaceutical Pricing and Healthcare Reform",
          "data": [
            {
              "key": "Statute of Limitations",
              "value": "Increased period for government recovery of overpayments from 3 to 5 years"
            },
            {
              "key": "American Rescue Plan Act of 2021",
              "value": "Eliminates the Medicaid drug rebate cap set at 100% of a drug’s AMP beginning January 1, 2024"
            },
            {
              "key": "Government Scrutiny and Product Pricing",
              "value": "Heightened oversight of how manufacturers set prices, triggering Congressional inquiries and legislation for pricing transparency"
            },
            {
              "key": "Inflation Reduction Act of 2022",
              "value": "Signed into law on August 16, 2022; mandates Medicare price negotiations starting in 2026, imposes rebates under Medicare Part B/D for price increases exceeding inflation, and replaces the Part D coverage gap discount program beginning in 2025"
            },
            {
              "key": "EU Health Technology Assessment Regulation",
              "value": "Regulation No 2021/2282 adopted on December 13, 2021; to be implemented from January 2025, fostering joint clinical assessments and cooperation among EU member states"
            },
            {
              "key": "Future Legislative and Regulatory Measures",
              "value": "Anticipates additional state and federal reforms that could affect government reimbursements for healthcare products and services"
            },
            {
              "key": "Data Privacy and Security Laws",
              "value": "Discussion of numerous state, federal, and foreign laws governing health-related personal information and data security"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 57,
          "title": "Regulatory Challenges and Product Approval",
          "data": [
            {
              "key": "Regulatory Issues",
              "value": "Discovery of previously unknown problems with products could lead to regulatory agency actions."
            },
            {
              "key": "Possible Regulatory Actions",
              "value": "Could include warning letters, civil or criminal penalties, suspension of approvals, and product recalls."
            },
            {
              "key": "Impact of Regulatory Actions",
              "value": "Failure to comply could adversely affect product commercialization and company value."
            },
            {
              "key": "Healthcare Regulations",
              "value": "Ongoing compliance with healthcare laws is critical and violations could lead to sanctions."
            },
            {
              "key": "Market Impact",
              "value": "Changes in regulation could limit or delay product approvals, affecting the ability to sell."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 59,
          "title": "Regulatory Compliance in Healthcare",
          "data": [
            {
              "key": "Overview",
              "value": "This section discusses the ownership and investment interests of physicians and their immediate family members in relation to state laws."
            },
            {
              "key": "State Laws",
              "value": "Includes state antikickback and false claims laws that apply to sales or marketing arrangements."
            },
            {
              "key": "EU Laws",
              "value": "Discusses similar healthcare laws and regulations in the EU, including reporting requirements."
            },
            {
              "key": "Consulting Agreements",
              "value": "Details financial relationships and compensation for physicians, highlighting potential conflicts of interest."
            },
            {
              "key": "Regulatory Risks",
              "value": "Describes risks of non-compliance with healthcare laws and the impact on marketing approvals."
            },
            {
              "key": "Costs of Compliance",
              "value": "Notes that compliance with healthcare laws can involve substantial costs and potential penalties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 65,
          "title": "Regulatory Challenges in Clinical Trials",
          "data": [
            {
              "key": "Impact of Regulatory Changes",
              "value": "Changes in laws, rules, and regulations by the FDA, EU institutions, and EMA can significantly affect operational costs and revenue."
            },
            {
              "key": "Global Clinical Trials",
              "value": "Conducting trials in multiple jurisdictions may increase costs due to diverse regulatory requirements."
            },
            {
              "key": "EU Clinical Trials Regulation (CTR)",
              "value": "CTR allows a single application process across member states, with implications for ongoing and new trials."
            },
            {
              "key": "UK Regulatory Framework",
              "value": "UK regulation is influenced by EU legislation, with ongoing consultations to potentially realign or diverge from EU standards."
            },
            {
              "key": "Geopolitical Risks",
              "value": "Conducting trials outside the US and EU introduces risks from non-compliant CROs and other external factors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 71,
          "title": "Regulatory Approval Challenges",
          "data": [
            {
              "key": "Issue",
              "value": "Regulatory authorities have discretion in approval processes."
            },
            {
              "key": "Challenge",
              "value": "Possible denial of marketing approvals."
            },
            {
              "key": "Impact",
              "value": "Potential delays or failures in product candidate approvals."
            },
            {
              "key": "Regulation Changes",
              "value": "Changes in marketing approval policies may delay approvals."
            },
            {
              "key": "EU Legislation Review",
              "value": "Revisions to EU pharmaceutical legislation expected to affect long-term industry regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 79,
          "title": "Risks Associated with Manufacturing and Regulatory Approvals",
          "data": [
            {
              "key": "key_risks",
              "value": "The company is dependent on Contract Manufacturing Organizations (CMOs) for compliance with Good Manufacturing Practices (cGMPs) and regulatory requirements."
            },
            {
              "key": "consequences",
              "value": "Failure to meet compliance could lead to sanctions, including delays, fines, or withdrawal of product approvals."
            },
            {
              "key": "manufacturing_capacity",
              "value": "Limited number of manufacturers under cGMP, leading to potential supply chain risks."
            },
            {
              "key": "alternative_manufacturers",
              "value": "Finding replacement manufacturers could incur additional costs and delays."
            },
            {
              "key": "Regeneron_exclusivity",
              "value": "Regeneron has exclusive rights to produce ARCALYST, impacting replacement options."
            },
            {
              "key": "regulatory_approvals",
              "value": "Replacement suppliers would require qualification and potential additional regulatory approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 90,
          "title": "Patent Protection and Legal Challenges",
          "data": [
            {
              "key": "Trademark Protection Issues",
              "value": "The USPTO and other entities may deny trademark applications, affecting brand and goodwill protection."
            },
            {
              "key": "Patent Uncertainty",
              "value": "The patent position for biotech and pharmaceutical companies is uncertain and complex."
            },
            {
              "key": "Expiration of Patents",
              "value": "The U.S. patent covering ARCALYST expired in 2020; other patents have varying expiration dates."
            },
            {
              "key": "Regulatory Exclusivity",
              "value": "Regulatory exclusivity periods differ by jurisdiction and depend on product approvals."
            },
            {
              "key": "Patent Term Extensions",
              "value": "Extensions may be unavailable if deadlines are missed; previous extensions were not secured for certain approvals."
            },
            {
              "key": "Impact of Patent Extensions",
              "value": "Not receiving extensions can shorten the enforcement period of patent rights, allowing competitors to market products sooner."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 94,
          "title": "Intellectual Property Litigation Risks",
          "data": [
            {
              "key": "Dispute over obligations",
              "value": "Disputes over obligations or intellectual property that we have licensed-in, licensed-out or acquired may impair ability to maintain arrangements on acceptable terms."
            },
            {
              "key": "Termination rights",
              "value": "If breached, licensors/sellers can terminate agreements and re-obtain related technology."
            },
            {
              "key": "Loss of exclusive rights",
              "value": "Uncured breach may result in loss of exclusive rights, impairing ability to raise capital or generate revenue."
            },
            {
              "key": "Regeneron rights",
              "value": "Regeneron retains worldwide rights to develop and commercialize ARCALYST, including rights in the Middle East."
            },
            {
              "key": "Litigation impact",
              "value": "Potential legal proceedings can have a material adverse effect on our commercial success."
            },
            {
              "key": "Third-party patents",
              "value": "Uncertainty regarding infringement of existing or future third-party patents."
            },
            {
              "key": "Patent applications",
              "value": "Many companies are filing patent applications related to immunomodulation, which may impact our products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 97,
          "title": "Patent Protection Compliance Risks",
          "data": [
            {
              "key": "Compliance Threats",
              "value": "Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements."
            },
            {
              "key": "Consequences of Non-compliance",
              "value": "Non-compliance may result in abandonment or lapse of patent rights, limiting enforcement capabilities."
            },
            {
              "key": "International Issues",
              "value": "Significant challenges in enforcing intellectual property rights in developing countries and regions with different patent laws."
            },
            {
              "key": "Infringement Risk",
              "value": "Competitors may develop products in jurisdictions without patent protection or adequate enforcement."
            },
            {
              "key": "Cost of Enforcement",
              "value": "Enforcement proceedings for patents outside the U.S. could incur substantial costs and divert resources."
            },
            {
              "key": "Legal Changes Impacting Patent Rights",
              "value": "Changes in laws and court decisions may affect the ability to enforce intellectual property rights."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 98,
          "title": "Changes to Patent Law and Its Implications",
          "data": [
            {
              "key": "Summary",
              "value": "Changes to patent law in the U.S. and other jurisdictions may diminish the value of patents, affecting the ability to protect product candidates."
            },
            {
              "key": "Key Legislation",
              "value": "Leahy-Smith America Invents Act (signed September 16, 2011) impacts patent prosecution processes."
            },
            {
              "key": "Key Changes",
              "value": "Transforming U.S. patent system to first-to-file system and redefining prior art."
            },
            {
              "key": "Risks",
              "value": "Increased uncertainty and costs in patent application prosecution and enforcement."
            },
            {
              "key": "Impact on Business",
              "value": "Could materially adversely affect business, financial condition, and operational results."
            },
            {
              "key": "Supreme Court Rulings",
              "value": "Recent rulings could narrow patent protection and weaken rights of patent owners."
            },
            {
              "key": "Future Changes",
              "value": "Potential additional changes to patent laws could further impact patent protection and enforcement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 105,
          "title": "Drug Pricing Regulations and Legislative Changes",
          "data": [
            {
              "key": "Eligibility for Federal Funds",
              "value": "Participation in VA/FSS pricing program required."
            },
            {
              "key": "Federal Agencies",
              "value": "VA, U.S. Department of Defense, U.S. Coast Guard, U.S. Public Health Service."
            },
            {
              "key": "Rebates",
              "value": "Must pay rebates on products purchased by military personnel."
            },
            {
              "key": "State Legislation",
              "value": "States enacting laws for healthcare cost growth limitation."
            },
            {
              "key": "Drug Price Transparency Legislation",
              "value": "May limit price increases and impose reporting requirements."
            },
            {
              "key": "Enforcement Mechanisms",
              "value": "Civil monetary penalties for non-compliance."
            },
            {
              "key": "MDRP Compliance Costs",
              "value": "Complex pricing calculations may increase compliance costs."
            },
            {
              "key": "Civil Monetary Penalties",
              "value": "Applicable for false reporting or late data submission."
            },
            {
              "key": "Inflation Reduction Act Impact",
              "value": "AMP figures reported will compute rebates under Medicare Part D."
            },
            {
              "key": "Health Care Regulatory Initiatives",
              "value": "Legislative changes may adversely affect operations."
            },
            {
              "key": "Affordable Care Act Changes",
              "value": "Subjected biologics to competition and changed rebate calculations."
            },
            {
              "key": "Budget Control Act Impact",
              "value": "Reductions of Medicare payments will remain through 2032."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 109,
          "title": "Regulatory Compliance and Risks",
          "data": [
            {
              "key": "Interpretation of Standards",
              "value": "Standards and enforcement practices may remain uncertain for the foreseeable future."
            },
            {
              "key": "Impact on Operations",
              "value": "Could affect the ability to operate in certain jurisdictions and necessitate onerous obligations in contracts."
            },
            {
              "key": "Cost of Compliance",
              "value": "The cost of compliance with laws and regulations is high and likely to increase."
            },
            {
              "key": "Potential Consequences of Non-compliance",
              "value": "Failure to comply could result in negative publicity, investigations, claims, and damage to reputation."
            },
            {
              "key": "HIPAA Compliance Status",
              "value": "Currently not acting as a covered entity or business associate under HIPAA, but risks exist."
            },
            {
              "key": "State Privacy Laws",
              "value": "May face substantial penalties for non-compliance with state laws concerning personal information."
            },
            {
              "key": "California Consumer Privacy Act (CCPA)",
              "value": "Enacted on June 28, 2018; effective January 1, 2020, expanding rights for consumers."
            },
            {
              "key": "California Privacy Rights Act (CPRA)",
              "value": "Effective January 1, 2023, significantly amends CCPA, imposing additional obligations."
            },
            {
              "key": "Other States Legislation",
              "value": "States like Virginia, Colorado, Connecticut, and Utah have enacted similar privacy laws."
            },
            {
              "key": "FTC Enforcement",
              "value": "FTC enforces consumer protection laws against unfair or deceptive practices regarding personal information."
            },
            {
              "key": "GDPR Compliance",
              "value": "International data protection laws including GDPR may apply, imposing strict requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 119,
          "title": "Legal Risks Related to Shareholder Rights and Jurisdictional Issues",
          "data": [
            {
              "key": "Jurisdiction",
              "value": "Supreme Court of Bermuda"
            },
            {
              "key": "Bermuda Company Law",
              "value": "Governs shareholder rights and corporate governance"
            },
            {
              "key": "Enforcement of Judgments",
              "value": "Difficult for US shareholders in Bermuda"
            },
            {
              "key": "Shareholder Rights",
              "value": "Limited ability to bring claims against directors"
            },
            {
              "key": "Judicial Forum Limitation",
              "value": "Choice of jurisdiction may discourage lawsuits"
            },
            {
              "key": "Corporate Structure",
              "value": "Registered under Bermuda law"
            },
            {
              "key": "Derivative Actions",
              "value": "More restricted under Bermuda law compared to US"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 120,
          "title": "Regulatory Considerations for Share Transfers and Tax Liabilities",
          "data": [
            {
              "key": "Legal Authority",
              "value": "Supreme Court of Bermuda"
            },
            {
              "key": "Shareholder Rights",
              "value": "Limited claims against directors/officers unless for fraud or dishonesty"
            },
            {
              "key": "Regulatory Limitations",
              "value": "Ownership and transfer of shares subject to Bermuda laws and approval by Bermuda Monetary Authority"
            },
            {
              "key": "Tax Liability Risks",
              "value": "Potential for unanticipated tax in multiple jurisdictions"
            },
            {
              "key": "Transfer Pricing Laws",
              "value": "Compliance with laws required but not guaranteed against challenges by tax authorities"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 78,
          "title": "Table of Contents ability to meet commercial or clinical demand for ARCALYST",
          "data": [
            {
              "key": "Manufacturing & Supply Chain Risks",
              "value": "The text highlights potential supply chain disruptions and manufacturing challenges including unexpected costs, technology transfer risks, inability to secure a suitable CMO, and delays or quality issues arising from changes in manufacturing sites or processes."
            },
            {
              "key": "Technology Transfer",
              "value": "There is discussion about potential technology transfers from Regeneron to either the company or another CMO, which might occur as early as March 2023, and the associated risks if the transfer is unsuccessful."
            },
            {
              "key": "Impact on Business & Operations",
              "value": "Any failure in maintaining sufficient production—whether due to supply shortages, inability to meet clinical demand, or regulatory issues—could adversely affect business, clinical trial timelines, and overall financial performance."
            },
            {
              "key": "External Factors",
              "value": "The passage also notes external challenges such as the impact of the COVID-19 pandemic on suppliers and global supply chains, further compounding the risk factors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "supply_chain_disruption",
          "page": 81,
          "title": "Supply Chain and Manufacturing Risks",
          "data": [
            {
              "key": "Supply Chain Impact",
              "value": "Potential delays or shortages in the supply and distribution of ARCALYST and its ancillary products could reduce revenue, profitability, and harm the company’s reputation."
            },
            {
              "key": "Third-Party Dependence",
              "value": "Reliance on a network of specialty pharmacies and limited suppliers for drug substance and product increases the risk of supply disruption."
            },
            {
              "key": "Regulatory and Compliance Risks",
              "value": "Failure by third-party manufacturers to comply with cGMP and other regulatory standards could lead to production delays, increased costs, and potential penalties."
            },
            {
              "key": "Clinical Trial Implications",
              "value": "Shortages of specialized placebo required for clinical trials could substantially delay trial timelines."
            },
            {
              "key": "Single-Source Risk",
              "value": "Dependence on single-source or limited suppliers for critical materials heightens vulnerability to supply disruptions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "supply_chain_disruption",
          "page": 82,
          "title": "Supply Chain Disruption Risks",
          "data": [
            {
              "key": "Issue",
              "value": "Dependence on single-source suppliers for products and product candidates."
            },
            {
              "key": "Challenge",
              "value": "Potential inability of suppliers to meet demand due to limited experience or importance as a customer."
            },
            {
              "key": "Manufacturing Capacity",
              "value": "Need for increase in manufacturing capacity and potential for alternative sources."
            },
            {
              "key": "Regulatory Approvals",
              "value": "Additional regulatory approvals may be required for increased capacity."
            },
            {
              "key": "Business Impact",
              "value": "Material negative impact on business if suppliers experience disruptions, financial difficulties, or other challenges."
            },
            {
              "key": "Collaboration Agreements",
              "value": "Future agreements may require commercial or clinical drug supply, adding complexity."
            },
            {
              "key": "Replacement Suppliers",
              "value": "Finding replacement suppliers may take years and involve significant challenges."
            },
            {
              "key": "Material Shortages",
              "value": "Shortages of biologically derived materials could adversely impact manufacturing."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 43,
          "title": "Human Capital and ESG Initiatives Overview",
          "data": [
            {
              "key": "Privacy and Security Laws",
              "value": "Certain foreign laws govern the privacy and security of personal data, including health-related data. These evolving laws and regulations may conflict and lead to investigations, proceedings, or actions resulting in significant civil and/or criminal penalties and restrictions on data processing."
            },
            {
              "key": "Employee Count",
              "value": "As of December 31, 2022, approximately 220 full-time employees, with about 210 located in the United States and 10 outside the United States."
            },
            {
              "key": "Compensation and Benefits",
              "value": "Employees receive competitive fixed salaries, cash bonus opportunities to incentivize achievement, equity awards, and opportunities for equity ownership through an employee share purchase plan, alongside a robust benefits package."
            },
            {
              "key": "Diversity, Equity and Inclusion (DEI)",
              "value": "A diversity statement was launched in 2021 along with a monthly DEI dashboard. The company has committed to DEI goals, incorporated DEI principles in its Code of Business Conduct and Ethics, and signed the MassBio’s CEO Pledge for a More Equitable and Inclusive Life Sciences Industry."
            },
            {
              "key": "Ethics and Workplace Conduct",
              "value": "The organization emphasizes running a compliant and ethical business, requiring employees to confirm understanding and compliance with policies on insider trading, bribery, corruption, and interactions with healthcare professionals, supplemented by periodic training."
            },
            {
              "key": "Health and Safety Measures",
              "value": "A comprehensive safety program, emergency response plan, and COVID-19-specific workplace safety protocols are in place, along with regular safety trainings, drills, and audits to mitigate health and safety incidents."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 113,
          "title": "ESG Matters Impact on Business",
          "data": [
            {
              "key": "Impact of ESG Matters",
              "value": "Increased costs, harm to reputation, adverse impact on access to capital and financial results."
            },
            {
              "key": "Stakeholder Pressure",
              "value": "Pressure to set goals or commitments relating to ESG matters."
            },
            {
              "key": "Compliance Challenges",
              "value": "New reporting requirements and possible failure to comply leading to negative consequences."
            },
            {
              "key": "Ratings Impact",
              "value": "Unfavorable ESG ratings could lead to negative investor sentiment."
            },
            {
              "key": "Climate Change Impacts",
              "value": "Physical impacts could negatively affect operations and business."
            },
            {
              "key": "Ownership Concentration Risks",
              "value": "Concentration of common shares ownership may influence shareholder matters."
            },
            {
              "key": "Voting Rights of Shares",
              "value": "Class A common shares have one vote; Class B common shares have ten votes per share."
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 40,
    "EUR": 21,
    "AUD": 11,
    "CAD": 1,
    "INR": 5,
    "ZAR": 2,
    "RUB": 1
  },
  "sha1": "74c690176ce433301f4d1e808bb002a2f4dc321a"
}